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ABSTRACT 
 
 
Spi6 is a serine protease inhibitor. Its main function is inhibition of granzyme B 
(GrB): it is therefore an anti-apoptotic protein in cytotoxic T cells (CTL), where 
leakage of GrB from cytotoxic granules into the cytosol can trigger apoptosis. CTLs 
use GrB release to kill infected cells but they can also induce apoptosis in antigen-
loaded mature dendritic cells (DC) during priming. Mature DCs upregulate Spi6 and 
in vitro have higher resistance to CTL-induced apoptosis compared to immature ones: 
when Spi6 is absent, this resistance is lost. However, whether Spi6 protects DCs from 
CTL-mediated apoptosis in vivo is still under debate. Using mice deficient in Spi6, 
the project focuses on the role of Spi6 in DC survival during the priming of naïve and 
memory anti-Lymphocytic Choriomeningitis virus (LCMV) CD8 T cell responses. 
CD8α+ DCs are professional antigen presenting cells responsible for cross-
presentation of viral antigens in secondary lymphoid organs. Upon maturation, Spi6 
is expressed by CD8α+ DC in vivo. In our model, Spi6 KO DC antigen-presentation 
ability was comparable to wild-type (WT) but their survival was impaired. This 
resulted in defective expansion of WT LCMV-specific CD8 T cells. A similar 
requirement for Spi6 was found for DC priming of memory CD8 T cell expansion. 
GrB KO
 
CD8 T cells rescued the priming defect in Spi6 KO mice during both 
primary and secondary responses, demonstrating GrB is the physiological target of 
Spi6 in DCs. Thus, GrB is a major immunosuppressive agent controlling the DC 
priming of anti-viral T cell mediated immunity. 
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1. INTRODUCTION 
 
 
1.1 Motivation, assumptions and research challenges 
  
Infectious diseases are still today a very high priority in the agenda of the WHO, 
due to the high mortality rates they have among children and young adults, especially 
in developing countries (WHO). Six major diseases (tuberculosis, pneumonia, 
diarrhoea, HIV/AIDS, malaria and measles) cause the majority (90%) of deaths, and 
piling evidence suggests that some diseases once thought to be unrelated to 
pathogenic agents, like cancers, are or the greatest part the result of chronic 
infections. Viral infections in particular are at the origin of at least 4 of these 6 
threatening diseases and cause chronic conditions which account for major health 
burdens in developed countries, like hepatitis and AIDS. New strategies are needed in 
order to develop vaccines to successfully prevent especially lethal infections and 
innovative therapeutic approaches are desirable to tackle chronic diseases. 
Dendritic cells (DCs) are the main switch responsible for the activation of immune 
responses against viral pathogens, mediated by CD8 T cells. CD8 T lymphocytes are 
the cell type mainly responsible for anti-viral immunity as they are able to release 
cytotoxic agents. In order for antiviral responses to be properly and efficiently 
developed, dendritic cells need to be preserved and functional. Enhancement of DC 
survival is desirable to achieve improved activation of CD8 T cell responses. 
Dendritic cells are thus an ideal target of new therapeutic methodologies aimed at 
manipulating and ameliorating immune responses to viruses. CD8 T cells response 
manipulation includes efficient activation of a de novo response, which is needed for 
a vaccine to be effective, and re-stimulation of anergic or unresponsive CD8 T cells 
in treatment of chronic infections. The same CD8 T cell response is also highly 
involved in eradicating cancer cells, thus further widening the possible applications of 
therapeutic strategies improving DCs survival. Vaccination strategies that involve 
targeting of DCs with specific antigens to be used for activation of immune responses 
have already been tested, and proved to be promising (Belz et al. 2004). 
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1.2 Key contributions and achievements 
 
This project’s results have significance in the context of designing therapeutic 
strategies involving the preservation of dendritic cells. In the project are presented the 
results from the study of the role of Serine protease inhibitor (Spi)-6 in protecting 
dendritic cells involved in priming CD8 T cell responses against virus. A controversy 
recently was brought up when in vitro results supporting a protective role for Spi6 
were disproved by in vivo studies. The controversy was addressed by this project. 
  
The novelty of this study is in the analysis of DC survival in absence of Spi6 
expression an in vivo mouse model. The model, a KO mouse for the protein of 
interest, Spi6, allowed the study of physiological expression and function of Spi6 in 
two mouse DC subsets. The use of a KO mouse model for the protein of interest 
represents a novel approach to study Spi6 function in DCs. 
 
Key contributions include the identification of specific upregulation of Spi6 in 
CD8α DCs but not in pDCs in the spleen of infected mice, the demonstration that 
Spi6 absence in DCs induces defective CTL responses and the corroboration that 
granzyme B (GrB) is the cause behind DC and CTL deficient levels in absence of 
Spi6. 
 
This project is therefore important in sight of a potential use of DCs to manipulate 
CD8 T cell responses. Applications include but are not limited to vaccination design, 
treatment of chronic diseases, tumours and prevention or treatment of transplantation 
complications due to rejections.  
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1.3 Road map 
 
The background information available in the literature to better understand the two 
main cell types involved, DCs and CD8 T cells, together with a description of Spi6 
and its function, are laid down in chapter 2 (2.2). In the same chapter are described 
the viral model (2.7), the animal model of choice and the hypothesis on which the 
project is based (2.8.4). The materials and methods used to investigate Spi6 role in 
DCs during the priming of CD8 T cell responses are described in Chapter 3, while the 
results obtained from experimental investigations are reported in Chapter 4. Lastly, 
the discussion of the findings supported by these results and future work are 
illustrated in Chapter 5. 
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2. BACKGROUND 
 
The human body is furnished with an extremely clever and sophisticated defence 
apparatus, called the immune system. The immune system is a complex network of 
cells and molecular mediators which extend throughout our body and provides 
protection against pathogens, be they viruses, bacteria, parasites, or fungi. It can be 
divided into two arms, which interact closely with each other: innate immunity and 
adaptive immunity. CD8 T cells are the cellular mediators responsible for the killing 
of virally infected cells and are part of the adaptive arm of the immune response. 
These cells are nonetheless unable to recognise an infected cell unless previously 
instructed by a member of the innate immunity: dendritic cells. DCs can recognise 
invading pathogens and interact with CD8 T cells to instruct them on the type and 
levels of invader. They therefore play a key role in activation and shaping of the CD8 
T cell responses. Spi6 is a serine protease inhibitor expressed by DCs, but its function 
in these cells has, to date, not been clearly defined. This protein is expressed by CD8 
T cells as well where it protects them against self-inflicted death due to a cytotoxic 
molecule called GrB. The same function is predicted in DCs. To study Spi6 function 
in DCs, a viral infection model has been used, the Lymphocytic Choriomeningitis 
virus (LCMV). 
 
 
2.1 Innate and adaptive immunity: Two sides of the same 
coin  
 
Innate immunity is present in all life forms from plants to animal and it represents 
the first line of defence against infections. It includes anatomical barriers like 
mucosae and intestinal flora and it involves non-specific reactions to pathogen 
invasion triggered by its cellular components which are Mast cells, Macrophages, 
Neutrophils, Dendritic cells, Eosinophils, Natural killer (NK) cells, and γδ T cells. 
Considered part of the innate immune system are also the complement system, which 
allows opsonisation of pathogens when bound to antibodies, and cytokines and 
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chemokines. Examples of innate responses are septic shock (due to the systemic 
release of high levels of IL-1 and TNF-α) and the initiation of allergic reactions (due 
to local release of histamine by mast cells). The innate system is mobilised 
immediately upon pathogen invasion due to the recognition of PAMPs (pathogen-
associated molecular patterns), specific molecular patterns maintained in pathogens, 
like lipopolysaccharide (LPS) and double strand RNA (dsRNA). PAMPS are 
recognized by receptors called PPRs (pattern recognition receptors) expressed by 
various innate cells. The responses triggered when the components of the innate 
system are activated are non-specific and often systemic (Akira 2011). Moreover, this 
system does not provide long-lasting protection but rather quick and immediate 
defensive reactions. 
 
Adaptive immunity, on the contrary, is able to respond to pathogen invasion with a 
specific and local set of measures and cells to almost any pathogen and it can evolve 
(in the best of options) together with the pathogen during infection. Each response is 
based on the recognition of specific antigens derived from pathogen protein 
degradation via dedicated receptors like the T cell receptor (TCR) and the B cell 
receptor (BCR). These receptors, on the membrane of the main player of adaptive 
immunity, B and T cells, are able to recognize a very high number of antigens due to 
two main mechanisms: the V(D)J recombination of their loci in both T and B cells 
and successive somatic hypermutations in B cells. The adaptive system is dependent 
on the innate system in that it needs to be activated by it, and cannot mount a 
response in absence of the latter.  
 
What distinguish the adaptive immune arm from the innate one are not just the 
pathogen specificity of its responses and the need for activation, but also the duration 
and the “memory” of them. In fact, each adaptive response creates a set of cells able 
to reactivate in case of repeated pathogen invasion, called memory cells, which will 
be faster and more efficient in clearing the pathogen (Ahmed and Gray 1996). The 
adaptive immunity consists of two main arms: a humoral one, made by B cells and 
the antibodies they produce, and a cellular one, made by CD4 T helper, CD4 T 
regulatory and CD8 T cells. B cells can recognise a pathogen through their BCR. The 
activation of this receptor will trigger the production of antibodies and, once the 
pathogen is defeated, the B cell is set to become a long-lasting, quiescent antibody 
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reserve called plasma cell. T cells, instead, are broadly divided into CD4 and CD8 T 
cells. CD4 T cells are responsible for helping B cells and CD8 T cells reach the 
proper activation status and also have immune regulatory functions. CD8 T cells are 
the ones responsible for targeted and direct killing of infected or tumour cells. They 
have cytotoxic properties and their activation is sought-after in the design of vaccines 
and therapeutic strategies. For these characteristics, this project focussed on CD8 T 
cells. The specificity of the adaptive response also depends on the expression of 
major histocompatibility complex (MHC) molecules which are surface proteins 
loaded with peptides derived from the processing of intracellular molecules expressed 
in all the cells, with a few exceptions, like red blood cells. 
 
The two arms of the immune system are thus clearly interconnected, as the adaptive 
system needs to be activated by the innate system to be able to carry on its defensive 
functions. The cellular component of the innate immunity which is responsible for the 
cross-talk between the adaptive and immune arms is the Dendritic Cells (DCs). 
Discovered by the Nobel Prize Laureate Ralph Steinman in 1973 (Steinman and Cohn 
1973), these cells instruct T and B cells to develop either immunity or tolerance by 
presenting antigens acquired from the environment and by delivering costimulatory 
signals. The signals depend on the type of pathogen and, modality of the infection, 
the level of inflammation and other parameters and are of main importance to 
regulate the specificity of the adaptive immune response in terms of activation and 
extent. 
 
 
2.2  CD8 T cells 
 
CD8 T cells are the main cell component of the adaptive immune responses against 
intracellular pathogens and tumours. They are identified by the expression of a 
transmembrane glycoprotein called CD8 whose role is that of co-receptor to the TCR. 
CD8 T cells are mainly responsible for the killing of cancer cells and cells infected by 
intracellular pathogens like viruses and intracellular bacteria. Activation through 
contact with an antigen-loaded mature DC is necessary for activation and 
proliferation to be triggered. Once activated, CD8 T cells can recognise an infected or 
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tumour cell by means of interaction mediated by their TCR with peptides mounted on 
a MHC-I molecule and with the MHC itself. Once recognised, the infected cell can be 
killed by released cytotoxic molecules or via the engagement of death receptors. Once 
the infection is cleared, CD8 memory cells, progeny of the activated killer cells, 
develop to form a long-lasting quiescent population, ready to be activated by 
successive pathogen invasions. 
 
 
2.2.1 The T cell receptor 
 
The TCR is a highly variable surface protein composed by two chains which is 
always complexed with CD3 molecules, forming the TCR complex (see Figure 1). By 
recognising specific antigens loaded onto MHC, the TCR complex mediates, in 
concert with other receptors, activation and effector functions of the T cells (Janeway 
1992). Also, the TCR is solely responsible for giving T cells their specificity. The 
TCR molecule is a heterodimer composed by one α- and one β-chain. Each chain can 
be further divided into a constant (C) segment, the portion anchored to the membrane, 
a J (joining) segment and a variable (V) segment, which is the portion sticking out 
towards the intracellular space. The β-chain has a similar structure but also contains a 
D (diversity) segment between the V and the J. Each variable region has 3 different 
complementary determining regions (CDR) which are responsible for the recognition 
of MHC-loaded antigens. In thymocytes (the precursors of CD8 naïve T cells), during 
differentiation to naïve cells, a clever process of rearrangement of the exons of the 
gene segments V, D and J takes place in each of the chain loci. The result of this 
rearrangement is a unique combination translated in each T cell, leading to as many T 
cells with different specificity as binding and recognising sites can be formed by V 
(D) J rearrangements (Janeway 1992). In the beta-chain, Dβ-Jβ rearrange first, while 
Vβ to DJ rearranges when the thymocytes are in the double negative (DN) stage of 
differentiation in the thymus. The TCR β chain then binds to a pre-TCR α chain, and 
the thymocytes proceed in their proliferation and progress to the double positive (DP) 
developmental stage. The TCR α-chain will undergo rearrangement only after the 
proliferation. This is further described below (Chapter 2.2.2) 
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Figure 1: TCR complex: in yellow the two chains of the TCR 
(α and β), in purple the CD3 complex, in red the co-receptor 
(CD8 or CD4) and in light blue the MHC-I/II on the target 
or dendritic cell (Gascoigne 2008). 
 
 
It has been calculated that the TCR rearrangement can produce 10
15–1020 unique 
TCR structures. In humans in particular there are 10
12
 naïve αβ T cells in the 
circulation of an adult, while in mice there are about 10
8
 T cells. The number of 
possible combinations of 11 amino acids, which is the average length of antigens 
loaded onto a MHC molecule, can be as high as 10
18
, although not all of them would 
be able to successfully associate with the MHC binding pocket (Miles et al. 2011).   
The CD3 molecule associated with the TCR is responsible for the signal 
transduction of the TCR: the TCR has in fact very few cytosolic amino acids, while 
the CD3 has long cytoplasmic tails. Studies in which it was tried to express the TCR 
without CD3 showed how co-expression of these two molecules is required (Weiss 
and Stobo 1984). The exact way TCR and CD3 interact is not fully understood, but 
recent studies showed how a conformational change happens in the TCR upon 
binding of the same to a pMHC (peptide-loaded MCH). The signals triggered by 
ligation of the TCR complex support CD8 T cell maturation to the effector status and 
stimulate proliferation, as reviewed below (Chapter 2.2.4). 
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2.2.2 CD8 T cell development 
 
CD8 T cells develop from hematopoietic stem cells (HSC) which, once mobilised 
from the bone marrow, are released in the circulation and periodically enter the 
thymus. It is not fully clarified at which step of differentiation these cells reach the 
thymus, but it is known that after leaving the BM, the HSC can proliferate and 
differentiate into common lymphoid progenitors (CLPs). Some of these will enter the 
thymus and settle there, thus becoming thymus-settling progenitors (TSP) and 
subsequently earliest T-lineage progenitors (ETP). ETPs, T cell precursors, enter the 
thymus via the post-capillary venules which penetrate the thymus in between the 
cortical and the medullary regions.  
The entry rate is regulated and one of the molecules implicated in this process is P-
selectin. P-selectin is in fact expressed on thymic epithelium and its levels have been 
shown to correspond to thymic niche availability (Rossi et al. 2005). Sphingosine-1-
phosphate (S1P) is an intracellular intermediate in the membrane sphingolipid 
metabolism and it is produced intracellularly by most cell types. Its extracellular 
levels seem to be correlated to the exit of mature lymphocytes from the thymus (in 
the same way in which, as we will see later, seems to work regulating egression from 
LN and spleen of T cells). Studies from Cyster and colleagues have indicated the 
egress regulation might be in place through the maintenance of a gradient between the 
blood and the (higher) thymic concentration of S1P (Cyster 2005; Cyster and Schwab 
2012).  
The ETPs can proliferate in the thymus giving origin to T cells which do not express 
either CD8 or CD4 and are therefore called double negative (DN, i.e. CD8
-
 CD4
-
) 
lymphoid precursors (Schwarz and Bhandoola 2006).  
 
The ETPs, defined as CD8
- 
CD4
- 
CD44
+ 
CD25
-
 or DN-1, undergo a maturation 
process which involves a migration in the thymus and during which the cells acquire 
specific surface markers and rearrange their TCR. DN-1 cells moving deeper into the 
cortex of the thymus express CD25
+ 
first, and then CD117
-
 (DN2). During the third 
stage (DN3), they become CD44
- 
CD25
+
 and localise in the external area of the cortex 
(see Figure 2). In the next step the precursors undergo their first selection, called β 
selection, which requires the β-chain to be properly bound to the pre-TCR-α-chain 
and mounted on the T cell surface to allow the cell to proceed in its differentiation 
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process and interact with stromal cells. The cells that pass this checkpoint become 
CD8
+ 
CD4
+ 
(DP), which is the most abundant sub-population in the thymus cortex. 
DPs then move to the medullar region to functionally differentiate and become CD8
+
 
or CD4
+
 single positive (SP) (Anderson and Jenkinson 2001; Singer et al. 2008). 
Passage from DP to SP happens through further selection, positive and negative, and 
requires the cells to pass a number of checkpoints. The positive selection happens in 
the cortex, where weak recognition of self-peptides mounted on MHC of cortical 
thymic epithelial cells (cTEC) by the newly formed TCR, triggers survival and 
maturation. The machinery that produces antigens to be presented by cTEC is 
different from the one in peripheral DCs (reviewed extensively in (Klein et al. 2009). 
Only TCRs with strong and intermediate affinity allow for positive selection of T 
cells, while failure to recognise MHC molecules induces death by neglect. The 
negative selection happens in the medullary region: here the same peptides are 
expressed by medullary TECs and DCs which, when the avidity of the T cell for 
pMHC is too strong, transmit an apoptotic signal, thus mediating the elimination of 
auto-reactive T cells (Ashton-Rickardt and Tonegawa 1994). 
 
In the thymus there is a strict correlation between localisation and maturation stage, 
suggesting that the orchestration of migration plays a fundamental role in the correct 
development of CD8 and CD4 T cells. Studies with 2-photon microscopy revealed 
that precursors move slowly and randomly before positive selection, then create 
temporary interactions with TECs for the positive selection itself, and only move 
more quickly once this phase is concluded (Witt et al. 2005). The peculiarity of 
thymic selection is the expression, by TECs, of genes previously thought to be 
exclusively expressed by peripheral specific organs (Kyewski and Derbinski 2004). 
These antigens can be cross-presented by medullary DCs or by the TECs and are not 
homogenously distributed in the medulla. These self-peptides also have a degree of 
cross-reactivity, thus allowing for the selection of a wide repertoire of T cells (Hu et 
al. 1997). The total time a precursor resides in the thymus for selection has been 
estimated in about a week (Shortman et al. 1990).  
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Figure 2: Thymocyte development: migration through the thymus and 
maturation to single positive T cells (Anderson and Jenkinson 2001). 
 
 
The selection process ensures that CD8 T cells do not trigger any auto-immune 
reaction and at the same time instructs these cells to tolerance mechanisms. When the 
selection process is terminated, CD8 T cells are released in the blood stream in the so-
called naïve form. This happens approximately 4-5 days after the positive selection 
has terminated (McCaughtry et al. 2007). Each cell leaving the thymus will have a 
different TCR and therefore different specificity of reaction, and will circulate in the 
blood stream in a naïve status, ready to receive activation signals. 
 
 
2.2.3 CD8 T cell migration to lymph nodes  
 
Naïve CD8 T cells circulate in the blood stream and home to secondary lymphoid 
organs to sample pathogen-derived antigens. The journey of a naïve CD8 T cell to a 
lymphoid organ (the lymph node in this case for simplicity), starts with the 
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extravasation from the capillary bed through the endothelial layer which happens via 
a process called tethering, mediated by selectins. The following step is the “rolling” 
of the T cell on the endothelial layer. During the rolling some receptors on endothelial 
cells are activated and integrin conformation is changed, increasing the affinity and 
avidity and allowing the T cell to adhere to the endothelial cells (HECs) and start the 
transendothelial migration. At this stage, chemokines produced by the HECs and 
bound by the basal lamina, especially CCL21, are crucial for efficient T cell entry 
into the lymph node (LN). In order to enter secondary lymphoid organs from the 
blood, CD8 T cells must express homing receptors, such as the selectin CD62L, the 
chemokine receptor CCR7 and the integrins α4β1 (VLA-4) and αLβ2 (LFA-1). 
Expression of CCR7, which binds CCL12, together with L-selectin and LFA-1 
(lymphocyte function-associated antigen-1) allows selective entry into the LN. One 
exception to this is central memory T cells, which can enter the LN in absence of 
CCR7 following CXCR4 signalling (Scimone et al. 2004).  
 
Thus, in naïve CD8 T cells the fundamental receptors are CCR7 and L-selectin. 
CCR7 ligands, CCL19 and CCL21, are expressed by HECs in the LN and bound by 
the basal lamina and it is currently believed that these drive extravasation by creating 
a gradient which guides the T cell across the endothelium. Once inside the LN, the 
signals that guide T cells to the T areas and direct them around are not known: CCR7 
deletion affects only marginally T cell migration inside the LN (Okada and Cyster 
2007). Some studies with pertussis toxin, which can block the function of the G-
proteins used by chemoattractant receptors to trigger the intracellular pathway, 
resulted in almost total inhibition of T cell migration in the LN (Huang et al. 2007). 
 
 
2.2.4 Naïve CD8 T cell priming  
 
Naïve CD8 T cells circulate in the blood and lymphatic system without specific 
direction in the steady state; in inflammatory conditions they can mature and acquire 
effector function. Priming of CD8 T cells happens mainly in the lymphoid organs, 
where mature DCs migrate to following chemotactic signals. Maturation from naive 
to cytotoxic T cell (CTL) is triggered by a number of signals, the first of which is the 
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recognition by the CD8 TCR of a peptide in a MHC-I context (pMHC). When 
recognition happens in a secondary lymphoid organ (mainly spleen and lymph 
nodes), and the MHC-I is expressed by a DC, activation of the CD8 T cell can be 
triggered (Figure 3). As explained by Polly Matzinger in 1994 (Matzinger 1994), the 
activation program is triggered in the CD8 T cell when the TCR-MCH-I interaction is 
associated with the delivery of inflammatory and co-stimulation signals from the DC. 
Activation leads to expression of de novo proteins, like GrB and perforin, to a high 
rate of proliferation, and to reorganisation of both cytosolic and membrane structures. 
CD8 T cells are therefore unable to kill unless activated by an antigen-presenting cell, 
and more specifically by a DC. 
 
2.2.4.1 Costimulation requirement 
Costimulation represents the second signal needed for CD8 T cell activation. Upon 
binding of the pMHC (complex of peptide and MHC-I) on the DC, the distribution of 
surface molecules in the CD8 T cell is reorganized to bring specific coreceptors (like 
CD40L and CD28) close to the TCR, ready to receive additional co-stimulatory 
signals. Several receptors have co-stimulation properties: among these, the most 
widely studied and the first to be identified is CD28. Not only CD28 ligation triggers 
a signalling cascade that activates cytokine production and promotes cell survival, but 
it also endorses proliferation through strengthening of the cell metabolism. CD28 is 
constitutively expressed by CD8 T cells, and it is the first coreceptor to be engaged 
after MHC recognition. It binds CD80 and CD86 on DCs, and its engagement 
activates the PI-3K-PDK1-Akt pathway which induces NF-kB translocation to the 
nucleus (Macintyre et al. 2011). CD28 signalling enhances TCR signalling in a 
quantitative more than qualitative way (Acuto and Michel 2003): its binding can 
promote the expression of co-stimulatory receptors OX40 and CD137, which 
reinforce the costimulatory signal when engaged by OX40L and 4-1BBL stimulation. 
OX40 and 4-1BB signals act along the same pathways as CD28 but more downstream 
(Watts 2005). The signal from these “secondary” costimulatory receptors is therefore 
important to sustain the immune response and fully activate CTLs.  
Among costimulatory receptors also are some with a negative regulatory function, 
in that they can downregulate activation signals. Among these are CTLA-4, which 
has strong homology to CD28 but binds CD80 and CD86 with a higher affinity than 
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CD28 (Walunas et al. 1994), ICOS, upregulated with T cell activation (Hutloff et al. 
1999) and PD-1, expressed on CD8 T cells upon activation. PD-1 is also upregulated 
in chronic infections where it is correlated to the exhaustion state of CD8 T cells 
(Barber et al. 2006). 
  
Other costimulatory signals are delivered by cytokines released by the DCs. IL-2 
for example is involved in the terminal differentiation of CD8 T cells, the expression 
of cytotoxic molecules and sustains proliferation. IL-2 has a quantitative effect, as the 
in vitro culture of naïve CD8 T cells with higher concentration of IL-2 results in more 
efficient cytotoxic T cells compared with cells differentiated in lower IL-2 conditions 
(Pipkin et al. 2010).  
 
Once fully activated, CTLs undergo a rapid expansion phase during which the 
duplicating time is 6 hours (Badovinac et al. 2007). 
 
Figure 3: Schematic representation of DC maturation (1-2), priming of a CD8 T cell (2), 
maturation of CD8 T cell to CTL (3) and CTL cytotoxic function on target cells (3). 
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2.2.5 CD8 T cell activation 
 
Upon activation, CD8 T cells undergo a series of changes among which increased 
uptake of glucose, iron and amino acids, and a metabolic switch from oxidative 
phosphorylation to aerobic glycolysis (Michalek and Rathmell 2010). The cell 
metabolism needs to adapt to the increased fuel request to sustain high-level 
proliferation and gene expression (Jacobs et al. 2008). The glucose metabolism in 
particular is highly increased as glucose availability impacts CTL proliferative and 
effector capacity (Maciver et al. 2008). In the resting state, CD8 T cells are mainly 
fuelled by an oxidative metabolism, which depends on growth factors to be 
maintained. During activation, aerobic glycolysis is activated by TCR triggering and 
costimulation (Frauwirth et al. 2002) and glucose transporter Glu-1 is upregulated to 
provide for the enhanced fuel needs (Rathmell et al. 2000).  
The clustering, or aggregation, of TCR molecules and the conformational changes 
in the TCR/CD3 complex trigger intracellular signalling from the cytoplasmic tail of 
CD3. Studies by Chan and colleagues showed how CD3 signalling is dependent on 
phosphorylation of the ITAM tyrosines in the cytoplasmic tail, which is a recruitment 
site for intracellular signalling mediators like ZAP-70 and PTK (Chan et al. 1992). 
Signalling through the TCR therefore activates an intracellular pathway that goes via 
PLCγ, an increase in intracellular Ca2+ (Imboden and Stobo 1985) and activation of 
DAG, which in turns activates NF-kB. Other effects of TCR signalling are 
cytoskeleton remodelling and membrane fluidity increase. Actin reorganization is in 
fact key for the cell to be polarised when activated. The CD8 T cell needs to round up 
and accumulate F-actin (filamentous) at the immunological synapse (IS), the point of 
contact between the T cell and the APC (Burkhardt et al. 2008) where the MTOC 
(microtubular organisation centre) moves towards (Kupfer et al. 1987). Also, 
cytoskeleton reorganisation is needed for the formation of the distal pole, a negative 
regulator of this process, which sequesters away the negative regulators (Burkhardt et 
al. 2008).  
TCR stimulation activates downstream pathways that can stimulate upregulation of 
the translation machinery, thus inducing death receptors and cytotoxic molecule 
expression (Salmond et al. 2009). TCR stimulation also induces MAPK and mTOR 
(mammalian target of rapamycin) and immunosuppressive drug used for CCR5 
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downregulation in HIV kidney transplant patients (Heredia et al. 2003). MTOR, also 
activated by IL-2 signalling (Rao et al. 2010), controls cell growth proliferation and 
metabolism and it also seems to be implicated in CD8 memory differentiation (see 
below).  
TCR stimulation, through involvement of the small GTPase Ras proximity-1 (Rap-
1), also increases affinity of integrins for their ligand (Menasche et al. 2007). The 
most important integrins affected by activation are LFA-1 which binds ICAM 
(intercellular adhesion molecule-1) and VLA-4 (very late antigen-4) which binds 
VCAM (vascular cell adhesion molecule) and fibronectin. Activation of these 
integrins is critical for the migration of CTLs outside the LN to the peripheral tissues 
(as described below). 
Once fully activated, CTLs undergo a rapid expansion phase during which the 
duplicating time is 6 hours (Badovinac et al. 2007). Of note is that proliferating cells 
are much more responsive to cytokine stimuli than non-proliferating ones.  
 
 
2.2.6 Cytotoxic T cell granule content and killing function 
 
The main differences between naïve CD8 T cells and CTL are in the surface 
receptor composition and in the presence and content of the so-called cytotoxic 
granules in the cytoplasm. The granules are lysosomal structures containing cytotoxic 
enzymes whose intactness is highly regulated. Granules are maintained at a very acid 
pH and granzymes, which are basic, are bound to the acidic serglycin proteoglycan to 
keep them stable and inactive. The content of these granules, together with the 
expression of Fas ligand (FasL), is what allows CTLs to kill upon recognition of the 
pathogenic antigens in MHC-I context in periphery. 
 
2.2.6.1  Granzymes 
Granzymes (granule enzymes) are serine proteases homologous to trypsin, whose 
transcriptional regulation seems to be dependent on two stimuli: activation of the 
TCR and cytokine (of the γc family) signalling, mainly IL-21 and IL-15 (Chowdhury 
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and Lieberman 2008). IL-15 in fact induces expression of GrA, GrB, IFN-γ, and FasL 
in lymphocytes (Ye et al. 1996) and IL-21 specifically enhances GrB transcription. 
There are 7 different granzymes in humans and 10 in mice, independently activated 
and transcribed. These are coded in three main clusters both in humans and mice: 
GzmA, GzmK on chromosome 5 (humans) and 13 (mice), GzmB and GzmH 
(humans) or GzmC (mice) on chromosome 14 of each species, GzmM on 
chromosome 19 (humans) and 10 (mice). The GzmB gene cluster also includes 
cathepsin G and mast cell chymase. Moreover, this last cluster is encoding for GrD, 
E, F, G, L and N (Russell and Ley 2002). 
Analysis at the mRNA and protein level showed that the expression machinery for 
granzymes is regulated in a two-step process with upregulation of the production of 
mRNA first, equipping the cell with a quick response to further stimuli. This is 
verifiable for example in NKs which, once activated, show high levels of GrB mRNA 
but low protein levels (Fehniger et al. 2007). The same has been shown for memory 
cells (Kaech et al. 2002) and human pDCs. Granzymes are translated with a leading 
peptide: this directs them to the ER first, where this signalling peptide is cleaved off 
and a mannose-6-phospate (M6P) sequence is added with the scope of successively 
directing them to lysosomes in the form of inactive zymogens. Granules are, in fact, 
specialised secretory lysosomes. Once in the granules they are activated by removal 
of the N-terminal dipeptide by cathepsin C and stored bound to highly acidic 
molecules, the serglycin proteoglycans, until degranulation is triggered (Smyth and 
Trapani 1995). The serglycins form the electron dense core visible with electron 
microscopy and make sure the granules are densely packed (Grujic et al. 2005). 
Granzyme B and granzyme A are the most abundant in CTL granules both in humans 
and mice. 
 
Granzyme B is the most studied of these granzymes and is present in both humans 
and mice. In humans, but not in mice, GrB is expressed by pDCs upon activation 
(Rissoan et al. 2002) and also by mast cells (Hirst et al. 2001). GrB can induce rapid 
apoptosis of target cells in vitro in a direct or indirect way (Martin et al. 1996). The 
specificity of this enzyme is different in the two species. GrB has a specific target in 
cleaving after aspartic acid residues and in particular after the tetrapeptide IEFD in 
mouse and IEPD in humans. Therefore, the human GrB, but not the murine one, can 
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directly cleave the targets of key caspases, such as Bcl-2-interacting domain (Bid) a 
pro-apoptotic molecule, and the inhibitor of caspase-3-activated DNase (ICAD) 
(Cullen et al. 2007). The activation of these two molecules causes caspase 3-
dependent DNA fragmentation (Shresta et al. 1995) and the induction of permeability 
of the outer mitochondrial membrane (Talanian et al. 1997; Sutton et al. 2000). The 
specific cleaving site of GrB makes it particularly specific for pro-caspase-3, but 
other caspases are nonetheless targets of GrB, among which are caspases 2, 7, 8, 9, 
10. Other intracellular targets of both human and mouse GrB include apoptotic 
nucleases and PARP (poly-ADP-ribose polymerase) and DNA-PK (protein kinase). 
In antigen-specific CTLs, GrB upregulation is extremely quick, and protein levels can 
be detected as early as within 2 days of an immune response, according to data 
tracking GrB expression in CD8 T cells during an influenza infection model (Bannard 
et al. 2009; Bannard et al. 2009). Growing evidence suggests that GrB can be 
expressed in other cell types in presence or absence of perforin and can have an 
extracellular role. GrB expressed by T regulatory cells has a perforin-dependent role 
in regulating the immune response (Gondek et al. 2005). Also, GrB has been shown 
to cleave vitronectin, a protein that allows extracellular matrix organisation (Buzza et 
al. 2005) and cartilage proteoglycans during inflammation and infection. This 
function could facilitate lymphocyte migration and cause tissue destruction and 
anchorage-dependent death. In humans, GrB levels are detectable and considerably 
higher than normal in serum during inflammation, for example in patients with HIV 
infection or rheumatoid arthritis, and bacteremia (Lauw et al. 2000). In the secreted 
form, GrB is inhibited by trypsin inhibitors antithrombin III and α-2-microglobulin 
(Spaeny-Dekking et al. 2000), while the cytoplasmic form is inhibited by serine 
protease inhibitor 6 (Spi6) in mice (Zhang et al. 2004). In some cases, the increase of 
soluble GrB is accompanied by the increase in soluble (released) serpin inhibitors 
although this is believed to be connected to release from damaged cells rather than 
secretion, as serpins do not have leading sequences for exocytosis (Rowshani et al. 
2005). GrB KO mice can control and clear viral infections but have a delay in the 
induction of apoptosis, specifically DNA fragmentation  (Zajac et al. 2003).  
The second more abundant granzyme in human and mouse is granzyme A. This 
granzyme is a triptase with a serine protease activity and it is regulated, in the same 
way as GrB, at a post-translational and activation level (Kummer et al. 1996). It has a 
different specificity from GrB therefore activating different downstream pathways. Its 
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structure is also quite different as it dimerizes to exert its cleaving function. GrA also 
has a well known extracellular proinflammatory activity as it cleaves pro-IL-1β 
(Irmler et al. 1995; Young et al. 2000). Among other substrates is SET, a reticulum-
associated oxidative stress response complex. SET is part of a DNA repair complex 
and when cleaved it allows for nucleases to be released and cut DNA into fragments 
(Fan et al. 2003). The dynamics of apoptosis induced by GrA are slower than for 
GrB. 
Studies with mice lacking both GrA and GrB have shown how other granzymes can 
compensate for lack of these two enzymes. Also, the phenotype and development of 
these mice are normal. Viral infections are cleared normally, although with a slightly 
different dynamic of clearance and apoptosis induced by GrA/GrB KO CTL is time-
wise and morphologically different from a WT (Waterhouse et al. 2006; Hoves et al. 
2011; Trapani 2011). 
 
2.2.6.2 Perforin 
Also released from the granules is perforin, a protein thought to be responsible for 
the delivery of granzymes to the target cell. Perforin (pfn) is a highly conserved pore-
forming protein sharing the structure of complement. It is stored in the granules 
complexed with reticulin, a calcium-storage protein which contains a KDEL sequence 
for ER retention in its C-terminal. Reticulin is also released upon degranulation and 
the rise in Ca
2+
 concentration permits a conformational change that unlocks perforin 
free (Andrin et al. 1998). Initial studies predicted a model of pore-forming function 
for perforin, hence the name, that would allow GrB to enter the target cell, but these 
were then challenged by the discovery that suboptimal concentration of perforin do 
not create pores in the membrane but still allow GrB entry (Metkar et al. 2002).  
The role of this protein and the exact mechanism through which it works has been 
widely discussed and a consensus has still not been reached. Some models propose 
that perforin polymerizes in presence of Ca
2+
 creating temporary permeable holes in 
the membrane to allow the passage of granzyme and ions (Liu et al. 1995). Other 
groups have reported the ability of GrB to enter the cells in absence of perforin 
through a mannose-6-phospate receptor (Motyka et al. 2000) or through Ca2
+
 
induced-cell repair mechanisms (Keefe et al. 2005). Despite controversial data, 
perforin is considered to be necessary for the cytolytic activity. Also unclear is the 
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mechanism that activates granzymes once the protein has reached the cytosolic 
compartment of the target cell: some evidence suggests a role for perforin in keeping 
the granzyme inactive until it reaches its target (Voskoboinik and Trapani 2006). 
Perforin-KO mice are severely immunodeficient and, during infection, a high 
accumulation of antigen-specific CD8 T cells is seen. CTLs in pfn KO mice are 
unable to perform cytotoxic activities and to deliver granzymes to the target cell 
(Kagi et al. 1996; Matloubian et al. 1999). Ashton-Rickardt’s lab demonstrated in 
2001 that pharmacological inhibition of pfn could improve survival of CTLs 
(Opferman et al. 2001). 
 
2.2.6.3 Granulysin 
Granulysin is a cationic protein that belongs to the saposin-like family of lipid-
binding proteins. It is expressed in two forms: a 15KDa that is constitutively secreted, 
and a 9KDa form that is stored and released from the granules together with 
granzymes and perforin. It has lytic properties and has been reported to lyse Gram 
positive bacteria and fungi (Stenger et al. 1998). For this reason, portions of this 
protein are being studied as drugs with antibiotic application (Krensky and 
Clayberger 2009). It seems to enter the target cell through cationic interaction with 
the membrane lipids. It triggers the intrinsic apoptotic pathway through release of the 
CytC from the mitochondria (Kaspar et al. 2001). It has also been shown to act as a 
chemoattractant for mature DCs, human monocytes, NK cells and T cells (Deng et al. 
2005). However, granulysin is not expressed in mice. 
 
 
 
2.2.7 Egress from lymphoid organs and migration of effector 
cytotoxic T cells to the site of infection 
 
Once undergone proliferation antigen-specific effector cells need to leave the LN 
(or spleen) to reach the tissue invaded by the pathogen and kill the infected cells. 
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Egress from the LN is controlled by downregulation of certain receptors and 
upregulation of others.  
 
During viral infections, local cytokines and chemokines are produced both by the 
innate and the incoming adaptive arms of the immune system: they are needed to 
elicit, direct and sustain the T cell response in loco. Local inflammation in particular 
will create two waves of chemokines at the site of viral infection (Figure 5). A first 
wave is represented by chemokines expressed by cells of the innate system upon TLR 
stimulation, like Type I interferons (IFN-α/β) attracting NK and CD4 T cells. A 
second wave is started by these NKs and CD4 T cells, which induce release of MCP-
1 from macrophages and MIP-1α and IFN-γ from T cells. Release of IFN-γ from local 
DCs induces a strong influx of antigen-specific CTLs to the infection site, resulting in 
a stronger cytolytic response (Nansen et al. 2000). CD8 T cell production of 
chemokines like MIP-1α stimulates macrophage production of other chemokines like 
MCP-1. The cytokines RANTES, MIP-1α and β, IP-10 and MCP-1 in particular 
appear to dominate during viral infections independent of virus type, organ site or 
phase of infection (Figure 4). As a consequence to the locally released chemokines, T 
cells that migrate to the site of infection express CCR2, CCR5 and CXCR3, binding 
the above ligands in a redundant but regulated way (Figure 5).  
Upregulated CXCR3, a chemokine receptor, leads the cell journey to the peripheral 
tissues (Groom and Luster 2011). Ligands for this receptor (Figure 5) are the 
chemokines CXCL9 (also known as MIG: monokine induced by γ interferon), 
CXCL10 (or IP-10: interferon-induced protein of 10 kDa), CXCL11 (or I-TAC: 
interferon-inducible T cell α chemoattractant) which induce migration of activated T 
cells in vitro and in vivo. Regulation of CXCR3 expression by t-bet has linked this 
transcription factor to CTL effector function activation. 
The role of CXCR3 in driving migration and differentiation of effector CD8 T cells 
is reviewed by Groom and Luster (Groom and Luster 2011), who explain that t-bet-
deficient mice experience a defect in CD8 T cell migration due to absence of CXCR3. 
The ligands for CXCR3, CXCL9 and CXCL10, are induced in a TNF-dependent way 
in the lumen of high endothelial venules (HEV) in LN and also in a type II interferon-
dependent way, locally at the site of inflammation (Groom and Luster 2011). The 
source of these chemokines is mainly peripheral DCs (Figure 5). These ligands can 
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also bind GAG (glucosamminoglycan)-containing molecules on the extracellular 
matrix thus prolonging their half life and activity in loco and maximizing the 
chemoattractant function for activated CD8 T cells. 
 
 
 
 
Figure 4: Chemokines redundancy in viral infection: 
chemokines and their receptors (Thomsen et al. 2003). 
 
 
Also upregulated in activated CD8 T cells are VLA-4 and LFA-1 (Issekutz and 
Issekutz 2002), while CCR7 and L-selectin, not required for migration to the inflamed 
tissues, are downregulated (Thomsen et al. 2003). During an infection about 90% of 
the CD8 T cells will upregulate LFA-1 and VLA-1, but only a small fraction of these 
will be antigen-specific. Thomsen and colleagues demonstrated that I-CAM and V-
CAM, receptors for LFA-1 and VLA-4 respectively, are required for migration of 
effector CD8 T cells to the site of inflammation as when these are knocked-down the 
migration is impaired. They also studied the specific role of selectins and integrins in 
a viral model of infection and verified that, while selectins are important, their 
absence, especially of E- and P-selectins expressed by endothelial cells, does not 
interfere with the immune response to a big extent. Also, L-selectin, which is not 
expressed by early effector cells, is later gradually re-upregulated in memory cells. 
This is correlated, among other things, to the capacity of these cells to re-access the 
LN, so that the number of memory cells that can access LN slowly increases with 
time (Thomsen et al. 2003). 
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Figure 5: Local and systemic induction of chemokines at the site 
of infection (Groom and Luster 2011). 
 
Chemokines released at the infection site are not the only players in the organisation 
of lymphocyte migration from the secondary lymphoid organs (SLOs): locally, 
lymphocyte retention or egress is regulated by S1P levels and by the lipid G protein-
coupled S1P receptor 1 (S1P1) expressed on CD8 T cells. At the very beginning of an 
infection, naïve T cells need to be kept in the LN or spleen for longer to increase their 
chances to encounter mature DCs. S1P1 binds S1P, which is released in the blood and 
lymph by lymphatic endothelial cells but is present at low concentrations in the 
lymphatic tissues (Pappu et al. 2007). S1P1 is downregulated during CD8 T cell 
migration in the blood in the naïve status and it is upregulated shortly after entrance 
in the SLOs, possibly by the local concentration of its ligand S1P (Lo et al. 2005). 
Upregulation of CD69, driven by interferon signaling, is also thought to be 
downregulating S1P1 in T cells during the early stages of the immune response, so to 
release CTL from the SLOs (Shiow et al. 2006; Bankovich et al. 2010). This process 
is also associated with the upregulation of IL-6 which induces increased expression of 
ICAM-1 and increased presentation of CCL21 on the HEV. These molecules induce a 
temporary decrease of the egress of T cells from LN and a transient increase in the 
homing. The process is called LN shutdown and it is aimed at facilitating T cell 
priming by prolonging naïve cells persistence in the LN stroma. A downregulation of 
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the homeostatic chemokine CCL21 and its receptor follows LN shutdown around day 
3 p.i., according to Mueller and colleague (Mueller et al. 2007). CCL21 and IL-6 thus 
work in concert with S1P1 regulation on the T effector cells and the local 
concentration of S1P to allow egress of CTLs from the LN.  
 
 
2.2.8 Effector function and killing pathways 
 
Once mature, the CTL leaves the lymphoid tissue through the efferent lymphatic 
vessel and enters the blood stream in order to reach the infected tissue. The cell will 
then extravasate from the blood vessels to the infected tissue following chemotactic 
and inflammatory signals. Once in the damaged tissue, identification and binding of 
the target cell is rapid and followed by a polarization of the T cell and triggering of 
degranulation.  
The recognition of the target cell happens via TCR-pMHC binding: the TCR of the 
CD8 T cell recognises a peptide in a MHC-I context on the target cell and the binding 
leads to the formation of an IS. Studies showed that the localisation of the IS between 
the effector and the target cell does not always coincide with that of the TCR-MHC 
complex, thus suggesting that mobility of the surface molecules is increased upon 
ligation of the TCR on a CD8 T cell (Favier et al. 2001). A single CTL can interact 
and kill several target cells, while surviving its own deadly weapons thanks to 
expression of Spi6 at cytoplasmic level. Once activated, in fact, the production of 
cytotoxic molecules is sustained and continuous, to the extent that granzymes, other 
than re-fill new granules, can be directly secreted in a constitutive, granule-
independent way. This is proven by the absence of the granule-leading sequence in 
these granzymes (Isaaz et al. 1995). As mentioned before, the highly targeted killing 
mechanism exerted through apoptosis can at this point be induced in two ways: 
release of granule-contained cytotoxic molecules and binding of Fas-FasL. 
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2.2.8.1 Granule-dependent secretory pathway 
Upon recognition of the cognate antigen in MHC-I context, microtubule structures 
form to allow the movement of the granules towards the IS, where the cytotoxic 
enzymes will be released (Kupfer et al. 1983). The granules then align along the 
microtubules and move towards the IS (Bossi and Griffiths 2005). The granule 
membrane fuses with the CTL plasma membrane, specifically releasing its content in 
the IS: this process is called degranulation. 
During degranulation, which is targeted and localised, the key players are 
granzymes and perforin. Once a granule fuses with the external membrane of the 
CTL, its content is released into the extracellular space between the two cells and 
perforin allows the granzymes to enter the target cell. As described above, the exact 
mechanism through which perforin mediates the entry of GrB into the target cells is 
still not clear. Granzymes are thought to dissociate from serglycin once in the 
intracellular space (Raja et al. 2005), but several ways have been proposed for entry 
into the cells, among which are association with lipids of the target cell plasma 
membrane due to cationic interactions (Bird et al. 2005), use of receptors and 
endocytosis due to perforin-mediated change in Ca
2+
 concentration endocytosis 
(Keefe et al. 2005). 
The first hypothesis about the way pfn mediates GrB entry described membrane 
damage in the target cells, but this was contradicted by Tschopp’s group which 
described formation of pores creating physical access for GrB in presence of pfn 
(Duke et al. 1989). A later work by Metkar showed that GrB, when released from the 
granules, is associated to serglycin to stabilise it (Metkar et al. 2002). These results 
opened the way to studies describing how serglycin associates through its negative 
charge to glucosamminoglycans on the membrane of the target cell thus having a 
fundamental role in GrB entry (Raja et al. 2005). Other groups showed how the 
uptake of GrB could be mediated by a M6P protein, CI-MSP (Motyka et al. 2000): 
the role of this protein as a receptor for GrB was confuted when Trapani’s group 
showed that CI-MPR KO mice were still susceptible to CTL-mediated killing 
(Trapani et al. 2003). 
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Figure 6: GrB-mediated apoptosis activation. The main targets of 
human GrB are shown (Cullen and Martin 2008). 
 
Once GrB reaches the cytosol of the target cell, it induces apoptosis mainly through 
the activation of the caspase cascade which causes hydrolysis of cytoplasmic and 
nuclear proteins leading ultimately to a contained disassembly of the cell, apoptosis 
(Figure 6). Capases are proteases present in the cytoplasm of a cell in an inactive 
form (Alnemri et al. 1996) and able to cleave targets which induce cytokine release, 
stress signals induction and apoptosis effector molecules. GrB can activate caspases 
directly through proteolysis of the inactive form, or through induction of permeability 
of the outer mitochondrial membrane. This in turn induces the release of cytochrome 
C into the cytosol and suppression of transmembrane potential and targeting of the 
pro-apoptotic molecule Bid (Talanian et al. 1997; Sutton et al. 2000). Activation of 
pro-caspase 3 in particular induces caspase 3-dependent DNA fragmentation (Shresta 
et al. 1995) and cleavage of Bid, a member of the pro-apoptotic family Bcl-2 (Sutton 
et al. 2000). In humans, as seen in chapter 2.2.6.1, GrB activates the caspase pathway 
through cleavage and activation of caspase-3, but it can also indirectly activate it 
through cleavage of caspase targets. Another target of the human but not the mouse 
GrB is ICAD, an inhibitor of CAD DNase (caspase-activated DNase). Proteolytic 
cleavage of ICAD induces CAD release, which mediates the internucleosomal 
degradation of DNA which is one of the hallmarks of CTL-induced apoptosis. CTLs 
protect themselves against the action of GrB thanks to an intracellular serine protease 
inhibitor called PI-9 in humans and Spi6 in mice. This is upregulated with CTL 
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maturation and it inhibits GrB in the cytosol by binding it irreversibly in an SDS-
stable complex in Western blot (Phillips et al. 2004). This protein and its role will be 
further described below (see Chapter 2.6).  
Granzyme A can enter the mitochondria, where it cleaves a component of the 
electron transport chain complex-I, thus stimulating a caspase-independent apoptosis 
program (Martinvalet et al. 2005). Once the mitochondrial redox function is damaged, 
the oxidative stress response complex (SET), itself a target of GrA, is activated. 
These mediators induce DNA fragmentation, and the fragments, much larger than 
those created by GrB, are released into cytoplasm (Beresford et al. 2001). The process 
is delayed compared to GrB-induced DNA fragmentation, working as a sort of back-
up.  
Among the other granzymes is granzyme C in mouse, homologous to granzyme H 
in human. Both these granzymes have chymotryptic activities that induce caspase-
dependent and CAD-independent death when released by NK cells (Hou et al. 2008). 
Two viral substrates have been identified, but no physiological ones: adenoviral 
proteins DBP and the previously described GrB inhibitor (Andrade et al. 2007).  
Granzyme Z is also a tryptase, it is encoded downstream of GrA and it is expressed 
in low amounts. GrK causes a caspase-independent death which is perforin-dependent 
and connected to loss of mitochondrial function, but this is inhibited in cells 
overexpressing bcl-2 (MacDonald et al. 1999) 
Granzyme M is different from the other granzymes and it is, in fact, more closely 
homologous to a neutrophil protease. It is mostly expressed in NK cells and γδ T 
cells. Its role in apoptosis triggering is still not clear. More studies are needed to 
clarify how it engages apoptotic pathways and to further prove its role in inhibiting 
PI-9, which has been shown in vitro but not confirmed in vivo (Mahrus et al. 2004). 
 
2.2.8.2 The engagement of the death receptors 
CTL can mediate apoptosis, also called programmed cell death (PCD), of infected 
and cancer cells in two ways. The first is through release of cytotoxic activity via 
degranulation, while the second is exerted through the engagement of the death 
receptors Fas (or CD95) on the CTL, and Fas ligand (FasL) on the target cell, 
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belonging to the tumour necrosis factor (TNF) receptor superfamily. Upon binding 
the interaction of the two receptors triggers trimerization of the Fas receptor which 
recruits caspase-8 and activates the caspase cascade (Berke 1995) and ultimately 
apoptosis via DNA fragmentation.  
 
 
When pMHC-TCR binding occurs in the context of an infection, degranulation is 
the major death pathway activated. Released granzymes enter the target cell, the 
action of GrB and GrA intracellularly is predominant and it induces different 
apoptosis pathways which include caspase activation and mitochondrial damage, with 
different dynamics. Fas-FasL triggering is involved in regulation of lymphocyte 
homeostasis. Apoptotic cells are then cleared by macrophages of other phagocytes 
without adding to the inflammatory status of the organism, which is why this pathway 
is so important. The granule secretory pathway is the one on which this project 
focuses as it is the main mechanism used by CTL to eliminate LCMV, the viral model 
of choice. 
 
 
 
2.2.9 Clonal contraction and memory formation 
 
In acute infection, following the elimination of a pathogen, antigen-specific CTLs 
represent a big fraction of the total T-cell repertoire. When a CD8 T cell is properly 
primed for activation, a reprogramming of its metabolism, transcriptome and protein 
expression is triggered. The reprogramming results in maturation to a fully effective 
CTL and proliferation occurs at a very high rate making these cells the predominant 
population in the T-cell repertoire. Studies from Badovinac show that a single CD8 T 
cell can undergo up to 19 cell divisions, which can bring the number of daughter cells 
close to 500,000: the mean division time is estimated to be 4-6hrs (Badovinac and 
Harty 2007). Once the pathogen is cleared, the removal of CD8 T effector cells starts: 
this phase is called contraction phase and it is characterised by high levels of 
apoptosis. About 90% of the effector CD8 T cells have to be eliminated to restore T-
cell homeostasis, while a little fraction remains to form the memory pool (Figure 7). 
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The mechanism through which the apoptosis program is triggered in these cells has 
not been uncovered, but hypotheses suggest that pathogen levels and DC feedback on 
activation status are responsible for activating apoptotic programs and the end of the 
expansion phase.  
 
 
Figure 7: CD8 primary and secondary responses dynamics. After the 
peak of the response, a contraction phase occurs, resulting in the 
formation of memory The same is repeated at each subsequent re-
invasion by the same pathogen (Harty and Badovinac 2008). 
 
 
Among the first factors involved in the triggering of contraction are the decrease in 
antigen levels and the lack of inflammatory signals and growth factors. As seen 
earlier, the environment influences the maintenance of the response, both by 
furnishing growth factors and regulating the intake of glucose. When these are 
lacking, or decline, survival of the CTLs is at risk. Recent studies proved that addition 
of cytokines like IL-15 (Yajima et al. 2006) and IL-2 (Blattman et al. 2003) during 
the contraction phase could rescue effector cells from apoptosis.  
In this context it is interesting to determine whether contraction is actively regulated 
during the expansion phase, or the fate of each cell is pre-determined. Prlic and Bevan 
showed that effector T cell fate is not regulated by competition for survival and 
growth factors: they demonstrated that CTL function is not affected by this 
competition and by higher numbers of effector cells (Prlic and Bevan 2008). Another 
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interesting and controversial result came from Harty’s lab, who showed that the 
amount of antigen per se does not seem to influence the initiation of the contraction 
phase or its extension (Badovinac et al. 2002).  
Mounting evidence suggests that anti-apoptotic molecules are particularly involved 
in shaping the fate of the effector cells during the contraction phase. Members of the 
Bcl family seem to be particularly important in this process. Bim, IL-7R, and IFN-γ 
all promote contraction after infection by non-cytololytic viruses like LCMV (Haring 
et al. 2005). Studies on cell death during contraction demonstrated that caspase-
independent apoptosis is triggered (Nussbaum and Whitton 2004), which cannot be 
rescued by overexpression of antiapoptotic molecules like bcl-2 or bcl-xl (Petschner 
et al. 1998). Bcl-2 is downregulated at the peak of response, initiating apoptotic 
events but it acts in concert with Bim: a deficit in contraction and higher levels of 
memory are observed when Bim is removed (Pellegrini et al. 2003). The lack of Bim 
might be responsible for rescuing the terminally differentiated effector cells (Prlic and 
Bevan 2008), but cells formed in these conditions are not good memory cells in that 
they lack the ability to undergo basal proliferation and can therefore survive only for 
a limited time after antigen clearance (Wojciechowski et al. 2006). 
Among cytokines contributing to the contraction phase and to the shaping of the 
memory pool, IL-7 seems to favour the skewing of the pool towards memory. 
Absence of IL-7Rα, one of the two subunit of IL-7 receptor, results in lack of 
memory, but IL-7 absence only results in impaired memory if the IL-7Rα is 
stimulated (Klonowski et al. 2006). Forced IL-7Rα expression on a CD8 T cell subset 
normally expressing low levels of this did not skew the cell population towards 
becoming memory (Hand et al. 2007). Also, IL-12 seems to influence memory 
formation as its absence allows the creation of a larger memory pool (Pearce and 
Shen 2007). The lack of type-I IFN receptors also produces a deficient memory 
compartment and leads to defective clearance. Lack of type-I IFN can also induce 
chronic infection in LCMV-infected mice according to the results published by Hand 
and colleagues (Hand et al. 2007).  
Fundamental in the transition between memory precursor and memory cell is also 
the level of IL-12. In absence of IL-12, more memory IL7Rαhi cells and fewer T 
effector cells are developed. Also, IL-12 inhibits IL-2 production and IL-7Rα 
expression. IL-12 acts on CD8 T cells directly through the IL-12Ra and signals 
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intracellularly towards the effector destiny (Kieper et al. 2001; Pearce and Shen 
2007). 
 
Transcription factors are also involved in shaping the contraction phase and memory 
formation. As briefly mentioned above, involvement of mTOR in the commitment of 
cells towards a memory phenotype has been described (Araki et al. 2009). Studies in 
LCMV-infected mice showed that administration of rapamycin, inhibitor of the 
mTORC1 (the complex which signals downstream from mTOR), induces a higher 
number and better “quality” of memory cells. The study showed that low doses of 
rapamycin administered at day 0-8 p.i. resulted in increased numbers of memory cells 
due to decreased contraction, while administration during the contraction phase (day 
8-30 p.i.) resulted in accelerated transition from effector to memory and in a better 
quality in terms of survival and effector function of the memory pool. The same paper 
showed that mTOR action is cell intrinsic, despite rapamycin having an effect on 
other cell types, like DC (Araki et al. 2009). One explanation as to why there is such 
difference depending on the timing of rapamycin administration might come from the 
work of Thomson and colleagues, who showed that mTOR seems to form complexes 
with different proteins/regulators, thus having different function depending on the cell 
phase (Thomson et al. 2009). T-bet involvement in memory development was also 
observed. Expression of t-bet is induced by IL-12 in CD8 T cells and in turn induces 
the expression of CD25 and KLRG1, driving the cell to a terminally differentiated 
status. In a study by Chang and colleagues the correlation between higher t-bet levels 
and a more terminally differentiated memory phenotype, effector-like, was 
demonstrated, while a lower amount of t-bet correlated with a less differentiated 
memory phenotype. The observation that antigen-specific stimulated CD8 T cells 
from IL-2ra
-/- 
mice (IL-2RA is also called CD25) can differentiate into memory 
precursors to a higher frequency than control cells supports the results, as CD25 is 
linked to terminal differentiation (Chang et al. 2011).  
Chemokines and their receptors are also involved in memory formation and clonal 
contraction. A recent study conducted by Woodland’s lab has shown how CXCR3 
and CCR5 have a role in determining the beginning of the contraction phase and 
memory generation (Kohlmeier et al. 2011).  They showed that CCR5 KO and 
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CXCR3 KO mice have a lower contraction and higher levels of memory cells after 
LCMV infection.  
Notably, several molecules, including cytokines, chemokines, transcription factors 
and surface receptors have been associated with contraction of the primary response 
and memory development. The mechanism underlying this high apoptotic rate is still 
not clear, but it is likely to require a combination of signals and the interaction of 
regulatory molecules. This need for multiple signals, including cytokines like IL-12, 
IFN-γ and activation of BIM, mirrors the three signals required for CD8 T cell 
activation, pMHC, costimulation and inflammation. This suggests that three or more 
signals might also be required for contraction and memory formation.  
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2.3 CD8 T memory cells 
 
 
Once the infection is cleared, 90-95% of the antigen-specific CTLs die through 
PCD: this phase is called contraction (Sprent and Surh 2002). The 5-10% that remains 
will form a pool of long-lasting memory cells: resting mature specialized CD8 T cells 
that survive in absence of antigenic stimulation (Lau et al. 1994), have a basal 
proliferation status and can easily and quickly re-activate effector functions (Barber et 
al. 2003) upon re-encounter with the antigen (Whitmire et al. 2008). These memory 
cells also have less stringent requirement for costimulatory signals compared to naïve 
CD8 T cells (Masson et al. 2008). Antigen-specific memory cells are in much higher 
frequencies than the initial antigen-specific pool. 
 
 
2.3.1 How is the CD8 T cell memory pool formed? 
 
The third phase of a CD8 T cell response, after proliferation and contraction, 
involves the appearance of memory cells. No agreement has been reached to date on a 
CD8 memory development model. How a heterogeneous population of effector and 
memory cells can descend from a single naïve CD8 T cell, whether the fate of an 
effector cell is decided during the effector phase or during the contraction phase, 
whether a memory cell has to go through the effector phase at all: all these questions 
have several answers based on the results obtained with various models. A study 
where reporter genes were inserted after the promoter of GrB or IFNγ showed how 
memory cells can arise from cells whose transcription path for GrB and IFNγ has 
been activated (Bannard et al. 2009). Other studies showed how memory cells can 
develop from cells which have not gone through an effector phase (Manjunath et al. 
2001). A definite answer has still not been found. 
A number of factors influence memory development. One of the main factors is the 
interplay of the 3 signals received by a CD8 naïve T cell during priming: MHC-
peptide signalling, costimulation and inflammatory signals. Among other factors 
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influencing memory development are the number of antigen-specific precursor cells, 
the antigen load, the inflammation severity and duration, the extent of CD4 help, the 
nature of the pathogen and the localisation of the infection.  
Some studies support a linear model, where memory cells are the next 
developmental phase of effector cells. Some others support an asymmetrical model, 
where the origin of memory cells is dictated during DC priming and during the first, 
asymmetrical, division generating to two different pools of cells which are the 
effector and the memory cells. Lately, much attention has been given to the role of 
inflammation during the development of effector responses, with data supporting the 
theory that CTLs follow a default pathway regulated by the levels of inflammation. 
Three main models have been proposed: 
A) The first model, called of “Linear differentiation” was proposed in 1999 by 
Ashton-Rickardt. He demonstrated that a population of fully differentiated CD8 
effector T cells that had undergone 5 divisions in vitro could differentiate into 
memory cells (Opferman et al. 1999). This model was broadened in 2003 by Ahmed 
who suggested that when a naive CD8 T cell is primed it can differentiate into one of 
two subsets of memory cells with different characteristics and expressing different 
markers, like CCR7 and CD62L. The ones that have low replicative capacity and are 
CD62L
lo
 CCR7
-
 are called effector memory (TEM) cells: they will survive at the end 
of the contraction phase and, later on, will develop into CD62
hi
 central memory, TCM 
(Wherry et al. 2003). The main difference between these two subsets is the anatomic 
location: CD62L
hi
 cells reside in the secondary lymphoid organs while CD62L
lo
 
reside in peripheral tissues and spleen due to the lack of expression of the homing 
receptor to the lymphoid tissue. These two populations also differ in terms of 
function; the first being able to quickly proliferate and the second being able to 
quickly exert effector functions instead. A variant of this model is the self-renewal 
model (Ahmed et al. 2009) that describes the possibility that effector cells can still 
revert to the TEM state after having developed into TCM. One of the key assumptions 
of this model is that, since effector CD8 T cells are very susceptible to apoptosis, 
some anti-apoptotic molecule must be switched on in the cells that progress to being 
memory cells (Kaech et al. 2002).  
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B) A second model, termed “Fixed lineage model” (Figure 8) accounts for the 
concomitant presence at early stages of the immune response of memory-destined and 
terminally-differentiated effector cells. This model maintains early commitment of 
the activated CD8 T cell into an effector or memory cell, like an early fate decision 
(Sallusto and Lanzavecchia 2001). This theory accounts for memory cells developing 
directly from naïve CD8 T cells, without going through the effector phase. The 
existence of a precursor subset, nonetheless, does not imply that the determination of 
the memory fate is cell-autonomous; this might depend on APC costimulatory signals 
or antigen load or inflammatory environment. It has in fact been shown that a weakly 
inflammatory environment can lead to the formation of a bigger-than-average 
memory cell pool in relation to the levels of effector cells at the peak (Badovinac and 
Harty 2007). A further widening of this model is represented by the asymmetrical 
model. This states that a primed naive CD8 T cell is directed by DCs to divide 
asymmetrically into two daughter cells with different properties: one will retain the 
effector machinery, which means expression of GrB, IFN-γ and CD25 and will be 
CD62L
lo
, and the other will be CD62L
hi
 and have no effector functions (Beuneu et al. 
2010). In this model the contribution of DCs to the formation of memory is 
fundamental.  
 
 
Figure 8: Memory development models: a) linear and b) fixed lineage 
model (Sallusto and Lanzavecchia 2001). 
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C) Having seen a high level of heterogeneity in in vitro experiments showing 
memory cell development from both effector and naïve cells (Manjunath et al. 2001), 
Ahmed and Gray formulated the “Decreasing potential model” (Figure 9) in an 
attempt to explain this discrepancy. The theory describes TCR stimulation as the 
determinant for T cell fate: when TCR stimulation is strong, the CD8 T cell will 
develop into an effector cell with short survival and poor proliferative capacity; 
reduced TCR stimulation would allow instead for the development of a cell with 
memory characteristics of long survival and proliferation potential (Ahmed and Gray 
1996). This model is challenged by the finding that even when very high antigen 
stimulation occurs, a memory pool is nonetheless created (Prlic et al. 2006). 
Badovinac’s study demonstrated that long-term exposure to antigen shapes the 
creation of a memory pool in the sense of generating an early subset of CD127
+
 (IL-
7Rα) and CD62L+ (L-selectin) cells but with no effect on its size, compared to short-
term exposure (Badovinac and Harty 2007). The role of antigen in influencing 
memory development was also studied by Sakar and colleagues who showed an 
inverse correlation between antigen and memory (Sarkar et al. 2008). Another version 
of this theory is the Progressive differentiation (Figure 9), proposed by Lanzavecchia 
and Sallusto, which considers the total of the stimulation signal strength received by a 
CD8 T cell during its life as determining for the fate of the cell. According to this 
model, CD8 T cells progress into differentiation stages due to the accumulation of 
activation signals (Lanzavecchia and Sallusto 2002). Both models predicts that an 
intermediate activation signal will drive the CD8 T cell to memory differentiation, 
while a too strong signal will induce terminally differentiated effector cells destined 
to die.  
 
 
Figure 9: Decreasing potential (A) and progressive differentiation models (B). TD: 
terminally differentiated cell; M: memory cell (Gerlach et al. 2011). 
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Of increasing importance is the role of inflammation in controlling the balance 
between effector and memory cells. This emerged from experiments in which the 
ratio between memory cells and effector cells was measured under controlled 
conditions. Lower inflammatory conditions were seen to induce shorter effector peaks 
and earlier memory cell development. Studies conducted by Badovinac in 2005 also 
demonstrated that reducing the inflammation during an infection accelerates the 
transition of effector into memory for CD8 responses (Badovinac et al. 2005). A 
follow-up paper showed that inflammatory signals at different stages of the CD8 
response can shape memory formation and influence its acceleration or slowing 
down. Inflammatory cytokines like IL-12 and IFN-γ, when present at day 2 p.i. but 
not before, can favour the generation of terminally differentiated effector cells, thus 
reducing the formation of the memory pool. In absence of high levels of 
inflammation, homeostatic cytokines like IL-15 and IL-7 drive the formation of 
memory (Sandau et al. 2010). The hypothesis states that CD8 T cells follow a default 
pathway of memory differentiation unless they receive inflammatory stimuli: when 
inflammatory signals are conveyed, the effector phase is sustained and maintained for 
longer. This is consistent with previous work showing that effector CTLs primed in a 
highly inflammatory milieu acquire a terminally differentiated effector phenotype and 
are short-lived, while in absence of inflammatory signals these cells become anergic 
or die (Joshi et al. 2007). In particular, exposure to inflammatory cytokines like IL-12 
and IL-4 induce the transcription factors T-bet and blimp-1 which in turn enhance 
expression of KLRG-1 and CD25, molecules highly expressed on terminally 
differentiated effector cells, see Chapter 2.3.2 (Kalia et al. 2010). T-bet is therefore 
involved in differentiation of CD8 T cells to the effector state.  
 
When thinking about how memory is formed, from these main models emerges an 
important issue regarding when this memory fate is written into the antigen-specific 
CD8 cell baggage. Three models, describing fate determination before the first 
division (or at division 0, D0), during the first division (D1), or after the first division 
(D1+) are illustrated in Figure 10.  
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Figure 10: Memory fate decision models. Three models currently 
account for memory fate determination before the first division (D0), 
during the first division (D1) or after it (D1+). TD is terminal 
differentiation and M is memory cell (Gerlach et al. 2011). 
 
The D0 model predicts that different signals can give rise to one specific subset 
(Figure 10, A), and this can be due to the fact that naïve CD8 T cells are intrinsically 
different and thus harbour the possibility of developing in only one subset (Figure 10, 
B). The hypothesis is that CD8 T cell destiny could be shaped by the combination of 
several signals received before the first cell division. Indirect evidence supporting this 
model,suggested by Farber (Farber 2000), comes from studies where antigen 
availability was controlled both in vitro and in vivo showing a correlation between the 
levels of antigen and the size of the memory pool (Prlic et al. 2006). Direct evidence 
can be found instead in Gerlach’s work which, with a very elegant technique of gene 
barcoding, allowed the identification of both effector and memory cells deriving from 
the same naïve CD8 T cell after LM infection (Gerlach et al. 2010). This evidence is 
quite compelling and it is reinforced by further gene profiling studies of memory cells 
(Turner et al. 2003). In another very elegant experiment the YFP reporter signal was 
fused to the IFNγ gene and its expression measured. Different intensity in the YFP 
was seen in antigen-specific T cells before the first division but after contact with a 
DC. The same study reported stability of YFP through successive divisions of each 
single T cell, and dependence on the signal intensity from the antigen-loaded MHC-I 
on the DC. 
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For the model predicting fate commitment at D1, during the first division, evidence 
comes from Reiner’s lab where activated but not dividing cells were isolated after 
LM infection in vivo and analysed with confocal microscopy revealing polarised 
expression of different molecules including CD8, LFA-2, IFN-γR (Chang et al. 
2007). This is in line with the common knowledge that during mitosis the intracellular 
pericentriolar material separates unevenly. Another study stated that the first division 
is critical and decisive to the fate of the daughter cells as it results in an uneven 
distribution of cellular machinery and especially of the transcription factor t-bet as 
described above (Chang et al. 2011). In more recent works, CD8 T cells were 
activated in vitro and differences in CD8 expression were seen among CD8 T cells, 
so that some were CD8
lo
 and others CD8
hi
. To test whether the difference was 
significant, CD8
lo
 and CD8
hi
 T cells were adoptively transferred into WT mice and 
analysed for their ability to clear a bacterial infection. CD8
hi
 cells were associated 
with a greater reduction of bacterial load, and these cells were described as DC-
proximal (Oliaro et al. 2010).  
Studies involving CFSE-labelled T cells which had already undergone divisions, 
like the experiment described for the linear differentiation model, showed that fate 
commitment can happen at a later stage than D1, thanks to the integration of different 
signals (Opferman et al. 2001; Sarkar et al. 2008).  
At present, data support a model in which memory cells can derive and be derived 
directly from both naïve and effector cells and whose fate is decided after the first 
division. Whether this happens through an asymmetrical division or depending on 
TCR/antigen stimulation is not yet clear but these two models might well coexist.  
 
 
2.3.2 Central CD8 T cell memory and CD8 T effector memory 
 
All the tree models have in common that a memory-committed precursor population 
can be clearly identified early during effector responses. The molecules used to 
identify and distinguish memory from effector cells are KLRG-1 (killer cell lectin-
like receptor G-1), CD127 and CD62L. The memory committed precursor population 
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can be identified and characterised by IL-7Rαhi (CD127hi) and KLRG-1lo and 
especially IL-7Rα is functionally required for the transition to memory cells (Kaech 
et al. 2003). Interestingly, IL-7Rα expression has been linked to memory precursors 
and has been shown to be fundamental for memory development (Schluns et al. 
2000), but IL-7 itself has not. In fact, there seem to be another ligand to the IL-7Rα 
receptor which activates it in absence of IL-7.  
Two subsets of memory cells had been initially described, as seen above: effector 
memory and central memory. CD8 T central memory (TCM) cells express CD62L and 
CCR7 for homing to SLOs, they can proliferate and revert to TEM when primed 
(Sallusto et al. 1999). CD8 T effector memory (TEM) cells are CD62L
-
 and CCR7
-
: 
they constitutively express GrB and pfn, migrate to the site of infection because of 
expression of CCR4, CXCR3 and CCR5, and quickly reactivate effector functions. 
 
 
Figure 11: CD8 memory cell populations. Development of memory cell subsets 
memory precursor effector cells (MPEC), short-lived effector cells (SLEC) and 
is dependent on cytokines like IL-2 and upregulation of transcription factors t-
bet and Blimp-1 (Kallies 2008). 
 
 
Recent findings have shown that the memory population is non-uniform in terms of 
gene expression, localisation, and proliferating and differentiating capabilities. The 
TEM subset has therefore been subdivided into two subsets based on the observed 
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capacity of some TEM to de-differentiate into TCM. The TCM population is considered a 
less differentiated population due to its proliferation and self-renewal capacity: a 
transitional subset, able to revert to TCM and a terminally differentiated, end-stage 
subset of TEM. These finding were obtained by Lefrancois’s work which showed the 
existence of memory precursor effector cells (MPEC) which are IL-7Rhigh and 
KLRG-1low, short-lived effector cells (SLEC) which are IL-7Rα- KLRG-1+, and 
early effector cells (EEC) which are IL-7Rα- KLRG-1- (see Figure 11) Interestingly, 
the last of these three subpopulations (EECs), can develop into the other two when 
adoptively transferred and properly stimulated (Lefrancois and Obar 2010). The 
developmental paths of these cells are shown in Figure 11. Very elegant experiments, 
where a single CD8 naïve cell was adoptively transferred, showed how that single 
naïve CD8 T cell can generate both effector and memory cells (Stemberger et al. 
2007; Gerlach et al. 2010).  
 
. 
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2.4 Homeostasis of CD8 T cell numbers and attrition 
 
 
 In the steady state, a homeostatic system exists to maintain a balance between long-
lived memory cells, mature naïve CD8 T cells and newly formed ones so that the total 
number of CD8 T lymphocytes is constant. The homeostasis is believed to be 
maintained by competition of the T cells for the limited amount of IL-7 and CCL19 
produced by the follicular reticular cells (FRC). As IL-7 and CCL19 availability is 
limited, the cells which do not have access to them will not proliferate and eventually 
die. In 2007, Luther’s lab demonstrated that the homeostasis of these cells is 
maintained in the periphery by the release of IL-7 by FRCs in the spleen and LN 
(Link et al. 2007). Additionally, CD8 T cells undergo homeostatic proliferation, 
which has been shown to be TCR-dependent, as it is abrogated in MHC
-/-
 mice (Ernst 
et al. 1999). According to mouse studies, naïve T cells can re-circulate in the body for 
up to 8 weeks before being eliminated (Tough and Sprent 1994). As a result, the total 
number of the T cell repertoire is maintained at a stable level in steady state 
conditions. Memory cells represent a small percentage of the T cell repertoire in an 
individual during young age, but they become a larger part of the total T cell 
population during adult age. The homeostasis of CD8 memory cells, which does not 
depend on antigen and MHC molecules, has been shown to be regulated by IL-7 as 
well (Schluns et al. 2000).  
 
During infections, the homeostasis mechanism is overcome by other signals. When 
a new CD8 T cell response is established, a phenomenon called “attrition” causes the 
existent memory pool and some of the unrelated naive CD8 T cells to die through 
apoptosis induced by anergic contacts with mature DCs during the first days of the 
expansion phase. 
 
Jiang and colleagues demonstrated that high levels of type-I IFNs are associated 
with early stages of inflammation between day 2 and 4 of an immune response. The 
levels of type-I IFNs also drive general upregulation of CD69. CD69 is a C-type 
lectin considered the earliest activation marker on lymphocytes, as explained in 
Figure 12: its function is to act as a costimulatory molecule. During infections, due to 
the systemic diffusion of inflammatory cytokines, non-specific T lymphocytes can 
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undergo cytokine-driven phenotypic changes — so-called bystander activation 
(Figure 12). Moreover, as reported above, an upregulation of CCL21 which induces 
CD8 T cell migration to the LN favouring bystander cell apoptosis, is associated with 
the early stage of infections, day 1-2 (Mueller et al. 2007). Type-I IFNs have also 
specifically been correlated to the apoptosis of these non-antigen-specific bystander T 
cells (both naïve and memory). The death of bystander T cells does not interfere with 
antigen-specific responses.  
 
 
 
Figure 12: CD69 and CD44 expression upregulation during the initial 
phases of the CD8 T response and attrition mechanism in bystander 
activated T cells (Jiang et al. 2003). 
 
 
The phenomenon of attrition facilitates the expansion of antigen-specific effector T 
cells as it physically increases the space available in the lymphoid organ. Attrition 
also allows for new immunogenic antigen-specific responses not to be overwhelmed 
by existing immune responses in the case of a re-infection with the same pathogen or 
a variant, as it is the case when different virus strains co-infect a host.  
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2.5 Antigen presenting cells  
 
  
B and T cells which belong to the adaptive arm of the immune system are, unlike 
the ones belonging to the innate arm, not fully activated when stimulated by 
pathogen-derived signals. Pathogen-derived antigens need to be presented in the 
context of MHC molecules, together with costimulatory and danger signals delivered 
by a professional antigen presenting cell (APC). Many cells can function as APCs, 
namely B cells, macrophages, and epithelial cells when activated by inflammatory 
signals. Among these cells, nonetheless, non-hematopoietic cells like epithelial cells 
lack costimulatory signalling molecules and are not able to initiate a MHC-I-
restricted CD8 T cell response (Sigal et al. 1999). Bone-marrow derived B cells, 
macrophages and DCs can deliver co-stimulatory signals and initiate a MHC-II-
restricted response. Nonetheless, only DCs are necessary to activate CD8 T cell 
responses. Since CD8 T cells are mainly responsible for direct elimination of viral 
responses and DCs are the cells in charge of activating them, DCs are a key player for 
the development and regulation of viral responses.  
 
 
Dendritic cells were first described by Ralph Steinman in the 1970s. He discovered 
a new cell type while performing an investigation on macrophage features in killing 
microbes. The new cell type had a branched morphology, loose adherence to plastic 
and high content in vacuoles and mitochondria. Because of the shape, Steinman 
called them dendritic cells, but their function remained not known for several years 
after. Steinman himself conducted more studies on these newly discovered cells, and 
characterized them as antigen presenting cells (Steinman and Cohn 1973). Steinman 
received the Nobel Prize in 2011 for this discovery and the successive work he 
carried on to study this cell type. 
 
In this chapter the characteristics of dendritic cells, their development and 
classification in humans and mice will be firstly described. Afterwards, the processes 
typical of the immature and the mature status will be presented (antigen uptake, 
pathogen sensing, maturation, presentation and costimulation of T cells). Finally, the 
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two main secondary lymphoid organs will be described, followed by a more detailed 
description of the two mouse subsets of interest for this project, CD8α+ DC and 
plasmacytoid DCs. 
 
 
2.5.1 Antigen-presenting cell specific functions  
 
Naive CD8 T cells circulate between lymphoid tissues and the blood stream in a 
naïve, inert status. This activation is carried out by APCs. Among APCs, DCs are the 
predominant cell type and because of their ability to fully activate naïve CD8
 
and 
CD4 T cells and to deliver costimulatory signals and inflammatory signals, they are 
called “professional” APCs. They have specific functions which include the ability to 
present uptaken antigens on their MHC class I and class II molecules and to convey 
activation, survival or apoptotic signals to T cells. DCs are the connectors between 
innate and adaptive immunity as they are able to stimulate T cells and drive T cell 
responses based on the signals received from the innate system. 
 As mentioned, non-hematopoietic cells are unable to present antigens to CD8 T cells, 
while bone-marrow derived B cells, DCs and macrophages have been shown to cross-
present in vitro (Bellone et al. 1997). A following experiment studying B cells and 
DC cross-presentation functions, showed that in vivo cross-presentation is not 
impaired when B cells are ablated (Schoenberger et al. 1998), but it is abrogated 
when phagocytes are ablated (Debrick et al. 1991). In 2001 Kurts demonstrated that 
in phagocyte-ablated mice, expression of MHC-I-restricted DCs can restore CD8 
priming/response, thus establishing that these cells have a fundamental role in cross-
presentation to CD8 T cells (Kurts et al. 2001). Further proof of their key function in 
cross-presentation was provided when conditional ablation of DC was performed by 
Lang’s group in 2001. A mouse was engineered to express the diphtheria toxin 
receptor (DTR) under the control of the murine CD11c gene promoter (Brocker et al. 
1997). This gene encodes the CD11c subunit of the CD11c/CD18 β integrin, which is 
expressed in all DC type in both immature and mature state except for the Langerhans 
cells which only upregulate it when activated. When the CD11c-DTR mice were 
injected with DT all and only the cells expressing the DT receptor (i.e. the DCs) were 
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target of its killer action, as mice are otherwise insensitive to DT (Jung et al. 2002). 
This system allowed the induction of temporary ablation of DCs. The study reported 
that elimination of DCs negatively affected the proliferation of CTL precursors after 
pathogenic challenge. It also showed that DCs are efficiently replaced in 3 days.  
DCs are a rare cell type widely distributed across all tissues: soon after their 
discovery, it was noticed that several different cell types, sharing a common 
hematopoietic origin and the same functions, but with different lineage precursors, 
fell under the definition of dendritic cell. When talking about dendritic cells, we refer 
to a heterogeneous population, consisting of cells with different specific tasks, tissue 
distribution, and surface molecules.  
 
 
2.5.2 Human and mouse denritic cell subpopulations 
 
DCs are a very heterogenic cellular population. Several subtypes can be identified 
based on surface markers and tissue localization. In humans, DCs were until not long 
ago mainly divided into lymphoid and myeloid cells based on the lineage, but recent 
studies have demonstrated that lineage origin is not a clear distinctive method and a 
marker-based approach has now been adopted. In mice, some subsets inhabit 
secondary lymphoid organs and others patrol the peripheral tissues. All the subsets 
are defined by the levels of their surface markers (like CD8, CD4, CD11c, CD205 
and CD11b, CD24) and when possible by a specific function, although more and 
more studies report a certain plasticity in the function of these cells (see Figure 13). 
 
Human DCs, the study of which mainly comes from in vitro work, as reviewed by 
Shortman and Liu (Shortman and Liu 2002), are now being categorized based on 
surface markers and the technique used to derive them from a CD34
+
 precursor. The 
classification of human blood-derived DCs, the most easily accessible, is based on 
expression of BDCA-1, -2 and -3 (blood dendritic cell antigen). 
In particular, according to a recent nomenclature definition there are 3 types of DC 
in the human blood, two of which are considered both immature and precursors 
(Ziegler-Heitbrock et al. 2010). The first two sets are myeloid DCs: one subset is 
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BDCA-1/CD1c
+
, which identifies a myeloid DC population, and the other one is 
BDCA-3/CD141
+
 which seems to represent the human counterpart of murine CD8α+ 
DC as they are also Clec9A
+
 (Dzionek et al. 2000). Both these subtypes are CD123
dim
 
CD11c
bright
, rather monocytoid in appearance, express CD45RO and spontaneously 
develop into typical mature DCs even when cultured without any exogenous 
cytokines. DCs in the third subset, considered immature, are called plasmacytoid DCs 
and are BDCA-2
+
 (CD303), a C-type lectin transmembrane glycoprotein that can 
internalize antigen for presentation to T cells, and also CD123
bright
 CD11c
-
. 
 
 
 
 
Figure 13: DC subpopulations in mice and principal markers for identification 
(Heath and Carbone 2009). 
 
 
Mouse DCs are mainly classified as mucosal DC and non-mucosal conventional 
DC (cDC). The latter including migratory cells (Langerhans cells and dermal DCs), 
resident CD8α+ and CD8α- DC which are found in LN and spleen, and plasmacytoid 
DCs (pDCs). Furthermore, in inflammatory conditions, monocytes can differentiate 
into DCs (Lopez-Bravo and Ardavin 2008). Due to the nature of my research and the 
model used, the focus is going to be on mouse subsets at this stage. 
 
Migratory DCs can be subdivided into immature dermal or interstitial DCs and 
immature epidermal or Langerhans cells (LCs), which represent respectively 
approximately 35% and 25% of total cDCs (Kamath et al. 2002) and can be found in 
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steady state each patrolling the respective layer of the skin. Migratory DCs constantly 
migrate from the peripheral tissues to the SLOs via the lymphatic system, but in 
absence of inflammation they are not retained: they have a role in antigen transport 
and transfer to residential DCs in spleen and LNs, which will be described later (Belz 
et al. 2004; Allan et al. 2006). Langerhans cells (CD9
+
 CD68
+
) are thymus-derived 
and found in the epidermis and in the oral, respiratory and genital mucosa. They have 
unique membrane-bound organelles, whose role is unknown, called Birbeck granules, 
and express the C-type lectin marker Langerin (Ebner et al. 2004).  
Interstitial, dermal, or submucosal cells have a more peripheral distribution: in 
humans they display specific surface markers as CD11c and CD1c, and express high 
levels of HLA-DR both in the immature and in the mature stage. Nevertheless, both 
of these subgroups behave in the same way: they are mainly phagocytic cells for most 
of their lifespan, but undergo phenotypical and functional changes upon stimulation, 
becoming efficient antigen-presenting cells. In mouse these cells are Langerin
+
 and 
CD103
+
 and can, under appropriate stimulatory conditions, cross-present antigens 
(Kaplan 2010). Studies with influenza virus have shed a light on the role of this 
subpopulation as an early presentation tool. Depletion of lung DCs in fact could 
impaire T cell expansion. The specific location where this happens in the lung is not 
clear still, but studies are ongoing (McGill et al. 2008).  
 
 
Resident DCs in the lymphoid organs are distinguished by expression of the CD8α 
homodimer, different from the CD8 heterodimer (CD8αβ) expressed by CD8 T cells, 
and divided into CD8α+ and CD8α-. CD8α- DC can be further subdivided into CD8α-
CD4
-
 and CD8α-CD4+ DC subsets (Villadangos and Schnorrer 2007), but because no 
exclusive functions in immune responses have been specifically ascribed to either of 
these subsets, the two are rarely described individually. In general, CD8α- DCs are 
better at presenting antigens on MHC-II context and thus induce CD4 T cell 
responses (Dudziak et al. 2007), with production of IFN-γ and IL-4 (Soares et al. 
2007), while CD8α+ DCs are better at cross-presenting to CD8 T cells and uptaking 
apoptotic cells (Belz et al. 2004). The distribution of these DC subtypes varies in the 
different lymphoid organs (see Figure 14): CD8α+ and CD8α- represent respectively 
the 25% and 75% of DCs in the spleen for example (Kamath et al. 2000). The 
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composition of the DC population in spleen and LNs will be further developed in the 
appropriate chapters below (see 2.5.9.1 and 2.5.9.2).  
Plasmacytoid DCs will also be the subject of a chapter below. They have lower levels 
of CD11c and high levels of the B220 surface marker (CD45R), are less involved in 
presentation of antigens but have been shown to be efficient producers of type I 
interferon (Villadangos and Young 2008).  
Monocyte-derived DC are present in humans and the correspondent subset is called 
inflammation-derived DC n mice as they are induced in inflammatory status and  
seem to be involved in antigen presentation to CD4 T cells when resident and 
migratory DC are not enough (Shortman and Naik 2007).  
 
 
Figure 14: Conventional DC population in mouse spleen and LNs. Modified from (Villadangos 
and Heath 2005). 
 
 
 
2.5.3 Dendritic cell origin and development 
 
DCs are cells of hematopoietic origin, their progenitors originate in the bone 
marrow (BM) and are then released in the circulation from which they colonise all 
tissue, except for the brain, eyes and testes (Hart 1997). Notably, DC progenitors can 
be found in the bone marrow (BM), blood, peripheral lymphoid tissues and various 
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organs at various differentiation stages and, depending on the subset, they can 
develop and mature into differentiated DCs in the BM or peripherally. 
The search for a common DC progenitor has just recently been fruitful. Studies 
conducted in the mouse have been able to shape-up the picture of DC development. 
In the past, a distinction had been made between myeloid and lymphoid DC, 
considering migratory and resident DCs as part of the former group and plasmacytoid 
as part of the latter. As brilliantly reviewed by Liu and Nussenzweig (Liu and 
Nussenzweig 2010), the combined efforts of several groups and techniques, like DC 
ablation and Lutz ‘s culture methods (Lutz et al. 1999), made possible to find a 
common progenitor in the bone marrow, described as the common myeloid precursor 
(CMP). Studies have shown that another common progenitor, the common lymphoid 
precursor (CLP), has the potential to give rise to DC eventually, but given the larger 
abundance of CMP in the BM, this has been elected to be the general precursor 
(Traver et al. 2000). Thanks to the finding that DC progenitors express FMS-related 
tyrosine kinase 3 ligand (Flt3) (Karsunky et al. 2003) and that flt3-deficient mice 
have impaired DC levels (McKenna et al. 2000), a downstream monocyte 
macrophage and DC progenitor was isolated. It was called macrophage-DC 
progenitor (MDP) for its ability to develop into monocytes, macrophages and DCs 
(see Figure 15). Shortly after, a progenitor giving rise to DCs (both conventional ones 
and pDCs) but not monocytes was identified in the bone marrow by Onai and 
colleagues (Onai et al. 2007). As DCs are replaced by blood-borne precursors, the 
blood is where the next developmental step was searched and found: it was named 
pre-DC and was shown to be the DC blood precursor. Pre-DCs exit the BM to never 
return: they circulate in the blood and eventually enter secondary lymphoid tissues. 
Once more, it was the expression of the transcription factor Flt3 to shed a light on this 
population (Liu et al. 2009). Pre-DC is the last developmental step before 
differentiated DCs, as shown in Figure 15. The differentiation pathways of mouse 
DCs is now clear, and the final precursors of tissue DCs are pre-DCs found in the 
circulation. 
Notably, all but the Langerhans DC subset are re-populated by the pre-DC 
precursor. A distinct LC precursor has been found, thanks to the observation that LCs 
resist irradiation and are not being repopulated by BM transfer (Ginhoux et al. 2006). 
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The LC precursor shares some characteristics with the MDP in that it is CD45
+
 
CX3CR1
+
 (Chorro et al. 2009). 
 
 
Figure 15: Mouse DC origin, development and tissue distribution (Liu and 
Nussenzweig 2010). 
 
 
The homeostasis of DCs has been described by Liu and Nussenzweig as dependent 
on “three parameters: continuous input of pre-DC from the blood, limited DC 
division in situ and cell death” (Liu and Nussenzweig 2010). In particular pre-DCs 
divide for 10-14 days once exited the BM (del Hoyo et al. 2002) under the regulation 
of lymphotoxin-β and Flt3. Terminally differentiated DCs can also divide, and their 
half life varies between 3 and 25 days depending on the subset and the site.  
The developmental path described is the one DCs follow in the steady state. During 
inflammation, monocytes can also develop into a specific subset of Ly6C
- 
CCR2
- 
CD11b
high 
CD4
- 
CD8
-
 DC (Geissmann et al. 2003). The same monocytes will not turn 
into DC in absence of inflammation. A role for monocytes as precursors of 
conventional DCs in the steady state has been ruled out in various experiments both 
in humans and in mice. When activated monocytes are injected locally in the skin, 
they migrate to the local LN, acquire some of the typical DC markers and can 
stimulate T cells, but they do not express all of DC markers and low levels of CD11c 
(Randolph et al. 1999). Activated monocytes where found to express TNF and iNOS 
and where therefore named TiP, as shown in Figure 15 (Shortman and Naik 2007). 
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DCs are a pool of cells with common general characteristics but in which several 
subtypes with specific function, location and surface receptors are distinguishable. All 
but LCs derive from a blood pre-CD precursor, which proliferates to maintain the DC 
population stable. Resident DCs in lymphoid organs are different from migratory DCs 
and they collaborate to make priming the most efficient. 
 
 
2.5.4 Antigen uptake 
 
In the immature state, migratory DCs are located in peripheral tissues where they 
scavenge for pathogens through phagocytosis of soluble proteins, apoptotic cells and 
other material. Immature dendritic cells are in fact highly phagocytic cells which 
uptake antigen through 3 main routes: phagocytosis, macropinocytosis, and receptor-
mediated internalization. 
 
2.5.4.1 Phagocytosis 
Phagocytosis  is a mechanism used mainly by macrophages to internalize and 
dispose of killed infected cells and pathogens and to cross-present them to CD8 T 
cells (Desjardins et al. 2005). It allows internalization of relatively large particles, up 
to 3.0 μm (Roberts and Quastel 1963), and involves actin-dependent cytoskeleton 
rearrangement: extension of pseudopodia and formation of a phagosome. The 
triggering signal is ligation of cell surface receptors. The extra membrane required for 
extension of psedudopodia and for pahgosome formation is contributed by the 
membrane of intracellular vescicles which migrate to the plasma membrane and fuse 
with it, thus increasing its extension. GTPases of the Rho family are then recruited 
and phagosomes become phagolysosomes through fusion to endolysosomes: this step 
seems to be regulated at least in part by some endosome-located TLRs (Shiratsuchi et 
al. 2004). TLRs can in fact localize in the forming vesicle and get activated by its 
content (Underhill et al. 1999).  
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During maturation of DCs lysosomes have been shown to be remodelled and 
activated through increased acidification, in order to enhance antigen processing and 
presentation (Trombetta et al. 2003; Nayak et al. 2006).  
 
2.5.4.2 Macropinocytosis 
Fluid phase endocytosis (pinocytosis) is the intake of soluble particles together with 
amounts of water, and it is used by many cells to engulf nutrients, growth factors and 
others particles. Macropinocytosis is a type of pinocytosis which involves actin-drive 
envagination of the plasma membrane with formation of large vacuoles (up to 2.5µm 
in diameter). Actin activation is mediated by, among others, activation of growth 
factor receptor signalling pathways (Lanzetti et al. 2004). Macropinocytosis is a non-
selective mechanism. The internalisation is mediated by membrane ruffling and 
cytoskeleton modification and produces early endosomes that later fuse with 
endosomes. In immature DCs, on the contrary, this uptake mechanism is 
constitutively activated and contributes to the uptake of antigens destined to be 
presented on MHC molecules (Sallusto et al. 1995).  
 
2.5.4.3 Receptor-mediated phagocytosis 
Receptor-mediated uptake is the main mechanism of internalization in most antigen 
presenting cells and it involves several types of membrane proteins. Once bound to 
antigens, the receptors are internalised through clathrin-coated pits or formation of 
vacuoles. The vacuole containing the antigen-receptor complex then fuses to primary 
endosomes, which become late endosomes and fuse to lysosomes where the proteases 
degrade uptaken antigens for loading onto MHC-II.  
Among surface receptors in DCs, mannose-6-phospate (M6P) is one of the most 
represented. Once internalised, the M6P receptor is transported to the endosomal 
compartment and then recycled to the plasma membrane (Engering et al. 1997). 
Uptaken antigens are processed through two main pathways and subsequently 
presented into two different contexts: MHC-II, which are expressed mainly by APCs 
and are recognized by CD4 T cells, and exceptionally MHC-I, which are expressed 
on almost every cell type and are recognized by CD8 T cells.  
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A broad array of receptors is expressed on immature dendritic cells, accounting for 
DC ability of recognizing and internalizing as many different molecules and as 
possible. Among others are C-lectins, Fc and complement receptors (Bajtay et al. 
2006), and Dectin-2 scavenger receptor. The most abundant receptor type on 
dendritic cells is represented by members of the C-type lectin family (Kanazawa 
2007). C-type lectins are responsible for binding to self glycoproteins and being 
mediators of important cell-cell interactions in processes like maturation or migration 
of several cell types. Both type I and type II C-lectins, such as DEC-205 (CD205), 
CLEC-1 (C-type lectin receptor-1), DC immunoreceptor (DCIR) or CLEC-4 
(Kanazawa et al. 2003), and dectin-2, DC-associated C-type lectin-2 (Ariizumi et al. 
2000), are highly expressed on DC surface and are endocytosis mediators of 
considerable significance. They are able to recognize, bind and internalise upon 
binding most pathogen carbohydrate patterns and form multimeric complexes which 
signal intracellularly. In particular, intracellular signalling depends upon binding as 
each of them has a unique intracytoplasmic tail. DEC-205 binding, for instance, 
triggers its internalization, formation of clathrin-coated pits and directing to the 
lysosomal compartment. DEC-205 endocytic function is very efficient and it has been 
used to specifically target antigen to MHC-II in DCs (Mahnke et al. 2000). 
DC-SIGN, dendritic cell-specific intercellular adhesion molecule (ICAM)-3-
grabbing non-integrin (CD209), is another C-type lectin, specifically expressed on 
resident DCs of SLOs. For its ability to bind ICAM-2 and ICAM-3 (Geijtenbeek TB 
2000) on  epithelial and T cells (Geijtenbeek TB 2002), DC-SIGN has a role in 
intercellular adhesion It is nonetheless also a receptor for several pathogens and is 
able to mediate their internalization (Geijtenbeek TB 2003). DC-SIGN can also 
interfere with signalling from other molecules, e.g. TLRs, upon pathogen recognition 
and can downmodulate DC activation.  
Furthermore, immature dendritic cells express the CD36 scavenger receptor, a 
molecule able to recognize lipids, like long-chain fatty acids, and altered lipoproteins, 
whose binding induces inflammatory molecule release and is able to modulate DC 
function (Urban et al. 2001). Its role is complex as it acts both as a receptor for 
recognition of apoptotic cells and as a positive regulator of dendritic cell maturation, 
as co-receptor for TLR2/6 in microbial recognition.  
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Another receptor involved in the uptake of apoptotic and necrotic cells is DNGR-1 or 
Clec9A, especially expressed by CD8α+ DCs, which recognizes and binds molecules 
extracellularly exposed on necrotic cells (Sancho et al. 2009). 
 
The receptors involved in Phagocytosis, like DC-SIGN, Clec9, CD36, are down-
regulated during dendritic cell maturation, so that the antigens presented in the SLOs 
mirror the peripheral tissue antigenic content. This downregulation demonstrates that 
the phagocytic function is only the first stage of DC functional complexity and it 
demonstrates the many functional and phenotypical changes these cells undergo. 
 
 
 
2.5.5 Antigen processing and presentation 
 
Antigens uptaken by DCs through the different routes described in 2.5.4 are directed 
to the intracellular sites of degradation. Proteins and material phagocytised through 
different routes are processed into lysosomal compartments and then presented on the 
cell surface in the context of either class I or class II MHC molecules. The two MHC 
molecules share the same genetic locus, as they originated from a common ancestor 
gene by duplication, but have different distribution in tissues and cell types. MHC-II 
is expressed by immune cells like macrophages, B cells and dendritic cells while 
MHC-I is expressed by all cell types except for red blood cells. MHC biogenesis 
occurs with a strict compartmentalization: mostly exogenous antigens are loaded on 
class II molecules through the endocytic pathway and only endogenous and 
intracellular infection-derived peptides are presented on MHC-I molecules. This 
accounts, at the cellular level, for the selective activation of CD8 T cells as they can 
bind MHC-I through CD8, in the case of virally cells for example, and for the 
activation of naïve CD4 helper T cells and direction to a TH1 or TH2 type of response 
through MHC-II, for example in the case of extracellular pathogens. Exceptions are 
possible and the presentation of exogenous antigens in the context of MHC-I 
molecules can be achieved through a mechanism called cross-presentation (Ackerman 
et al. 2003). 
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Figure 16: Antigen degradation and presentation pathways: MHC-
I (2) and cross-presentation (1) routes on the left; MHC-II route on 
the right (Lipscomb and Masten 2002). 
 
 
  The intracellular route that leads to the formation and localization of the MHCs 
determines which antigens are presented by each of the two molecule, with the 
exception of endogenous molecules presented on MHC-I molecules in DCs. 
 
2.5.5.1 Major histocompatibility complex-II  
MHC molecules are surface receptors able to bind processed peptides deriving from 
phagocytised or endogenous antigens. MHCs are encoded on chromosome 6 in 
humans and on chromosome 17 in mice. In humans, the MHC-II is encoded by 3 
different genes which are polymorphic and express one α- and one β-chain (to be 
combined) each: HLA-DR, HLA-DQ and HLA-DP. In mice, the gene complex 
contains two loci, A and E, each of which encodes α- and β-chain polypeptides. This 
gene complex is referred to as Ir (immune response) as the genes encoded determine 
the level of immune responsiveness to specific antigens of different mouse strains. 
The products of the A and E loci are therefore often called I-A and I-E. 
 Antigens from the endocytic pathway, i.e. the ones that have been internalized, bind 
predominantly to MHC class II molecules, although many reports show endogenously 
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synthesized antigens on MHC class II molecules (van Niel et al. 2008). Internalized 
extracellular proteins are transported through the acidified endocytic vesicles and 
localize in either endosomes or phagosomes, subsequently fused to lysosomes. In 
lysosomes, internalized proteins are processed into peptides and then transferred to 
the MHC class II compartment (MIIC), where degradation into smaller peptides and 
loading on to a class II MHC takes place. MIIC have a high content in both 
lysosomal-associated membrane protein (LAMP), Cathepsins (Cresswell 2005), and 
class II molecules, and the enzymatic processing that takes place produces the 
cleaving of proteins into peptides of 10 to 20 residues in length. The MHC molecules 
are formed in the Endoplasmic Reticulum (ER), where α- and β- chains, already 
bound to each other, are associated with the invariant chain (Ii). Ii stabilizes the 
complex by occupying its free cleft and by binding to the vesicle membrane through 
the insertion of its class II-associated invariant chain peptide (CLIP) portion. The 
cytoplasmic tail of Ii contains a motif for delivery and retention of the αβ-Ii complex 
to the endocytic route. Once the MHC-containing vesicle fuses with the MIIC, 
containing the processed peptide coming from the endocytic pathway, the invariant 
chain and its CLIP are removed from the αβ-Ii in order to give room to the processed 
antigens. The removal is achieved through degradation of the Ii itself, which is 
processed in various steps involving activity of cathepsins. This process is 
fundamental for the release of MHC complexes from the endosomal compartment. 
The retention signal is in fact contained in the cytosolic tail of the Ii chain and it has 
to be clipped off in order to get translocation and insertion in the cell membrane. In 
DCs, one of the steps of degradation of the CLIP is carried out by Cathepsin S (Shi et 
al. 1999). Subsequently, the low pH favouring an “open” conformation of the MHC 
dimer, the activity of a chaperone acting as a peptide-CLIP exchanger (HLA-DM in 
humans and H2-DM in mice), and the proteolytic elimination of the region flanking 
the CLIP, collaborate to the removal of the remaining peptide. Once the whole Ii is 
eliminated, internalized antigens can be loaded. The MHC-II molecule, which is a 
dimer, is stabilized again by peptide binding. The stable complex is ready to be 
delivered to the cell surface.  
The half life of pMHCs depends upon the affinity of MHC-antigen interaction 
(Nelson et al. 1994): the MHC molecule itself is otherwise highly unstable and 
rapidly degraded, especially in immature DCs (Colledge et al. 2002; Wilson et al. 
2004). In these cells, MHC-II complexes are transiently expressed on the plasma 
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membrane and are rapidly reendocytosed and delivered to lysosomes (Villadangos et 
al. 2001). MHC-II loading is a delicate mechanism which receives regulatory signals 
from several sources and adjusts very finely to the cell stage. The complexes are 
sequestered in MIIC during the immature stage of a DC life and they are transported 
to the cell surface, through tubular endosomal structures, when the cell receives 
danger signals and its maturation is triggered. Interestingly, immature DCs have 
shown to express empty MHC-II molecules on their surface, which seem to be loaded 
with peptides processed by secreted proteases from extracellular antigen 
(Santambrogio et al. 1999; Potolicchio et al. 2005). From a T cell response point of 
view, the number of MHC loaded molecules displayed on the dendritic cell surface at 
any given time is of a great importance for the regulation of activation and potency, 
and so is their half-life. Permanence of MHC complexes on the surface is dictated by 
a complex balance between loading plus delivery to plasma membrane, and kinetics 
of removal and destruction.   
MHC-II half-life at DC surface has been estimated in ~5-10 hrs (Eberl et al. 1993). 
Regulation of MHC-II is mediated by transcription factors, like TGF-β and by 
chromatin modification. The transcriptional co-activator CIITA specifically regulates 
MHC-II levels in DCs. CIITA promotes MHC-II transcription when DCs are 
immature and but not when DCs are mature. CIITA promoter, CIITApI, is in fact 
silenced during maturation (Smith et al. 2011), MHC-II levels are further regulated by 
IL-10 in immature DCs and CD83 in mature ones (Thibodeau et al. 2008).  
 
2.5.5.2 Major histocompatibility complex-I 
MHC-I molecules are expressed in most cell types. They are mainly responsible for 
the maintenance of peripheral tolerance and for activation of CD8 T cells responses 
against cancer cells and intracellular pathogens. In humans, the class I gene complex 
contains three major loci, B, C and A. In mice, there are two loci, K and D. Each of 
these loci encodes for a polypeptide, the α-chain, which contains antigenic 
determinants and is polymorphic. The α-chain associates with β-2 microglobulin or β-
chain, which is encoded by a gene outside the MHC complex. Without the β-2 
microglobulin, the class I molecule is not expressed on the cell surface. The MHC-I 
expression and loading, and the processing of endogenous antigen destined to this 
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molecules are separated from that of MHC-II. Nonetheless, antigens from the 
endocytic pathway can be presented on MHC-I thus favouring priming of CD8 T 
cells, hence named “cross-priming” (Bevan, 1976): this will be the subject of the next 
chapter.  
The antigens loaded onto MHC-I via the default pathway are derived from either 
protein at the end of their half-life, or misfolded, or from the so called DRiPs 
(defective ribosomal products). DRiPs are the results of defective translation or 
transcription and need to be degraded to prevent aggregation: this happens to between 
30-70% of all the proteins made (Schubert et al. 2000). The discovery of DRiPs 
clarified how viral proteins uploading onto MHC-I is achieved rather quickly after 
infection, faster than the expected half-life of the proteins. MHC-I molecules in fact 
present also antigens from intracellular pathogens and internalized extracellular 
antigens through cross-presentation.  
Intracellular proteins ready to be degraded are tagged with a polyubiquitin chain to 
be transported to the proteasome where they will be processed. Antigens are cleaved 
into peptides by nuclear or cytoplasmic proteases which form a proteasome. Once 
formed, the peptides, which are between 8 and 16 amino acids, are transferred to the 
ER by the specialized transporter protein called TAP, transporter associated with 
antigen processing (Owen and Pease 1999). TAP also mediates contact with tapasin, 
the MHC chaperone, acting as a platform for the correct binding of the peptide to the 
MHC chains. In the ER, the MHC heterodimer formed by a polymorphic heavy chain 
and a light chain called (β2-microglobulin) are assembled and stabilised by a number 
of chaperons (the chaperon calreticulin, the transmembrane protein tapasin, TAP 
itself and the protein disulfide isomerase ERp57). The loading happens under the 
control of a loading complex composed of several ER resident chaperons, including 
tapasin, calnexin and calreticulin (Cresswell et al. 1999; Cresswell et al. 1999). Once 
associated to peptides, MHC class I molecules are rapidly transferred through the 
Golgi apparatus to the plasma membrane.  
Notably, there is growing interest on differences in the proteasome composition 
between non-immune cells and antigen presenting cells. The proteasome common to 
all cell types is called 26S, because formed by a 20S core barrel and two 10S caps 
(Unno et. al 2002). Macagno and colleagues showed the existence of a special 
proteasome in APCs, called immunoproteasome. This special proteasome has been 
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shown to be made of 3 special subunits out of the 14 which form the 20S barrel. 
These 3 subunits (called β1i, β2i, β5i) are IFN-γ inducible homologues of the normal, 
constitutively expressed subunits and are expressed exclusively in immune cells, 
together with the “common” one (Macagno et al. 2004). The immunoproteasome has 
been reported to have a special processing activity resulting in formation of peptides 
different from the ones processed by common proteasome, having the 
immonoproteasome distinct proteolytic specificities (Toes et al. 2001). The reason for 
this different processing machinery is probably associated with the maintenance of 
tolerance. Self-peptides normally processed and presented on MHC-I in non-immune 
cell types are not meant to stimulate an immune response. Antigens processed and 
presented on dendritic and antigen-presenting cells that are deriving from infected or 
malignant cells instead should be able to induce, together with other signals, a 
specific response: a different processing could help allowing the differentiation of 
antigen presentation and T-cell activation specificity in this cell type. On the other 
hand, tumours have been shown to escape immune responses by producing peptides 
trough the immunoproteasone against which CTL responses are not induced 
(Chapatte et al. 2006). Also a thymic-specific proteasome has been reported in the 
epithelial cells of the thymus (Sijts and Kloetzel 2011).  
These 3 different proteasomes have been accounted for the specificity of degradation 
of antigens in immunogenic peptides and the last two in particular are stimulated to 
work at a faster rate under IFNγ and stress signals.  
  
2.5.5.3 Antigen cross-presentation 
When internalised antigens are efficiently presented on MHC-I, the process is called 
cross-presentation. Cross-priming is the ability of DCs cross-presenting exogenous 
antigen in order to achieve activation of CD8 T cells. Data reports that cross-
presentation and cross-priming are more efficient with cell-associated antigens than 
with the corresponding soluble protein (Li et al. 2001). During infections, cross-
presentation and presentation ability are likely to depend on the kinetic of viral 
invasion and spreading. The nature of the virus and its lytic or non-lytic 
characteristics might be of importance as well. Also, during intracellular infections 
MHC-I expression can be upregulated by interferon stimulation, in viral infections, or 
by tumour necrosis factors, in microbial ones.  
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Cross-presentation of antigen was discovered by Bevan in 1976: while studying 
immunization with fully allogenic antigens he found out that minor histocompatibility 
antigens could be transferred between cells for presentation on APCs and stimulate a 
CTL response (Bevan 1976). Burgdorf and colleagues, moreover showed that cross-
presentation, which depends on TAP, is induced by TLR4 engagement and it is kept 
separated from endogenous antigen presentation on MHC-I (Burgdorf et al. 2008). In 
Keller et al. the authors use VPL-encapsulated gp33 in presence and absence of RNA 
to show how TLR stimulation enhances cross-priming of DCs. They demonstrate that 
signalling through MyD-88 is not necessary for cross-presentation but fundamental, 
together with type-I interferon production and signalling, for T cell priming (Keller et 
al. 2009). Moreover, engagement of type-I interferon receptor on the DCs enhances 
their ability to activate T cells during cross-presentation due to the expression of 
subunits forming the immunoproteasome (see above). Other than the presence of the 
immunoproteasome, two more factors seem to be involved in improving effectiveness 
of cross-presentation in DCs: reduced lysosomal proteolysis and expression of 
protease inhibitors. These two characteristics specifically described in DC, prove that 
these cells have an intracellular endocytic pathway adapted for antigen processing 
rather than degradation (reviewed in Lin et al. 2008)  
Two models have been described to explain how endocytosed exogenous antigens 
are presented on MHC-I: the first is called “cytosolic pathway” and the second is 
termed “alternative vacuolar pathway”. 
The first model proposes that antigens uptaken and internalized into phagosomes, 
are translocated to the cytosolic compartment of the DC where they are process by the 
proteasome and then transported to the ER: in the ER they are loaded onto MHC-I 
and finally transported to the plasma membrane by budding vesicles (Rock and Shen 
2005). Data has shown the involvement of Sec61 in traslocation of antigens from the 
phagosome to the cytosol for processing (Ackerman et al. 2002). Transport of 
peptides to the ER from the cytosos after processing has been proposed to be TAP-
dependent. An alternative model has been described: it involves budding of vescicles 
loaded with the entire MHC-I loading machinery from the ER which would fuse with 
pahgosomes having proteasomes for antigen processing associated: nonetheless, this 
model has not been clarified yet. 
The second, less understood, model describes a TAP-independent pathway which 
involves degradation of endocytosed antigens in the lumen of the phagosome 
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mediated by cathepsin activity and consecutive loading of the peptides on MHC-I 
molecules in the same phagosomal vacuole (Rock and Shen 2005). 
Cross-presentation can be seen as an “emergency” mechanism allowing efficient 
immune responses to intracellular pathogens that do not infect DCs and to tumour 
cell-derived antigens. On the other hand, cross-presentation has a key role in inducing 
tolerance to self-antigens not synthesised within DCs. Cross-presentation has been 
demonstrated to depend on high antigen availability and protein stability (Kurts et al. 
1998). 
 
 
 
2.5.6 Pathogen and danger sensing 
 
Antigen scavenging and presentation is not the only function of immature DCs: the 
presence of several specific surface receptors allows DCs to sense an ongoing 
pathogen invasion (Matzinger 1994). The ability of DCs to recognise pathogen-
associated patterns is unique to the innate immune system and it is fundamental for 
the initiation of adaptive responses. Pathogen recognition is coupled to intracellular 
signalling and results in regulation of antigen uptake, MHC presentation, DC 
maturation and expression of specific cytokines and coreceptors. DCs express Fc 
receptors, pattern recognition receptors (PRRs), scavsenger receptors, cytokine 
receptors and complement receptors CR3 and CR4 (Reis e Sousa et al. 1993). This 
wide array of surface molecules allows the recognition of classical signals of 
inflammation, like inflammatory cytokines, together with other danger signals. 
Inflammation and danger signals are fundamental for DC maturation and for the 
initiation of immune responses.  
PRRs are all able to recognize pathogen-associated molecular patterns (PAMPs) 
and are constitutively expressed by macrophages, DCs and epithelial and fibroblast 
cells, but also in some T and B cells. Several families of PRRs have been discovered, 
some of which are cytosolic: the Toll-like receptors (TLRs), the retinoic acid-
inducible gene I (RIG-I)-like receptors (RLRs) and the nucleotide-binding domain 
and leucine-rich repeat-containing receptors (NLRs). RLRs detect viral pathogens and 
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are expressed by most cells, while NLRs detect intracellular pathogen and stress 
signals. Due to their location, stimulation of these last two classes of receptors in 
most cases happens in infected cells. TLRs, instead, are expressed on the plasma 
membrane or on the membrane of endosomes and lysosomes. 
TLRs have specific ligands and are non-redundant. They can be divided in 
subfamilies depending on the molecules they recognise and their location. On the 
plasma membrane are expressed: TLR4 which recognises LPS (Medzhitov et al. 
1997) and viral proteins; TLR5 which recognises flagellin; TLR1/TLR2 and 
TLR2/TLR6 which recognise bacterial lipoproteins and peptidoglycans (TLR2 alone 
also recognises viral proteins, micobacteria and bacterial lipids). The recognition 
specificity of endosomal/lysosomal TLRs is more focused on nucleic acids: TLR3 
recognises double-stranded RNA (dsRNA), TLR7 and TLR8 recognise single-
stranded RNA (ssRNA), and TLR9 recognises double-stranded DNA. TLRs signal 
through dimerisation, recruitment of MyD88 (Takeda et al. 2003), the intracellular 
TIR (Toll/IL-1R homology domain and phosphorylation and degradation of IkB. 
When stimulated in DCs, TLRs have been shown to be potent inducers of adaptive 
immunity. Medzithov reported that TLR signalling is able to increase the phagocytic 
ability of DCs and also improve endosomal maturation, thus facilitating antigen 
association and presentation in MHC context (Blander and Medzhitov 2006). 
Stimulation of TLRs is now being tested in clinical trails as adjuvant. 
 
During viral infection TLR3, TLR4, TLR7 and TLR9 in particular assume an 
important role in DCs, as they induce type I IFN secretion and proinflammatory 
signals. Their stimulation also leads to DC maturation and upregulation of 
costimulatory molecules (Durand et al. 2004). TLR3 is a strong inducer of Type I IFN 
after dsRNA recognition. TLR3 is localized on endosomal membrane thus suggesting 
that viral entry route may determine the magnitude of its contribution to DC 
activation and secretion of IFN. Nonetheless, since newly-synthesized dsRNA and 
dsRNA from released viral genomes are not accessible to TLR3, production of type I 
IFN can also occur in a TLR3-independent manner through stimulation of 
cytoplasmic RIG-1, retinoic-acid-inducible protein-1 (Yoneyama et al. 2004). TLR7 
and TLR9 are highly expressed in pDCs and in this cell type they induce IFN-α 
secretion when stimulated. Among other receptors recognising pathogen-associated 
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patterns are the C-type lectins Dectin-1 and Dectin-2: they recognise β-glucan and 
mannan, respectively, from fungal cell walls (Iwasaki and Medzhitov 2010).  
Danger signals differ from pathogen-associated signals as they are induced by self 
proteins whose availability or presence in the intracellular space indicates cellular 
stress or necrosis. Certain self proteins are in fact released when stress or necrosis 
occur in cells: among others are heat shock proteins, (Arnold-Schild et al. 1999), the 
high mobility group box-1 or HMGB-1 (Rovere-Querini et al. 2004), and intracellular 
molecules which are exposed externally on the plasma membrane like the ligand for 
CD36. Also, danger signals can derive from matrix degradation products such as 
hyalurotnan, cellular cytokines and cell surface ligands related to cell damage and 
necrosis such as TNF-α, IL-1, and CD40L. CD40L is very important in this context as 
the stimulation of CD40 is needed for maturation of DCs to occur (Cella et al. 1997).  
Danger signals and the recognition of pathogen-associated patterns are necessary for 
proper maturation of DCs and for the secretion of pro-inflammatory mediators and 
upregulation of coreceptors. The activated receptors induce different intracellular 
signalling and thus regulate maturation of DCs, representing the first stage of 
differentiation of an immune response. 
 
 
 
2.5.7 Dendritic cell migration to lymph nodes 
 
Upon receiving danger and inflammatory signals from the microenvironment, the 
maturation program is triggered in DCs. Maturation induces internalisation of 
endocytic receptors, down-regulation of the antigen processing machinery and of the 
synthesis rate of MHC-I complexes (Rescigno et al. 1998) and an increase in the half-
life of MHC-II complexes on the plasma membrane. Additionally, maturation induces 
upregulation of receptors for homing to LNs like RAGE (Manfredi et al. 2008), 
chemokine receptors like CCR7, and adhesion molecules like caderins, together with 
co-stimulatory molecules like CD80, CD86 and CD54. The secretion of cytokines is 
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also increased: in particular IL-2, which enhances and sustains T cell survival and 
proliferation. Finally DCs undergo cytoskeleton reorganisation, as mobility needs to 
be increased, and the cells round-up losing their dendritic projections. 
Migration out of the infected tissue is led by the newly expressed chemotactic 
receptors. DCs follow chemotactic signals to the LNs and spleen where they will 
mediate presentation of antigen to T cells. The entry route and localisation in SLOs 
will be analysed in more detail below (Chapter 2.5.9). CCR7 is the main responsible 
for leading migration of DCs to the LN and also their positioning deeper into the 
cortex. CCL19 and CCL21 are instead involved in getting DCs to cross the 
subcapsular sinus floor of the LNs (see below). Notably, mature DCs cannot enter the 
thymus, where immature DCs and precursor have instead free access. Limitation of 
DC access to the thymus seems to be aimed at maintaining peripheral tolerance; 
mature DCs are not allowed to enter the thymus to avoid deletion of T cells 
recognising foreign antigens (Bonasio and von Andrian 2006). Both immature and 
mature DCs can enter the BM, which can function as a secondary lymphoid organ (Di 
Rosa and Pabst 2005). 
DCs reach the LN after skin challenge in 16-18 hrs, but soluble antigen in the blood 
can be presented after about 4 hr. Soluble antigen in fact travels to the LN itself, 
where it can be uptaken by resident DCs and presented right away as described below 
(Kissenpfennig et al. 2005).  
 
 
 
 
2.5.8 Presentation and priming: co-stimuli and cytokines 
 
Presentation of antigens and priming of CD8 T cells occurs in SLOs, where DCs 
migrate after maturation led by receptors like CCR7. The importance of DCs as 
initiators of the immune response is in the capacity of these cells to convey multiple 
signals, thus being able to tune and modulate CD8 T cell activation. Three signals, 
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according to the Danger Theory (Matzinger 1994), must be conveyed to a T cell for 
full activation to be achieved: antigen in MHC context, costimulation and 
inflammatory signals. Only DCs can deliver these 3 signals to a T cell through their 
MHC molecules, B7-1 and B7-2 receptors and cytokine production.  
The clustering between a DC and T cell is mediated by the interaction between 
MHC and coreceptors, and by adhesion molecules, like integrins and proteins of the 
immunoglobulin superfamily LFA-2 and ICAM-1. The role of costimulation has been 
reviewed for CD8 T cells in the corresponding section of this manuscript (see 
2.2.4.1), and it is now reviewed describing some of the main DC costimulatory 
receptors in this chapter. 
 
 
Figure 17: Scheme of the three danger signals needed for T cell 
activation – the figure illustrates the signals for CD4 T cells, 
which, apart from MHC-II, are the same as in CD8 T cells 
(Lipscomb and Masten 2002).  
 
 
DCs are able, through production of cytokines and transmission of costimulatory 
signals, to instruct T cell activation. CD28 and its ligands B7-1 (CD80) and B7-2 
(CD86) were the first costimulatory molecules to be discovered (see Table 1). CD28 
role in stimulating proliferation, antigen sensitivity and survival and in decreasing 
activation threshold and doubling time has been widely demonstrated both in vivo and 
in vitro (Harding et al. 1992). CD80 and CD86 are expressed in DCs upon TRL 
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stimulation and maturation. These receptors bind CD28 but can also bind CTLA-4 
which, especially on Tregs, has an inhibitory role (Grohmann et al. 2002). CD86 is 
constitutively expressed at low levels and rapidly upregulated upon maturation, 
whereas CD80 expression is inducible. Turley and colleagues showed that B7 
costimulatory molecules are loaded in the endosomes where MHC-II are loaded and 
are transferred to the plasma membrane together with the MHC (Turley et al. 2000). 
Specific depletion of CD28 costimulation induced apoptosis in antigen-specific cells, 
which resulted to be Fas- and CD4-independent (Dolfi et al. 2011).  
 
A new B7 family member, which acts as a costimulating receptor, was identified by 
Chapoval and colleagues and named B7-H3 (Chapoval et al. 2001). This membrane 
protein is expressed on immature and mature human myeloid DCs and it is induced 
by LPS and IFN-γ (but suppressed by IL-4) in mouse DCs. Studies in KO mice 
support an inhibitory role for B7-H3 in polarised TH1 responses (Suh et al. 2003) but 
its T cell receptor has not been identified yet. B7-H3 is also released by human DCs 
and can be found in the serum. Another member of the B7 family has been recently 
discovered and called B7-H4. Its ligand is not known and it is induced on B and T 
cells, DC, some NK and monocyte lineages in humans, therefore its role is not of too 
much interest for the scope of this project (Prasad et al. 2003).  
 
During DC-T cell interaction, the ligation of coreceptors signals back to the DC as 
well sustaining further maturation. CD40 interaction with CD40L on T cells is 
required for IL-12 production, which is important for CD4 T cell responses (Cella et 
al. 1996). DCs also receive additional maturation signals from CD40L, 
RANK/TRANCE, 4–1BB, and OX40 ligand molecules, which induce the release of 
chemokines such as IL-8, fractalkine, and macrophage derived chemokines that 
attract lymphocytes (Tang and Cyster 1999). 4–1BB ligand expression and interaction 
with its receptor on T cells not only induces CD8 T cell proliferation but also 
production of IFN-γ (Shuford et al. 1997). 
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DC CD8 T Cell  
B7 family and receptors  
B7-1 (CD80) CD28, CTLA-4 (CD152) 
B7-2 (CD86) CD28, CTLA-4 (CD152) 
B7RP-1 ICOS 
PD-L1 (B7-H1) PD-1 
PD-L2 PD-1 
B7-H3 Not known 
TNF family ligand and receptors  
CD40 CD40L (CD154) 
OX40L OX40 (CD134) 
4-1BBL 4-1BB (CD137) 
TRANCE 
(RANK) 
TRANCE (RANK-L) 
CD27 CD27L (CD70) 
CD30L (CD153) CD30 
Miscellaneous  
ICAM-1 (CD54) LFA-1 (CD11a/CD18) 
DC-SIGN 
(CD209) 
ICAM-3 (CD50), ICAM-2 (CD102) 
SLAM(CD150)  SLAM (CD150) 
CD58 CD2 
Table 1: Costimulatory molecules on DCs and receptors on T 
cells (Lipscomb and Masten 2002). 
 
 
Engagement of RANK, receptor activator of NFkB, a member of the TNFR family, 
on DCs by its ligand RANKL/TRANCE expressed on activated T cells, stimulates the 
secretion of inflammatory and TH1 cytokines like IL-1, IL-6, and IL-12. Once 
triggered, RANK signalling also sustains DC survival through the upregulation of the 
antiapoptotic molecule Bcl-XL (Wong et al. 1997). 
Costimulation also occurs by means of activation downregulation. B7RP-1 (or 
ICOS-L), the ligand for ICOS, is important mostly for T cell instruction of B cell 
activation (Yoshinaga et al. 1999). ICOS is upregulated on CD4 T and CD8 T 
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following activation and is present on effector and memory T cells. ICOS expression 
is stimulated on T cells by both TCR and CD28 signals and its interaction with the 
ligand provokes its downregulation, as a mean to control immune responses 
(McAdam et al. 2001). Another DC costimulatory molecule with negative regulatory 
effect on immune response is PD-L1 (programmed death ligand 1, also called B7-HI) 
which binds to PD-1 receptor on T cells, downregulating T cell activity (Liang et al. 
2003). PD-L1 is constitutively expressed on DCs. What determines the final 
activation status of the CD8 T cell is therefore the result of stimulatory signals 
transmitted by coreceptors like CD28 and ICOS and inhibitory ones from PD-1 and 
CTLA-4. 
 
DCs have been shown to be able to prime T cells responses outside lymphoid sites 
during influenza infection: this priming can for example take place in structures 
called induced BALT (iBALT) (Moyron-Quiroz et al. 2004; Moyron-Quiroz et al. 
2006). In a paper published last year by Dolfi and colleagues, it was demonstrated 
that costimulation is needed in CTL responses at peripheral sites during the advanced 
phases of the response, as depletion of DCs at day 6 p.i. resulted in impaired CTL 
expansion. These results are important for determining the need for sustained versus 
limited antigen presentation in the stimulation of optimal CTL responses. This will be 
object of further discussion below. 
 
 
2.5.9 Secondary lymphoid organs 
 
When describing the lymphatic system, the organs generating immune cells are 
considered “primary”, like the thymus and the bone marrow, while those where the 
immune responses are initiated are deemed “secondary lymphoid organs”. Spleen and 
LNs are therefore considered secondary lymphoid organs together with tonsils, 
Peyer's patches, and the mucosa-associated lymphoid tissue (MALT). They have a 
very similar structure for lymphoid purposes which will be reviewed here for the 
purposes of my research.  
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Figure 18: Lymphatic system and LN distribution in the human 
body (http://www.gorhams.dk/html/the_lymphatic_system.html). 
 
 
LNs are spread across the body, usually at the junction of 2 or more lymphatic main 
vessels and receive the lymph drained from the neighbouring organs (Figure 18). The 
spleen acts as a blood filter, and due to this activity it also acts as a lymphoid organ as 
it houses T and B cell conglomerates which are ready to proliferate and activate when 
pathogens are sense during blood “filtration”.  
 
 
2.5.9.1 Lymph node structure and function 
Lymph nodes are filter structures which sit at the junction of lymphatic vessels 
collecting the lymph out of peripheral tissues and operate as a check point (von 
Andrian and Mempel 2003). There are 450 identifiable LNs in humans (Figure 18) 
and 22 in mice (Figure 19) (Van den Broeck et al. 2006). These small spheroid organs 
have the key function of facilitating encounters between pathogen-derived antigen 
and the cellular compartment of the adaptive immune system.  
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Figure 19: LN location in mouse (Dunn 1954). 
 
 
The LN structure quite amazingly explains the reason for having several subsets of 
DCs and for a distinction between resident and migratory ones. Each lymph node is 
made of a capsule, the most external section, a cortex, where mainly B cells reside, 
and a medulla, which is the most internal area and where the T cells transiently reside 
(see Figure 20): B and T cells are therefore separated in the parenchyma of the organ. 
 
Each LN receives several afferent lymphatic vessels and has one efferent vessel. LNs 
can contain one or more functional and anatomical units called lobules, each of which 
receives a single afferent lymphatic vessel and is formed by a capsule-surrounded 
follicle in the cortex and a deep cortical unit (DCU) in the medullary section. The 
lymph enters through the subcapsular sinus, flows down the sides of the lobule 
through the transverse sinuses and then flows into the medullary sinuses. In the 
peripheral DCU and in the interfollicular cortex run arterioles, high endothelial 
venules and paracortical sinuses. Arterioles and venules are then conveyed in the 
medullary cords, which form the efferent vessels. 
 
Each lobule contains a dense reticular meshwork, composed of stellate, spindle 
shaped or elongated FRCs (Clark 1962), which provide a three dimensional scaffold 
for lymphocytes, APCs and macrophages to interact (Figure 20 and Figure 21). Each 
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cortical follicle, delimited by cortex, is home to B lymphocytes and allows them to 
interact with special DCs called follicular dendritic cells (FDCs). 
 
 
Figure 20: Structure of a lymph node: identification of lobule 
units, medullary and cortical regions and afferent and efferent 
vessells (http://www.acm.uiuc.edu/sigbio/project/updated-
lymphatic/lymph7.html). 
 
 
Stimulated B cells proliferate within the follicles forming distinctive germinal centres 
and the follicles are then referred to as secondary follicles. In the medullary section, T 
lymphocytes home to the deep cortical unit (DCU) where they interact with dendritic 
cells. T lymphocytes home to the paracortex and interfollicular cortex to survey DCs. 
Because each afferent lymphatic collects lymph from a different drainage field, each 
lobule is potentially exposed to a different set of antigens, APCs and inflammatory 
mediators (Sainte-Marie et al. 1982). Activated T lymphocytes proliferate in the DCU 
but do not form a germinal-centre-like structure.  
 
Surrounding each lobule are the lymphatic sinuses, delimited by a trilaminar 
membrane formed by a layer of sinusal FRCs, a layer of lobular FRCs and a layer of 
basal lamina between them (Kaldjian et al. 2001). This thin membrane prevents 
lymph, cells and particulates from passively entering the lobules. Inflammatory 
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mediators such as MCP-1 and IL-8, secreted by innate cells upon TLR stimulation, 
are transported to the local lymph node in the lymph.  
 
 
There are a few main points to be considered for our purposes. i) T cells are 
segregated in the T cell area and have high motility, driven by CCL19 and CCL21 
chemokines. ii) A population of resident DCs inhabits the sinus and continuously 
migrates between this and the T cell area. iii) LNs receive lymph from afferent 
lymphatic vessels but the soluble particles which are in the lymph never directly get 
into contact with T cells, they rather go through ducts called conduits. iv) DCs in the 
T cell area seem to be responsible for uptaking antigens that flow through the LN: 
they can uptake soluble particles by extruding their dendrites into the lumen of the 
conduits. DCs in the T cell area can therefore receive information from the periphery 
via cytokines and other inflammatory mediators released in periphery and reaching 
the LN via the lymph (Sixt et al. 2005). 
 
 
Figure 21: Lobule structure (Willard-Mack 2006). 
 
 
The location of resident DCs resonates with a role for these cells in activating naïve 
T cells and modulating the developing CTL response. In addition, migratory DCs can 
be found in the spleen in inflammatory conditions. These cells can reach the LN from 
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the periphery when inflammatory stimula cause their maturation. Only mature DCs 
can cross the subcapsular sinus. Migratory DCs usually reach the T cell area first, 
showing high motility that slowly disappear as these cells join the network of resident 
DCs. Resident DCs have a much more limited motility but boast very contractile 
dendrites (Lindquist et al. 2004). The cortex structure is maintained in place by FRCs 
which create a network along which naïve T cells migrate constantly. It has been 
shown how this portion of the parenchyma almost totally excludes liquid and consists 
of 95% naïve T cell and 5% FRC. The reticular system has a role in facilitating 
encounters between naïve T cells and DCs, and in assist resident DCs in making 
contact with migratory ones, as this process needs to be efficient and quick.  
 
As naive lymphocytes recirculate in the circulating and lymphatic systems 
uninterrupted, the body’s pool of lymphocytes turns over 10 to 48 times every 24 
hours. In particular, lymphocytes enter the LN continuously via the high endothelial 
venules (HEV) and exit via specialized sinuses called paracortical sinuses. Once 
inside, they move around in a narrow perivenular space between the endothelial 
basement membrane and the surrounding pericytic FRCs called the perivenular 
channel (Gretz et al. 1997). The perivenular channel receives inflammatory mediators 
from the conduit system. Lymphocytes spend 10 to 100 minutes in this space and 
inflammatory signals received in this area influence their subsequent behaviour. 
Lymphocytes then move out into the corridors of the paracortical cords by crawling 
along FRCs. T lymphocytes interact with dendritic cells positioned within the cords 
while B cells move through the cords to the follicles where they interact with FDC). 
The migration is guaranteed and maintained by chemokines (mainly CCL19 and 
CCL21) expressed by the FRC network. FRCs themselves can uptake, and transfer to 
the conduit system through transcytosis, both soluble antigens and inflammatory 
mediators (Anderson and Shaw 1993). T cells are also attracted by existing CD4 T 
cell-DC interactions which result in the release of cytokines and chemokines to attract 
CD8 T cells.  
CXCL9 and CXCL10, CXCR3 ligands, are induced in a TNF-dependent way in the 
lumen of high endothelial venules in correspondence with the initial inflammatory 
status of peripheral tissues and expression of CCL3 and CCL4 in the lumen of HEV 
enhances early recruitment of DCs and pDCs to the LN (Yoneyama et al. 2004). 
These chemokines also attract T cells which are CXCR3
+
, like CTLs and memory 
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cells, which are thought to be the component of the initial increase of cellularity in the 
LNs. CTLs and memory cells can kill resident DCs when activated. This mechanism 
seems nonsense, but may make the main contribution to the resolution of immune 
responses and was analysed in Chapter 2.4. 
 
The LN architecture and its FRC system are very efficient at making sure low-
frequency antigen-specific T cells are able to get in contact with antigen-bearing 
mature DCs quickly and efficiently. Also, it allows soluble signals to reach the LN in 
a matter of seconds from their release in the periphery. Naïve lymphocytes can spend 
from hours to days in a LN, looking for antigen (Gowans and Knight 1964). During 
their wandering around, sliding on each other to make contact, naïve lymphocytes 
interact with thousands of DCs and FRCs. Most lymphocytes do not bind cognate 
antigen and will eventually leave the lobule via the paracortical sinuses and 
recirculate to another lymph node to continue their search for antigen. 
 
The DC population of the LN is quite complex. Five populations have been 
identified (Henri et al. 2001). As well as the CD4
+ CD8α- DEC-205-, the CD4- CD8α- 
DEC-205
-
 and
 
the CD4
- CD8α+ DEC-205+ subsets, there are two additional DC 
subsets that lack CD4 and express only moderate levels of CD8α, but clearly express 
DEC-205 and high levels
 
of MHC class II. One subset expresses moderate
 
levels of 
DEC-205 and may represent interstitial tissue-derived
 
DC, monocyte-derived DC, or 
an activated version of the splenic CD4
- CD8α- DC (described in 2.5.9.2). The second, 
more
 
distinctive subtype, expresses
 
higher levels of DEC-205 and appears to represent 
a mature form
 
of LC. Both of these subsets are among the DCs that
 
migrate out of the 
skin into the draining LNs. The migration pattern was described by Kamath and 
colleagues by catching
 
DCs that emerge from skin explants before locating in LN
 
and 
tracking skin-derived DCs after painting the skin with
 
a fluorescent dye (Kamath et 
al. 2000). These cells cannot be found in the spleen due to the absence of afferent 
lymphatic in this organ. In lymph nodes, CD8α+ and CD8α- DC each represent 20% 
of the total DC population. Within the LN, both CD8α+ and CD8α- DC display a half-
life of 4.5 days. Analyses of BrdU-labelling kinetics of LCs and dermal DCs within 
the per-LNs of C57BL/6 mice revealed that migratory cDCs have a slow turnover 
with an half-life of > 21 days for LCs and of 12 days for dermal DCs (Kamath et al. 
2002). 
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The LN structure allows for maximal chance of encounter between a mature, 
antigen-loaded DC and a cognate CD8 T cell. This is also due to the continuous flow 
of naïve T cells and of migratory DCs contributing to supplying antigen from the 
periphery.  
 
 
2.5.9.2 The spleen as a secondary lymphoid organ 
The spleen is a bean-shaped organ primarily acting as a filter for the blood. The 
blood reaches the organ though the afferent splenic arteries and leaves the circulation 
to enter the red pulp via the central arterioles, where it percolates to its cords via a 
system lacking endothelial lining but full of macrophages and lymphocytes. On the 
way to the afferent venules of the red pulp, the blood encounters the white pulp, 
sheets of lymphoid tissue (which contains T and B cells, but also DCs and 
macrophages) organized around the branching arterial vessels. The spleen therefore 
not only works as a filter to retain old stiffening erythrocytes and recycle the haems, 
but also as a secondary lymphoid tissue where naïve lymphocytes are able to interact 
with antigen-loaded dendritic cells and start an immune response. The external 
section of the spleen is called marginal zone (MZ) and its architecture is dictated, as 
explained below, by the function. Deeper than the marginal zone sit the germinal 
centers (B cell follicules) and the T-cell areas (Figure 22). 
In the same way as in the LN the stromal component is fundamental not just for the 
tridimensional structure of the organ, but also for the organization and interaction of 
its cellular components, the non-lymphoid component of the spleen defines its 
architecture and function and controls the homeostasis of the T and B cell component. 
The structure of the spleen allows for maximized odds of encounter between an 
antigen-specific naïve lymphocytes and mature antigen-carrying DCs. A dense 
network of FRCs guides lymphocyte to travel inside the marginal zone first and the 
white pulp afterwards. These cells allow for close interaction between the resident 
DCs and the migrating T cells in the same way as they do in the LNs. Also mirroring 
the LN conduit system is a tubular network that permits the quick transport of solutes, 
cytokines and chemokines between the sheets of the lymphoid tissue to facilitate the 
diffusion of antigens. 
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Expression of CCL19 and CCL21 chemokines by FCRs in the T-cell zone makes 
sure entering T–lymphocytes find their way to the T-cell zone after accessing the 
organ via the terminal arterioles which feed the MZ. Lymphocytes then travel along 
narrow bridging channels that connect the MZ to the T-cell area, before extravasating 
into the white pulp. Once homed to the white pulp, they remain in the organ for a few 
hours during which they migrate within the T-cell zone directed and sustained by 
chemotactic signals released by the networking FRCs. During this time, they interact 
with resident DCs which might or might not present antigen and costimulatory 
molecules.  
 
 
Figure 22: Spleen structure (a) and differences between 
mouse and human spleen, b (Mebius and Kraal 2005).  
 
 
The spleen has three populations of resident DCs: CD8α+ DC, CD8α- DC CD4+ and 
CD8α- CD4-, of which the last is the biggest in number (Vremec et al. 2000). As 
described above, resident DCs developmentally arise from pre-DCs and proliferate in 
the spleen, regulated by lymphotoxin-β (Kabashima et al. 2005). Proliferation occurs 
at a fast rate, as the half-life of these cells here is about 3 days (Kamath et al. 2000). 
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Among the 3 spleen-resident conventional DC populations, CD8α+ DCs have the 
fastest turnover, with a half-life of 1.5-2 days. CD8α- DCs have a slower turnover 
with a half-life of 3 days. Mattei and colleagues showed that type I IFN regulates DC 
turnover in vivo (Mattei et al. 2009).  
CD8α+ DCs are mainly located within the T cell areas and marginal zone, whereas 
CD8α− DC are preferentially located in antigen-capture areas, i.e. in the spleen red 
pulp and bridging areas and MZ and in the per-LN subsinusal layer beneath the 
subcapsular sinus (Idoyaga et al. 2009). Mature DCs move from the marginal zone to 
the inner pulp where they interact with antigen-specific T cells.  
It is still unclear to what extent migratory DCs contribute to the spleen resident 
population. In the spleen there is no specifically directed trafficking of migratory DCs 
from the lymphatic, but migratory DCs can still reach the organ through the 
circulation and enter the marginal zone. When they enter the spleen through the 
circulation, DCs go through the Marginal zone first as well. CD47 has been involved 
in homing of DCs to the spleen, as in CD47
-/-
 mice there is a substantial reduction of 
DCs in the MZ. Precursors of DCs at any developmental and differentiation stage also 
circulate freely and are retained in the spleen.  
 
 
2.5.10 CD8α+ dendritic cells 
 
Mouse DCs are an extremely complex population made up by several subtypes 
which reside in peripheral lymphoid and non-lymphoid tissues. Among all subsets the 
CD8α+ DCs (hereafter named CD8α DCs) are the cells that have been shown to be 
more efficient at cross-presenting antigen in MHC-I context to CD8 T cells. This 
subset is also mainly responsible for activation of CD8 memory responses. For this 
reason it will be the object of a more detailed description in this chapter. 
The CD8α DC subset is characterised by the expression of CD8α as a homodimer, 
α-α as opposed to α-β which is found on CD8 T cells, and specific langerins and C-
type lectins. The subset is identified as CD8α+ CD11chigh CD205high CD24+ Clec9A+ 
CD11b
low 
and MHC-II
high 
when mature. CD8α DC is the subset mainly responsible 
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for the priming of CD8 T cell responses, particularly during viral infections (Belz et 
al. 2004). When pMHC complexes were analysed in splenic dendritic cells presenting 
soluble or cell-associated OVA, CD8α+ CD11b− dendritic cells resulted more efficient 
for MHC class I cross presentation (den Haan et al. 2000; Pooley et al. 2001) and 
CD8α− CD11b+ dendritic cells for MHC class II–restricted presentation (Chung et al. 
2007).  
The high cross-priming efficiency of CD8α+ DCs has been correlated with their 
ability to internalize dying cell-associated antigens (Iyoda et al. 2002) through the 
expression of specific scavenger and death recognition receptors. Clec9A (or DNGR-
1) is a C-type lectin involved in the uptake of dead cells like DEC-205 (see 2.5.4.3). 
Clec9A is specifically expressed in pDCs in humans (Huysamen et al. 2008), and in 
CD8α DCs and pDCs in mouse, where it acts as a monomer. Clec9A recognises a 
self-component internal molecule that becomes exposed only when membrane 
integrity is compromised, this has recently been described to be actin (Sancho et al. 
2009). Interestingly, several groups reported how antibody-conjugated targeting of 
antigen to this receptor resulted in an enhancement of antibody and CD4 T cell 
responses in both humans and mice (Caminschi et al. 2008; Idoyaga et al. 2001). 
Expression of CD36 is also characteristic of this DC subtype. CD36 (see 2.5.4.3) is 
another surface molecule involved in the recognition and endocytosis of dead cells. 
The presence of molecules like Clec9 and CD36 on this DC subset strongly suggests 
its involvement in the phagocytic uptake of dead or dying cells. Experimental 
evidence supporting this theory includes the verification that antigens uptaken 
through these receptors are efficiently processed and presented on MHC-I and MHC-
II complexes (Inaba et al. 1998). The ability to specifically phagocytose apoptotic 
cells correlates with the need to prime and develop CD8 T cell responses against 
intracellular pathogens like viruses which do not infect DCs and against altered self-
proteins derived from cancer cells. Moreover, through this mechanism DCs can 
prolong antigen presentation past their life. The uptake of an apoptotic DC by another 
DC would allow the presentation on the phagocytic cell of the antigens processed and 
presented by the dying cell. The ability of these apoptosis receptors to send 
internalised antigens to the cross-presentation pathways has been exploited to 
specifically deliver antigens to the cross-priming processing pathway, for example 
targeting of C-type lectin receptors such as DEC-205 (Dudziak et al. 2007) and the 
recently described DC, NK lectin group receptor-1, DNGR-1 (Sancho et al. 2008). 
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The specific composition of the TLR repertoire expressed by the CD8α DCs also 
supports the specificity of this subset for CD8 T cell priming during viral infections. 
The specific TLRs expressed indicate a role for CD8α DCs in sensing viral infections, 
for example through TLR3, which recognises dsRNA and drives DC maturation when 
engaged. TLR3 is expressed in early endosomes in immature DCs and migrates to 
LAMP1
+
 endosomes when stimulated with short sequences of dsRNA, as showed by 
Jenilek and colleagues. They also demonstrated that the potency of DC activation was 
directly correlated to the size of the dsRNA (Schulz et al. 2005; Jelinek et al. 2011).  
Interestingly, TLR7 is not expressed in this subset while it is abundant in pDCs. 
Analysis of gene-expression profiles suggests that CD8α DCs, in contrast to CD8α- 
DCs, are endowed with an antigen-processing machinery specifically required for 
cross-presentation (Iyoda et al. 2002; Dudziak et al. 2007). The presence of antigen-
specific machinery has been shown to be important for cross-presentation more than 
antigen capture levels, which are comparable in the two subsets (Schnorrer et al. 
2006). Having shown how CD8α+ DCs compared to CD8α- DCs are more efficient at 
cross-presenting and priming CD8 T cells, further studies focussed on the mechanism 
that make this possible. The suggestion that a specific subset of proteases might be 
present in the former, therefore making the cells more efficient at processing antigens 
to be loaded on MHC-I, has been tested. Two more studies, by Dudziak and by Kurts, 
have recently shown that quantitative differences in MHC-I and MHC-II processing 
machinery-related protein might exist in different DC subsets: for example CD8α 
DCs were shown to be enriched in proteines involved in MHC-I presentation like 
Tap1, Tap2, calreticulin, calnexin, Sec61, ERp57, ERAAP, as well as cystatin B and 
C, which is in line with their bias towards CD8 T cell priming (Dudziak et al. 2007; 
Burgdorf et al. 2008). 
 
These results are also consistent with the localisation and predominance of this 
subtype in SLOs. The CD8α DC subset resides in the spleen and LNs, but not in 
peripheral tissues. How these cells enter in contact with antigens other than soluble 
ones travelling through the lymphatic system or dead cells in the same condition was 
studied. It has been proposed that CD8α DCs acquire antigen from mature migratory 
dendritic cells which enter the LNs of infected mice through the blood stream (Allan 
et al. 2006). For example, priming of HSV-specific CD8 T cells after skin inoculation 
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of HSV has been shown to be mediated by CD8α DC and not dermal/Langerhans or 
epidermal (skin-derived) ones. Nonetheless, the latter are present at the site of 
priming in the draining lymph-node, suggesting a role in transporting the antigen 
from peripheral tissues to resident CD8α DC to allow for specific and strong cross-
presentation. Proof of this mechanism was found by the same group when, by 
blocking migration out of the skin of dermal and Langerhans cells, T cell priming was 
prevented (Allan et al. 2006). Also, in 2004, Belz and colleagues carried out some 
experiments in which, through intra nasal instillation of a CFSE solution and 
infection with a flu virus, they investigated the origin of the DCs involved in 
presentation of MHC-I restricted antigen. Results showed that CD8α DCs did not 
derive from the lungs, while another subset indirectly involved in cross-priming was. 
The latter was identified as CD8α- CD11b- DC and was shown to be lung-derived. 
These results prompted the scientists to wonder how the CD8α+ DC population could 
acquire antigen if it had not met the pathogen in the lung. The same group 
demonstrated in vitro that the CD8α- CD11b- DC population alone cannot prime CD8 
T cells but, when an external CD8α DC population is added to the culture, CD8 T cell 
proliferation is obtained (Belz et al. 2004). They could therefore explain how 
migratory tissue-derived DCs can function as shuttles for peripheral antigens which 
would otherwise not reach the site of CD8 T cell priming. 
 
One further function of CD8α DCs seems to be to act as early shuttles of 
intracellular or blood-borne pathogens like Listeria and Toxoplasma from the MZ to 
the T cell area of the spleen (Figure 23). This role is in line with the theory depicting 
CD8α DCs as highly endocytic machines for the uptake of soluble antigens and 
apoptotic cells locally in the LNs and spleen. A model has been proposed by 
Neuenhahn and Busch in 2007 whereby this subset would be mainly located in the T 
cell area but with an outpost in the Marginal zone where it patrols the blood for 
antigens to be taken to the T cell area (Neuenhahn and Busch 2007).  
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Figure 23: Shuttle function of CD8α DCs for blood-born 
pathogens inside the spleen (Neuenhahn and Busch 2007). 
 
 
Production of high levels of IL-12p70 has been demonstrated when CD8α DCs are 
stimulated in an inflammatory environment, for example when CD40 stimulation is 
conveyed by CD4 T cells in presence of cytokines like IL-4, GM-CSF, IFN-γ, and 
engaged through a TLR molecule recognising a pathogen-associated pattern (Schulz 
et al. 2000). The CD8α subset is therefore capable of inducing a very strong CD8 T 
cell response: for this reason its regulation, both in the steady state and in the mature 
state has to be rigorous. 
In humans, the identity of this subset has been long elusive, but the counterpart of 
murine CD8α DCs has now been identified in humans in BDCA-3+ (CD141) cells. 
The first study to indicate these cells as possible candidate was a gene chip analysis 
of the transcriptome done by Robbins and colleagues in 2008 (Robbins et al. 2008). 
This same subset has been more recently shown to be highly efficient at cross-
presenting to CD8 T cells and to express high levels of XCR1 in 2 of 4 studies 
published in 2010 although the latter was only confirmed with PCR (Crozat et al. 
2010; Jongbloed et al. 2010). These cells also express Batf-3 and IRF-8, TLR3 but 
not TLR9 which is expressed on the murine DCs, and produce IL-12 when 
stimulated. Furthermore, they have been shown to be able to phagocyte dead cells. As 
described by Villadangos and Shortman (Villadangos and Shortman 2010), the 
studies to search for a homologue of the CD8α DC subset had been concentrated on 
SLOs like spleen and tonsils as the cells develop into immature DCs once accessed 
the organs themselves. The problem faced by scientists in defining the exact 
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correspondence of these cells to CD8α DCs regards the poor accessibility of LNs in 
humans due to ethical and logistical issues. Further functional studies can therefore 
only be conducted in in vitro systems.  
 
CD8α DCs have to date been described to be highly involved in cross-presentation 
of soluble and intracellular antigens to CD8 T cells and to aided by migratory DC in 
this task. They are the most efficient DC subset in cross-presentation and have 
specific membrane receptors which mediate uptake and phagocytosis of apoptotic 
cells. 
 
 
2.5.11  Plasmacytoid dendritic cells 
 
Plasmacytoid DCs were first identified in human blood at the end of the 1950s by 
three groups, but their existence was not confirmed in mouse and linked to the human 
counterpart until the mid 1990s (Galibert et al. 2001). Human pDCs are distinguished 
by their phenotype, defined as CD4
+
, CD45RA
+
, CD123
+
 (IL-3Rα), (MHC-II) HLA-
DR
low
, CD11c
-
, BDCA2
+
 and BDCA-4
+
. Rarely found in the spleen in the steady 
state, this subset resides mainly in secondary lymphoid organs and in the blood. 
Mouse pDCs are CD11c
int
 B220
+
 Ly-6C
hi
, express TLR7 and TLR9 but not TLR2, 
TLR3, TLR4, or TLR5 being therefore unable to recognise bacterial products like 
LPS. They recognise viral DNA through TLR7 and TLR9 and produce type-I IFN as 
a response: this induces cDC proliferation and increases their ability to cross-present. 
They also stimulate CTL and NK cytotoxic activity functioning as a link between 
innate and adaptive immunity. Plasmacytoid DCs are localised in SLOs, and other 
peripheral organs like lung, skin and liver. 
The precursor for pDCs is believed to be of lymphoid origin despite experiments 
suggesting that there might be a common progenitor to myeloid cDCs and pDCs (Liu 
and Nussenzweig 2010). This precursor is immobilized from the BM by GM-CSF  
and stimulated to develop and differentiate into immature pDCs by Flt3 both in 
humans and mice (Arpinati et al. 2000). Flt3-deficient mice in fact have lower 
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numbers of pDCs while transgenic mice overexpressing Flt3 have elevated numbers 
of pDCs (Brawand et al. 2002). Moreover, Oldstone’s lab showed in 2004 how 
persistent viral infection with LCMV CL13 is able to reprogram pDCs into cDCs 
(Zuniga et al. 2004). In the immature state, pDCs have a half-life of about 2 weeks 
(O'Keeffe et al. 2002). 
Plasmacytoid DCs were originally called IPC (interferon-producing cell) as their 
role is mainly associated with viral and intracellular bacterial infections, which they 
help to clear mainly through the secretion of type I IFNs. They sense viral nucleic 
acid through the endosome-located TLR7 and TLR9: TLR7 senses ssRNA and TLR9 
senses dsDNA and CpG oligonucleotides, synthetic mimickers of bacterial DNA 
which is rich in CpG regions (Iwasaki and Medzhitov 2010). TLR ligation in early 
endosomes triggers the production of type I IFN through the phosphorylation and 
translocation of IRF7 to the nucleus. Activation of the TLR in the late endosomes 
instead triggers maturation of the pDCs, cytokine production and at high levels, 
antigen presentation. Plasmacytoid DCs can produce, other than type I IFN, cytokines 
like IL-6, IL-12, TNF-α and chemokines like MIP-1α, MIP-1β, and RANTES. IL-6 
and both type-I IFNs in particular can induce B cell maturation to antibody-producing 
plasma cells (Poeck et al. 2004). The production of these cytokines suggests that 
pDCs are involved in the regulation of inflammation, thus providing a link between 
adaptive and innate immunity. Type-I IFNs and IL-12 stimulate cytotoxic activity 
from NK cells and INF-γ production (Krug et al. 2004), and can stimulate 
macrophages and their release of inflammatory molecules.  
In steady-state conditions pDCs are particularly abundant in the extra nodular 
compartment of LNs, around the HEV and in mucosal-associated lymphoid tissues, 
but they can accumulate in infected tissues when inflammatory signals are released, 
due to expression of CXCR3. CXCR3 binds chemokines CXCL9 and CXCL10 and 
its expression seems to be required for migration of pDCs to LNs in inflammatory 
conditions (Cella et al. 1999). Since pDCs are present in the blood it is also thought 
that these cells can travel to the LNs in the steady state through the HEV: they 
express CCR7 for constitutive migration to the LN through the lymphatic system. 
Nonetheless, pDCs are more frequently found in lymphoid tissues during infections. 
They are therefore thought to be important in bringing the necessary costimulation 
signals for activation during systemic infections, for prolonged in loco antigen-
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dependent CTL stimulation and for priming of responses against pathogens with 
tropism for lymphoid tissues. Also, various studies demonstrated how the 
contribution of pDCs in interferon production might be only secondary when other 
cell types are also stimulated (as alveolar macrophages for example). This will be 
discussed further in the Discussion Chapter. 
The role of pDCs as antigen-presenting cells has been long debated. They are poor 
inducers of T cell stimulation since they display low levels of costimulatory 
molecules, have scarce endocytic capacity and do not have an efficient antigen 
processing and presentation machinery. Plasmacytoid DCs express both MHC-I and 
MHC-II but have a different regulation system of the complexes’ half-life compared 
to cDCs. In particular, the promoter of the transcription factor regulating MHC-II 
transcription machinery, CIITA, in pDC is not silenced upon maturation of the cell. 
The direct consequence is that pDCs continuously recycle MHC-II to the surface, 
presenting antigens they encounter but not retaining presentation of antigens 
previously encountered. Low expression of two cathepsins involved in antigen 
processing (Cathepsin S and Cathepsin L) has been found in pDCs (Fiebiger et al. 
2001): therefore, pDCs cannot be as efficient as cDCs at presenting antigen at a 
lymphoid site. Nonetheless, pDCs are apt at presenting antigens in very high systemic 
antigen concentration or when antigen is available locally at the site of pDC-T 
interaction. Based on the latter assumption, and also due to their capacity of migrating 
to the infected tissue, pDCs might be involved in presenting antigens at the site of 
infection to sustain the T cell response, other than providing costimulatory signals as 
described above. This happens for example in malaria immunity (Cockburn et al. 
2010). Moreover, stimulation with CpG-rich oligos has been shown to induce antigen 
presentation in pDCs, which can promote a Th1-polarised proliferation of CD4 T 
cells (Boonstra et al. 2003). Recent studies conducted by Pucchio and colleagues, also 
suggest that human pDCs could, when activated with influenza virus, induce 
proliferation of T cells, both CD8, therefore demonstrating ability to cross-present, 
and CD4 T cells (Di Pucchio et al. 2008). 
Lastly, studies in humans and in mouse have suggested that pDC might be inducers 
of Tregs: freshly isolated antigen-pulsed immature pDCs can only stimulate a poor 
proliferation of T cells but, in presence of IL-2, they have shown to confer T cells a 
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regulatory function (Boonstra et al. 2003; Moseman et al. 2004). This tolerogenic role 
has been suggested to be location-dependent. More studies are needed in this regard. 
Plasmacytoid DCs have a different developmental path compared to other 
migratory DCs. They have a longer half-life and are high producers of type I 
interferon, a fundamental tool in immune responses against viruses. They have an 
indirect role in the priming of CD8 T cells as they are not good antigen presenting 
cells unless highly stimulated. Their role is mainly that of supplier of costimulatory 
signals and cytokines. 
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2.6 SERPINB9: of humans and mice 
 
 
Spi6 (SerpinB9) is a murine serine protease inhibitor (serpin) that has been shown 
to inhibit intracellular neutrophil elastase (Zhang et al. 2007) and to be a 
physiological inhibitor of granzyme B (Sun et al. 1997; Zhang et al. 2006). Spi6 is 
expressed in CD8 T cells, where it has a protective function against self-inflicted 
apoptosis, and in DCs, where its expression is upregulated specifically after 
maturation, its role is still controversial. Spi6 has a human homologue, PI-9 
(SERPINB9) (Sun et al. 1996; Sun et al. 1997). 
 
 
2.6.1 Protein structure, location, function 
 
Spi6 is composed of nine α-helices, three β-sheets and a flexible reactive centre 
loop (RCL). The RCL structure is essential for its function, as it contains a sequence 
that resembles the natural substrate of the protease targeted (Wei et al. 1994). The 
serpin is held in a metastatic state until it reaches the target, with the RCL exposed as 
“bait” for the protease. As the protease binds to the serpin and cleaves it, it undergoes 
a conformational change that locks the protease in place and keeps it bound 
irreversibly with a covalent link (Huntington et al. 2000). The stoichiometry of this 
reaction is 1 : 1, therefore a tight regulation of the levels of Spi6 is crucial for its 
proper function. Once locked in place, GrB cannot be released and the conformational 
change of the protease makes the complex highly susceptible to proteolysis 
(Huntington et al. 2000) and stable when run on a Western blot (Phillips et al. 2004). 
Inhibition of the ubiquitin-proteasome machinery in fact showed accumulation of PI-
9/GrB complexes in YT cells (Hirst et al. 2003). 
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2.6.2 Serpinb9/Spi6 in CD8 T cells 
 
Spi6 in mice is expressed at low levels in naive CD8
 
T cells and is significantly 
upregulated following activation and maturation to CTL and memory cells. In both 
cases, Spi6 expression has been proven to correlate with that of GrB and to have a 
protective function against the action of GrB that leaks from the granules and could 
trigger apoptosis in the CTL itself. In the same study, Ashton-Rickardt and colleagues 
also demonstrated that Spi6 has a role in maintaining cytotoxic granule architecture in 
place, as detailed in Figure 24 (Zhang et al. 2006).  
 
 
Figure 24: Spi6 role in maintaining cytotoxic granule architecture. Spi6 binds GrB 
leaking in the cytosol from the granules in WT CTLs thus inhibiting its pro-
apoptotic activity. In absence of Spi6 the number of granules in CTLs is defective 
and GrB activity is increased intracellularly (Zhang et al. 2006). 
  
 
A transgenic mouse expressing Spi6 under the human D2 promoter (Zhumabekov et 
al. 1995) was created to study Spi6 role in the development of memory cells. 
Overexpression of the serpin in these cells promoted long-term survival during the 
memory phase therefore increasing the size of the memory pool after LCMV 
infection, not affecting the size of CTL expansion (Phillips et al. 2004). Notably, 
other experiments conducted later in absence of Spi6, showed that the CTL clonal 
burst in these mice is impaired but the memory pool is comparable to WT mice, thus 
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demonstrating that the size of the memory pool is likely not to be directly correlated 
to Spi6 (Zhang et al. 2007). The proposed explanation for this is that memory 
precursors might express low levels of GrB therefore not needing to upregulate the 
anti-apoptotic molecule Spi6. In this model, Spi6 is not needed for memory 
formation. Notably, Spi6 levels in memory CD8 T cells have been shown to be 10 
times higher than in naïve CD8 T cells (Bots et al. 2005). This can be explained by 
the property of memory cells to be able to rapidly re-activate effector functions. In 
this context, Zhang and colleagues showed that Spi6 absence in memory cells causes 
impaired re-expansion when memory cells are stimulated (Zhang et al. 2007).  
 
This serpin is also expressed in NK cells, where it protects from misdirected GrB 
action as reported just last year by my colleagues (Ansari et al. 2010). It is also 
upregulated in DC during maturation induced by both CD40L and LPS, although 
studies on both PI-9 in humans and on Spi6 in mouse reported low levels of Spi6 
mRNA also in immature DCs (Medema et al. 2001).  
A recent report by El Haddad and colleagues in collaboration with our group has 
also shown expression of Spi6 in mesenchimal stem cells mirroring the human 
homologue expression (El Haddad et al. 2011). Notably, in a study by Medema and 
colleagues, Spi6 over-expression could protect tumour cell lines from CTL-induced 
apoptosis (Medema et al. 2001). 
 
 
2.6.3 SERPINB9/PI9 
 
PI (proteinase inhibitor)-9 is the human homologue of Spi6 and, like Spi6, can 
irreversibly inactivate GrB (Sun et al. 1996). Studies with PI-9 have shown its 
localisation is not limited to the cytoplasm as it has also been identified in the nucleus 
(Bird et al. 2001). It is expressed in CD8 T lymphocytes upon maturation with 
ConA/PMA, which mimics TCR triggering, but not with IL-2 alone, and in NK cells 
upon activation (Hirst et al. 2003). Its function in these cells is that of an anti-
apoptotic molecule, as it is for the murine homologue (Figure 25). It is also expressed 
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in DC upon maturation (Bladergroen et al. 2001), in endothelial and mesothelial cells 
(Buzza et al. 2001), mast cells (Bladergroen et al. 2005) and at immune-privileged 
sites (Hirst et al. 2001). Studies have been conducted to investigate the modulation of 
the protein and reported that PI-9 has a slow turnover rate. It is upregulated by IL-2 
and LPS in generic monocyte population but not in lymphocytes, and this effect is 
inhibited by blocking NF-kB (Classen et al. 2006). PI-9 has been shown to have an 
estrogen-responsive unit downstream of its promoter and to be expressed in an 
estrogen-dependent way in hepatocytes (Kanamori et al. 2000). Similarly, PI-9 is 
overexpressed in the estrogen-responsive cells of breast cancer (Jiang et al. 2006) .  
 
 
Figure 25: Mechanism of CTL protection from apoptosis mediated by PI-9. 
PI-9 inhibits small amounts of GrB that might be endocytosed after 
degranulation (1), GrB leaking from loaded granules (2), GrB that might 
escape loading into granules during synthesis and storage processes. When 
GrB concentration is higher, PI-9 is not able to control its cytotoxic action 
and apoptosis is triggered (4). PI-9 has not apoptosis inhibition ability when 
this is triggered by death receptors (Kaiserman and Bird 2010).   
 
 
Overexpression of PI-9 has been shown to protect CTL-induced killing via the 
indirect pathway, involving GrB and perforin, of HeLa cells in vitro (Bird et al. 1998; 
Cunningham et al. 2007). This anti-apoptotic expression of PI-9 has been investigated 
in hepatocytes, where it has been found to be upregulated in a IFN-γ, TNF-α-
dependent manner, for protection from CTLs and as a shield against cellular 
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immunity in estrogen-sensitive tumours (Kanamori et al. 2000; Barrie et al. 2004; 
Jiang et al. 2006; Stout-Delgado et al. 2007). 
 In a paper from 2006 Kaiserman and colleagues describe differences in the RCL 
sequence, in the kinetics and in the affinity to GrB for PI-9 compared to Spi6. The 
anti-apoptotic function of serpins was thus shown to be species-specific (Kaiserman 
et al. 2006; Kaiserman and Bird 2010).  
PI-9 expression seems to be correlated to the need of both effector and stromal cells 
to defend themselves against inflammation and GrB-induced tissue damage, thus 
making the molecule a mediator of protection from apoptosis. PI-9 is not only 
expressed by NKs, CTLs and T regulatory cells but also by endothelial and 
mesothelial cells and at immuno-privileged sites (testis and placenta). The hypothesis 
of a protective function is also supported by the observation that PI-9 is upregulated 
in infected hepatocytes (Stout-Delgado et al. 2007) and in tumour cells, where its 
function is involved in escape from the immune response (Medema et al. 2001a). 
Studies on PI-9 upregulation by tumors to evade the immune system have been 
conducted mainly on Hodgkin lymphoma, small-cell lung cancer and prostate cancer 
(Bladergroen et al. 2002; Ray et al. 2011). Other studies reported the presence of 
extracellular PI-9 in the serum of cancer patients and in highly inflammatory diseases. 
As PI-9 has no secretory sequence, a role for extracellular PI-9 is highly unlikely and 
its serum levels are thought to be due to release by necrotic cells (Kaiserman and Bird 
2010). 
The inhibition of lytic enzymes is, as expected, a mechanism also exploited by 
viruses to evade the immune response: a number of viruses encode  viral granzyme 
inhibitors. The pox virus, for example, is able to inhibit GrB by binding it with its 
cytokine response modifier gene-A (CrmA), which also binds and inhibits caspase-1 
and -8 (Quan et al. 1995). The parinfluenza virus 3 instead degrades GrB mRNA with 
an unknown mechanism. In humans, adenovirus inhibits GrB through its Ad5-100k, 
which binds GrB and gets cleaved at a very slow rate. This is expressed in very high 
concentration in infected cells so that GrB action is completely absorbed by it 
(Andrade et al. 2001). 
Since inhibition of GrB is desirable in a number of cases, where for example the 
expression of GrB is at the basis of disease pathogenesis, like in autoimmune diseases 
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(Casciola-Rosen et al. 1999), synthetic inhibitors of GrB have been produced. They 
include derivatives of isocoumarin, peptide chloromethyl ketones, and peptide 
phosphonates. As these compounds lack specificity, new compounds are being 
studied that have a specific 1,2,3-triazole moiety which confers more specificity 
(Willoughby et al. 2002)   
An interesting report was that of Mharus and colleagues’ in 2004: GrM was 
reported to be able to inhibit PI-9 activity when released extracellularly cleaving its 
RCL in an in vitro study about PI-9 expression in tumours. However, the study 
involved pretreatment of the cells with GrM before degranulation of CTLs, therefore 
not showing direct competition between GrM and GrB for binding to PI-9, not 
allowing to verify whether the affinity of GrM for PI-9 is higher than that of PI-9 for 
GrB, which would have meant this granzyme can efficiently bind PI-9 before it 
inhibits GrB and therefore can inhibit its activity (Mahrus et al. 2004). The road to a 
synthetic optimal GrB inhibitor is therefore still long. 
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2.7 Lymphocytic Choriomeningitis Virus  
 
 
The Lymphocytic Choriomeningitis Virus (LCMV) is an enveloped single strand 
RNA virus, member of the Arenaviridae family which has now been widely accepted 
as a model for the study of CD8 T cell immune responses. Its name was coined in 
1934 by Charles Armstrong who had isolated it from humans for the first time in 
1933. Nevertheless, the common reservoir and host is the common Mus musculus 
(mouse).  
In mice, the virus is transmitted vertically to the litter though intrauterine infection 
and it is spread among mice via saliva, faeces, nasal mucus, milk, semen, urine. When 
in contact with these, humans can become infected and the virus is especially 
dangerous when caught by pregnant women as it can be passed on to the foetus. 
Studied and characterised by Oldstone in 1986 (about), the virus can cause a readily 
resolved acute infection in low doses in an immunocompetent mouse, while it can 
cause chronic infection if the mouse is immunodeficient. An immunosuppressive 
strain called Clone 13 (CL13) has been characterized as able to induce chronic 
infections in immunocompetent mice.  
The genome of LCMV is composed by 2 segments of RNA: S and L. S (short) 
encodes, at its 5’ end, for a precursor of the glycoprotein (GP), post-transcriptionally 
cleaved into GP-1 (amino acids [aa] 1–264) and GP-2 (aa 265–486), and for 
nucleoprotein (NP) genes at the 3’ end. GP-1 and GP-2 form tetramers and are 
responsible for receptor-binding to the target cell (Borrow and Oldstone 1994), while 
NP associates with the viral RNA to form the nucleocapsid (NC) used by the viral 
polymerase as a template. L (long) encodes for the viral polymerase (L) and Z genes, 
a small RING finger protein (Pedersen 1971). The association of NC and the 
polymerase forms the so-called viral nucleoriboprotein (RNP) which is the smallest 
actively infective unit of LCMV and any Arenaviridae virus.  
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2.7.1 The Armstrong strain of Lymphocytic Choriomeningitis Virus  
 
 The virus is available for research purposes in several derived strains, classified by 
their capacity to establish an acute versus a chronic infection in mouse. The strains 
causing an acute non-cytolytic infection are LCMV-Armstrong (Arm), -WE/Arm 
reassortant, -Traub and –DOC, all of which induce a strong CD8 T cell response. 
LCMV Armstrong 53b (LCMV Arm) is a clone triple-plaque purified of ARM CA 
1371: the virus is non-cytolytic and in immune-competent mice it provokes a strong 
CTL-dominated immune response which resolves itself in about 8-10 days. MHC-II, 
IFN-γ genes and CD4 T cells are not required for its clearance, therefore making 
infection with LCMV Arm a good model for studies on CD8 T cells responses and 
CTL-mediated viral clearance (Matloubian et al. 1994). The critical importance of the 
CTL response is evident in perforin-deficient LCMV-infected mice, which cannot 
clear even a low dose of non-immunosuppressive virus (Kagi et al. 1994; Zhou et al. 
2002; Fuller and Zajac 2003).  
LCMV is detectable in the blood of an intact B6 mouse from 24h p.i. and it reaches 
its peak by day 3-4. LCMV acute infection causes the upregulation of RANTES, 
MIP-1α and β, IP-10, MCP-1 and of the receptors CCR1, CCR2, CCR5 and CXCR3 
(Thomsen et al. 2003). Intracranial inoculation of the virus in adult 
immunocompetent mice leads to a lethal meningitis, from which its name derives 
(Hotchin 1962). 
 
 
2.7.2 The Clone 13 strain of Lymphocytic Choriomeningitis Virus 
 
The LCMV Armstrong Clone 13 (LCMV CL13) strain can cause chronic 
infections. A triple plaque purified from the spleen of an adult BALB/WEHI mouse 
infected neonatally with LCMV Arm, CL13 has 5 nucleotide changes out of the 
10.600 nucleotides which compose the RNA genome of the virus compared to Arm. 
Of the 5 changes, only 2 have a significant impact on its viral activity. The first one is 
in the L segment, the Lysine (K) in Arm to Glutamine (Q) in CL 13 at aa 1079, while 
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insignificant ones are at positions 1268, 3267, 6192  (Salvato et al. 1991). The second 
significant change is on the S segment and results in 1 aa difference as well: in 
position 856 there is a change from A to G, meaning the aa 260 (of GP-1) is a 
Phenylalanine (small aliphatic) in Arm and a Leucine (bulky aliphatic) in CL13. The 
second, irrelevant, change on the S segment is in position 1298 (again A to G) and 
doesn’t result in any amino acid change (Salvato et al. 1988). Worth noticing is that 
the site of major CTL recognition is unchanged in the two strains, meaning that the 
antigen-specific CD8 T cells arisen by an Arm infection can also recognise CL13 
virus (Salvato et al. 1991). This is a major point for my study as we will see later.  
 
2.7.2.1 CL13 causes chronic infection  
There is in CL13-infected mice but a minor depletion of T cells as LCMV infects a 
very low level of lymphocytes (Borrow et al. 1991). Depletion of antigen-specific 
CTLs directly induced by CL13 is therefore not at the basis of the chronic infection 
established by CL13. At the origin of persistent infection is, instead, the specific 
affinity of CL13 for α-distroglycan (α-DG), a surface molecule highly expressed by 
DC in the white pulp (interdigitating dendritic cells), which makes DCs the cell type 
the most susceptible to CL13 infection. Alpha-DG has a role in cell assembly and 
organisation of the basement membranes as it is a highly versatile cellular receptor 
for proteins of the extracellular matrix (ECM). Αlpha-DG was identified as the 
receptor for LCMV in 1998 (Cao et al. 1998) and is a receptor for several other 
arenaviruses. Since Arm and CL13 only differ in their GP, the discovery of this 
receptor opened the discussion on the importance of the receptor binding in the 
dynamics of infection of the two viral strains and on how this point mutation was 
influencing this binding to the receptor. Studies before this discovery had already 
indicated that LCMV Arm and CL13 were showing a coincident pattern of infection 
in the spleen at day 1 p.i., but by day 3 this pattern had differentiated. Arm-infected 
mice showed viral nucleic acids within the red pulp while in CL13-infected these 
were localised within the white pulp. In the same piece of work, it was demonstrated 
that CL13 infects more DCs (about 60%) than Arm does (about 15% or less). CL13 
achieves immunosuppression using these cells as a conduit for infection. The 
Armstrong strain, was confirmed, replicates in the red pulp of the spleen, while CL13 
replicates in DCs in the T-cell areas. Finally, they concluded that “Immune 
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suppression induced by LCMV clone 13 is associated with a CD8-dependent loss of 
interdigitating dendritic cells from periarteriolar lymphoid sheaths in the spleen and, 
functionally, with a deficit in the ability of splenocytes from infected mice to 
stimulate the proliferation of naive T cells in a primary mixed lymphocyte reaction. 
Dendritic cells are not depleted in immunocompetent Armstrong-infected mice” 
(Borrow et al. 1995). As further confirmation, only antibodies against GP-1 exhibit 
neutralizing activity (Borrow and Oldstone 1992). Sevilla and colleagues 
conclusively showed that the point mutation in CL13 strain augments the affinity for 
the α-DG receptor (Sevilla et al. 2000). In particular, this α-DG is highly expressed 
by splenic CD11c
+
 DEC-205
+
 DC: the CL13 strain infects and replicates in DCs at a 
high rate, in particular DCs of the white pulp, causing immunosuppression (Sevilla, et 
al. 2000) and/or direct viral effect on DC function (Sevilla et al. 2000; Smelt et al. 
2001). In both splenic and LN DCs, CL13 infection results in low levels of MHC-I, 
MHC-II and costimulatory molecules and in failure to migrate. The inability to 
stimulate T cells is a consequence of this lack of migration. Immunosuppressive 
strains also infect BM precursors therefore blocking development into new DCs 
(Sevilla et al. 2000). DC loss in CL13 infection is clearly CD8-dependent. When the 
antibody NLDC145 (anti-DEC-205), which recognises long-lived DCs, is used to 
stain CL13 chronically infected mice, no staining is obtained, thus indicating that 
these cells are depleted from the spleen. High doses of immunosuppressive virus 
initially induce a very strong CTL response which is effective but not long lasting and 
that progressively turns into exhaustion (Zhou et al. 2004). 
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2.8 Dendritic cell priming of viral responses: Rationale of 
the study and Spi6 role 
 
 
The project focuses on the function of Spi6 during DC priming of CD8 responses in 
viral infections. More specifically, it investigates Spi6 ability to protect mature 
antigen-presenting DCs from GrB-induced apoptosis during the process. This chapter 
contextualizes CD8 T cells and DCs describing the interactions and dynamics 
between these two cell types during a viral infection, including the CTL-mediated 
killing of DCs during priming. It also describes the work supporting the need for a 
prolonged antigen presentation to achieve optimal CTL activation and it includes 
previous data supporting the hypothesis and the rationale of the study. 
 
 
2.8.1 Naïve CD8 T cell and dendritic cell interaction 
 
Interaction between DC and T cells is of primary importance, as it can shape the 
immune response. The strength and magnitude of the CTL response are crucial in 
viral infections to achieve clearance of the pathogen. A sufficient amount of specific 
CD8
+
 T cells needs to be activated to produce a clonal burst quantitatively and 
qualitatively adequate to successfully address the infection. Several APCs can 
partially activate CD8
+
 T cells, but DCs only (Jung et al. 2002) are able to present 
exogenously captured antigens on MHC class I molecules through cross-presentation 
(Heath et al. 2004). Cells presented with an antigen in an MHC context alone will not 
be activated but, on the contrary, become anergic. The Danger Theory (Matzinger 
1994) states that the immune system cannot really distinguish between self and non-
self by itself: discriminatory in this process are the type and strength of signals 
conveyed by professional APCs, inflammatory cytokines and danger molecules to a T 
cell during priming. For an effective activation of the maturation program of CD8 
naïve T cells to CTLs, together with inflammation and danger signals, costimulatory 
signals have to be delivered to the T cell. Only professional APCs can deliver 
costimulatory signals through their B7 and other coreceptor molecules. This tripartite 
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signalling system sustains maturation and proliferation of the cell and triggers the 
production of IL-2 to ensure survival of the T cell.  
 
2.8.1.1 Short-term versus prolonged antigen presentation  
DC maturation status, adequate survival and lifespan and kinetics of antigen 
presentation are critical to convey adequate signals to naïve CD8
+
 cells (Kaech and 
Ahmed 2001). The duration of antigen stimulation needed for appropriate T cell 
priming has been a much debated issue. According to the original “Autopilot theory”, 
a 2hr-contact is enough for full activation of CTLs, with development of cytotoxic 
functions in the same cell in the following 8 hrs (Bevan and Fink 2001), but other 
studies show the need of an additional 48-72 hrs to develop further effector functions 
(Curtsinger et al. 2003). Also, division of antigen-specific CTLs is observed in the 
LNs by 66-72 hrs (Hermans et al. 2000).  
Several studies report the importance of long-term antigen presentation in primary 
immune responses to sustain and ensure the development of a proper CTL response 
through activation, differentiation and proliferation of naïve CD8 T cells (Usherwood 
et al. 1999; Belz et al. 2004). Prolonged presentation involves a steady presence and 
flux of antigen to the draining LNs: this is strongly correlated to DC availability. DC 
availability depends on DC survival and migration ability, which when optimal in 
mature DCs, allow for continuous recruitment of migratory DCs to the LN and 
antigen transfer to the resident ones.  
The overall magnitude and duration of a CTL response are the result of a delicate 
balance between timing of migration, level of maturation, antigenic load and survival 
of DCs. To note, pre-DCs inhabit SLOs therefore participating to the replenishment 
of killed DCs. The dynamics of interaction between DCs and T cells are also 
dependent on the location in the SLO. 
 
2.8.1.2 Dynamics of dendritic cell-T cell interaction 
After a naive CD8 T cell has entered the LN during an infection, the search for 
antigen takes place in 3 stages: during the first 8 hours the CD8 T cells have short 
contacts with many DCs, they upregulate CD44 and CD69 but are not properly 
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activated. Between 8 and 24 hours, the T cell-DC interactions become more stable, 
lasting up to 1 hr: the CD8 T cells have started the activation program and release IL-
2 and IFN-γ but they do not divide yet. During the third phase, after approximately 24 
hrs, T cells dissociate from DCs, proliferate and migrate out of the LN (Mempel et al. 
2004). In the spleen, the pattern is similar: shortly after infection, CD8 T cells and 
DCs move to the subcapsular zone following an antigen gradient. In the subcapsular 
zone DCs can pick up antigen from resident infected macrophages which do not 
express the coreceptors needed for costimulation and which therefore cannot prime 
CD8 T cells responses (Mueller et al. 2007). 
The first few hours are of key importance in directing the initiation of a CTL 
response, but its sustenance requires longer interaction. In a study with influenza 
virus infection, Belz and colleagues showed that antigen presentation still occurs 
several days after CTL maturation in primary infections, but rapidly decreases in 
secondary infections. Through CFSE labeling in vivo, they showed that ablation of 
DCs from day 3 post-infection severely impairs CD8 T cell expansion, and that DCs 
still migrate to LN after day 2 post-infection. The impaired response is therefore due 
to elimination of DCs in the LN rather than inefficient migration. In memory 
response, the same impairment in the response is seen when ablation occurs at day 3, 
but not from day 5 onwards. In the same paper it was also showed how in pfn 
deficient mice there is an accumulation of antigen-specific CTLs. Prolonged antigen 
presentation is thus required for optimal expansion of CTL primary response, but not 
in memory responses. Also, the magnitude of T cell expansion is not strictly dictated 
by antigen load and persistence (Belz et al. 2007).  
 
2.8.1.3 Dendritic cell positioning in the secondary lymphoid organs 
Interactions between DCs and T cells and their location in the SLOs are tightly 
regulated and not left to chance. DCs enter LNs through the afferent lymphatic vessel 
and firstly line up around the HEV in a strategic position to maximise the encounter 
with T cells, which access the LNs coming from the blood. This was supported by 
Mempel’s work showing that T cells make contact with APCs in the HEV. Once 
inside the LN, the cells move on to the T-cell cortex. One study, performed with a 
viral infection model as opposed to previous works where DCs were loaded, labeled 
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and injected in the mouse model, has conversely shown that T cells entering the LN 
in a naive status encounter activated antigen-loaded DCs in the subcapsular sinus or 
in the interfollicular area instead (Hickman et al. 2008). Shortly after infection, the T 
cells were shown to move to the peripheral regions of the LN.  
In the spleen, similar results underlined the difference between a viral model and 
adoptive transfer of DCs. In mice infected with LCMV, the CD8 T cells were shown 
localise in the red pulp and not in the T cell areas like in naïve mice when DCs were 
loaded with antigen and injected in intact mice. It was also shown that 
downregulation of CCL21causes temporary abrogation of naïve T cell migration to 
the T cell zone and has an impact on DC migration as well (Mueller et al. 2007). The 
dynamics observed clearly demonstrate how the SLO environment changes between 
the steady and the inflammatory state, therefore making some in vitro models not 
suitable to test CD8 T cell priming.  
Interestingly, growing evidence is supporting a model whereby, for infections like 
influenza virus or herpes simplex virus, CD8 T cells are activated and fully matured 
in the SLOs but need continuous stimulation in the peripheral infected tissues.  
Studies showed that, after being primed and activated in the LN, CTLs reach the 
infected tissues where further in situ priming is required for optimal function and it is 
carried out by antigen-loaded CD103
+
 DCs (Bedoui et al. 2009; McGill et al. 2009). 
CD103 is an integrin that marks migratory DCs and has been found to be expressed 
by LN-resident CD8α+ DCs. McGill & Legge reported CD8 T cell proliferation in 
loco sustained by migratory mature DCs (McGill et al. 2008). One more argument in 
favor of this model is the ability of naïve CD8 T cells to be successfully activated and 
proliferate after contact with antigen-loaded skin-derived or lung-derived CD8α- DCs, 
as well as with CD8α+ LN-derived DCs (Belz et al. 2007). The need for further 
peripheral antigen presentation depends on virus type and infection modality. 
 
2.8.1.4 Collaboration between dendritic cell subsets: antigen transfer 
A distinct mechanism allows for the transfer of antigen from migratory DCs to 
resident ones both in the LN and in the spleen, so to amplify the number of antigen-
competent DC and therefore the chances of encountering the antigen-specific T cell 
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quickly (Carbone et al. 2004). Reports of migratory DCs instructing DCs resident in 
LN was also shown by Belz and Allan (Belz et al. 2004; Allan et al. 2006). Recent 
discoveries in the DC collaboration model describe a mechanism for antigen transfer 
called cross-dressing, where loaded MHC molecules are transmitted between DCs to 
activate memory CD8 responses (Figure 26).   
 
 
Figure 26: CD8 presentation modalities: a) direct presentation; 
b) cross-presentation and c) cross-dressing (Yewdell and Dolan 
2011). 
 
 
The process uses trogocytosis: the transfer of surface proteins or parts of plasma 
membrane between cells. Wakim and Bevan demonstrated that this mechanism is 
required in vivo for efficient memory CD8 responses, while it fails to promote and 
support maturation of naïve CD8 T cells. Exsosomes containing both pMHC-II and 
pMHC-I are released by DCs and uptaken by other DCs. When uptaken, the antigens 
loaded on MHCs are isolated and loaded on newly formed MHC molecules. Wakim 
and Bevan also showed that the cells involved in this cross-dressing are CD8α- DCs 
(Wakim and Bevan 2011). 
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2.8.2 Dendritic cell survival 
 
DCs regulate CTL responses through a feedback mechanism in place to avoid 
excessive CD8 T cell priming (Wong and Pamer 2003). This regulation is achieved 
by CTL-mediated killing of antigen-loaded DCs, allowing for the control of antigen 
availability. The higher the number of CTLs, the higher the number of DCs killed 
during priming and costimulation. DC levels, on which depend further CTL 
expansion and priming, are thus feeding back about CTL levels in a regulatory loop 
that keeps CTL expansion under control (Figure 27).  
The mechanisms regulating DC survival are currently poorly understood. The 
studies which have addressed the correlation between DC levels and CTL expansion 
have done so via manipulating either antigen or DC availability in infection models. 
Stock and colleagues showed that elimination of the antigen source after the CTL 
response had started could negatively affect CTL expansion during a viral infection 
(Stock et al. 2004). In a similar study, when the bacterial load was cut down, earlier 
contraction of the immune response was seen (Porter and Harty 2006). Similar results 
were also obtained diminishing antigen presentation through the reduction of DC 
survival: deficient immune responses and lack of CTL expansion where observed as a 
result in LCMV infection (Yang et al. 2006). Accordingly, prolonging DC half-life by 
TRANCE treatment resulted in increased DC numbers reaching the lymph nodes and 
increased CD8 T cell priming (Josien et al. 2000) Also the co-transduction of Spi6 
and viral DNA in a vaccine augmented the survival of DCs and the levels of the CD8 
T cell response (Kim et al. 2003). The half-life of antigen-bearing DC may thus 
represent a crucial parameter for successful CD8 T cell priming.  
The first to report that cytotoxic T cell-dependent killing of APCs can cause 
suppression of heterologous immune responses in intact wild-type mice was 
Zinkernagel in 1988 (Leist et al. 1988). Ex vivo antigen-loaded DC rapidly disappear 
from lymph nodes after antigen-specific interaction with naïve CD4 T cells (Ingulli et 
al. 1997). These cells have been shown to be rapidly eliminated by CD8 T cells: 
antigen-loaded DCs are cleared in 20 hours by CTLs
 
and in 72 hours by memory CD8 
reactivated cells. One proof of the direct role of CTLs in limiting the survival of 
mature antigen-loaded DC is that the time course of acquisition of lytic effector 
function (more rapid for memory than for naïve cells) parallels the kinetics of 
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elimination of antigen-bearing dendritic cells (Hermans et al. 2000). A negative 
regulating loop working through the killing of DCs has also been observed in 
memory CD8 T cell responses (Wakim et al. 2008) to allow the containment and 
efficient resolution of CTL expansion (Wong and Pamer 2003). 
 
 
Figure 27: Illustration of the negative feedback loop which regulates 
and limits the expansion of CD8 T cell responses (Ronchese and 
Hermans 2001). 
 
 
Guarda and colleagues studied how CTLs and central memory cells can access 
activated draining LNs, but not resting ones, as CXCR3 ligands are expressed on the 
lumen of HEV shortly after the beginning of a new response. Activated CTLs gain 
access to the activated LNs were they can kill DCs, therefore reducing the level of the 
ongoing primary response (Guarda et al. 2007).  
DC elimination might be somewhat involved in the so-called “original antigenic sin” 
a mechanism that describes the inability of the adaptive response to produce a new 
CTL response to antigenic variants expressed by a virus after an initial CTL response 
has already been developed, by eliminating antigen-bearing DC in lymph nodes 
(Klenerman and Zinkernagel 1998). This is nonethelsee not at all clear and remains 
an hypothesis. 
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Interestingly, pfn KO mice cannot control LCMV replication. Mice with non-
functional fasL and inactive Fas, on the contrary, can control LCMV infection (Walsh 
et al. 1994; Kagi et al. 1995). This suggests how the degranulation cytotoxic pathway 
is fundamental in this model and cytokines and Fas-FasL interaction alone are not 
sufficient to control the infection. In pfn KO mice there is a significant increase in 
IFN concentration, due to higher antigen presentation levels. In particular, DCs are 
not killed in pfn-deficient mice, demonstrating a major role for pfn in cytolytic 
activity of CTLs and also providing further testimony that DCs are target of GrB 
released by CTLs (Yang et al. 2006). Contrasting results were obtained by Lykens 
and colleagues when antigen presentation from pfn KO and WT mice was measured 
in a mixed leukocyte reaction. The results showed that responder cells (P14) were 
stimulated 5 times more by APC from pfn KO. No difference in the number of DC 
was seen in these mice, thus suggesting that these cells are just more efficient at 
presenting (Lykens et al. 2011). 
Some studies support the theory that NK cells could be implicated in elimination of 
mature antigen-bearing DCs through release of perforin. Data has been acquired by 
Andrews and colleagues studying the effect of elimination of NKs and pfn in B6 
(WT) MCMV-infected mice. They showed that the elimination of either NKs or pfn 
results in an increase in DC number during infection and that elimination of both 
results in no differences compared to an intact MVMV-infected B6 mouse (Andrews 
et al. 2010). It is important to notice that this viral infection is different from LCMV 
in that help by CD4 T cells and NK cells is required for the virus to be successfully 
cleared. 
 
 
 
2.8.3 CD8 memory T cells and dendritic cells 
 
In recall responses, the first and main signal for re-activation is antigen exposure in 
the context of DC priming. Therefore, an important factor in activation of CD8 
memory cells is the survival and lifespan of DCs: when DCs are systemically 
depleted in mouse models the response to infection is drastically reduced (Zammit et 
al. 2005).  
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Reviewed in Bedoui et al. is the current model of memory activation involving DC-
mediated antigen presentation (Bedoui et al. 2009). On this matter, Zammit and 
colleagues reported that the memory response to influenza is impaired in absence of 
CD11c
+
 DCs (Zammit et al. 2005). Presentation via MHC-I from other hematopoietic 
or non-hematopoietic APCs is therefore not sufficient. In this respect, the ability 
described above of migratory DCs to present antigen to CTLs cells in situ is not 
applicable when talking about memory CD8 cells (Khanna et al. 2008). Belz and 
colleagues in fact reported that memory cells are more selective than naïve CD8 T 
cells in terms of priming requirements: only the lymphoid tissue resident subset of 
CD8α+ DC can fully activate memory cells. These have in fact limited ability to 
respond to tissue-derived antigen-loaded CD8α- DCs but are instead primed 
efficiently by CD8α+ LN-resident DCs. This results show how the requirement for 
naïve T cells is less stringent, as some populations of CD8α- tissue-derived DC are 
able to prime naïve CD8 T cells, as demonstrated in influenza virus infection for 
example (Belz et al. 2007). 
As memory CD8 T cells require prolonged contact with antigen-loaded DCs (Iezzi 
et al. 1998), the latter are a target of degranulating memory cells. Secondary CD8 
responses are clearly characterized by CD8-mediated loss of DCs (Ingulli et al. 1997; 
Wong and Pamer 2003; Belz et al. 2007; Guarda et al. 2007). Previous reports have 
shown how, despite DC number being a limiting factor during the early phases of 
CD8 T cell response (primary expansion), in memory responses this loss is not a 
limiting factor. Results by Belz’s lab further reinforced the notion that memory cells 
mediate DC clearance in re-expansion, but in their hands data did not support such a 
mechanism in primary responses as the decrease in DC numbers seen was not 
proportional to the increase in CTLs (Belz et al. 2007). Interestingly, in contrast to 
primary immune responses, expansion of antigen-specific cells and viral clearance do 
not necessarily go together for secondary responses, as in some cases protection can 
be achieved without re-expansion of the existing pool. 
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2.8.4 Rationale of the study 
 
Better survival of DCs is desirable: in chronic infections to re-awake the CD8 T cell 
response, in transplants to facilitate tolerance of the transplanted tissue and as a 
vaccination strategy. Spi6-alike molecules might provide DCs with better resistance 
to CTL-induced apoptosis, make them more fit to prime effective CTL response and 
even be modified to allow for tolerance induction.  
Previous studies reported contrasting results regarding the role of Spi6 in protecting 
DCs from CTL-induced, GrB-dependent apoptosis. 
 
2.8.4.1 Supporting data 
The theory suggesting that CCR7 downregulation had a protective role for DCs in 
that it allowed to keep CTLs away from the LN was not satisfactory as, despite CCR7 
downregulation, mature antigen-loaded DCs were shown to be still eliminated in situ 
(Hermans et al. 2000).  
Evidence for Spi6 rendering mature DCs more resistant to cytotoxicity were 
reported in 2001 by Medema and colleagues. Murine cell line (D1) and murine 
BMDDCs were matured using LPS and CD40L, or TH1 cells, and apoptosis in these 
cells was measured by DNA fragmentation levels after culture with CTLs for 6 hrs. 
The results showed that after maturation with LPS or anti-CD40, the D1 cell line was 
protected against CTL-induced apoptosis (residual killing was explained most likely 
by the fraction of DC which would not mature), while immature cells showed high 
levels of fragmentation. As DNA fragmentation is a late event in apoptosis, caspase 
activity was measured as well: CD40L-stimulated D1 cells did not show signs of 
caspase activation. The cell line and mouse BMDDCs were then analysed for Spi6 
expression at mRNA level: immature cells showed some low expression, but CD40L-
stimulated or LPS-stimulated ones had high expression of the protein. Spi6 levels 
were then measured in vivo in splenic murine CD11c
+
 cells after an injection of anti-
CD40 and in human monocyte-derived DCs: in both cases an increase of Spi6/PI-9 
was seen after anti-CD40 stimulation. Spi6 expression and protection from CTL 
killing was then studied transducing D1 cells with a viral construct expressing Spi6: 
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these cells showed to be resistant to CTL killing even in an immature state. 
Interestingly, Medema and colleagues also showed that, although both TH1 and TH2 
can induce maturation of DCs, only TH1 cells can induce Spi6 expression in dendritic 
cells and make them insensitive to CTL killing in vitro, emphasizing the fact that 
protection is not directly correlated with maturation per se but with Spi6 expression. 
Finally, Spi6 levels were then measured by Western blot analysis in human 
monocyte-derived DC after LPS stimulation and were found to be high and stable for 
up to 96hr (Medema et al. 2001). 
Further studies in humans were conducted by Hirst and colleagues, determining PI-
9 levels by immunohistochemistry in human samples (Buzza et al. 2001). PI-9 levels 
were measured in different human cell types, included DCs, further strengthening the 
hypothesis that Spi6/PI-9 protects not only GrB-containing cells from self-inflicted 
apoptosis but also bystander and accessory cells from the effects of degranulation-
deriving GrB. Quite interestingly both these populations showed quite high levels of 
PI-9 in the imamature/steady state. Through analysis with monoclonal antibody 7D8 
(Buzza et al. 2001) Spi6 epression in blood-purified immature and, at higher levels, 
TNF-α-matured monocyte-derived DCs were also shown. Finally, lineage negative 
CD3
- 
CD19
- 
CD11b
- 
CD16
- 
DCs were isolated and PI-9 measured in Langerhans cell 
precursors (no expression) and pDCs (intermediate levels). This distribution suggests 
different needs in different cell subsets and is the reason for the analysis in different 
subset of mouse DCs which is achieved in this project. 
 
2.8.4.2 Controversial data 
The role of Spi6/PI-9 as a protective agent against GrB-mediated apoptosis was 
undermined in 2008 when Ronchese’s group published a study whose results 
contradicted Medema and Hirst’s in vitro results (Andrew et al. 2008). The same 
group had previously reported how DCs are susceptible to CTL killing when 
presenting cognate antigen on MHC class I molecules (Yang et al. 2006). They 
wanted to verify whether anti-CD40 and/or LPS stimulation could make DCs 
resistant to CTL killing in vivo.  
They investigated Spi6 levels in activated (LPS or CD40 stimulation) murine 
BMDDCs through detection of mRNA levels, showing upregulation after as early as 
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6 hrs, a peak at 24 hrs, and high levels until 48 hrs later in all conditions. Protein 
levels were then measured with an antibody against PI-9 in Western Blotting: to be 
noted is that, as previously discussed, the homology of Spi6 with the human protein is 
not 100%. BMDDCs were then cultured with activated effector cells from L318 mice 
and killing was measured by propidium iodide staining in presence of antigen. L318 
mice carry a transgenic TCR specific for fragment 33-41 of the gp of LCMV (gp33) 
in association with H-2D
b
 (Pircher et al. 1989). LPS-matured BMDDCs showed 
significant lower killing levels compared to the immature ones, like in previous 
results, but residual killing was seen. The residual killing was clearly due to the 
normal rate of death of cells in culture and to LPS pro-apoptotic action. A 
controversial point is the addition of peptide to the culture, which induces activated 
CTLs to degranulate independently from pMHC recognition.  
One further step with respect to previous results was then taken, and DC survival in 
vivo was measured. Mature BMDDCs were labelled with fluorochrome for 
identification and injected into naïve or gp33-DC-immunised mice. The cells 
survived to some extent in naïve mice, while they failed to survive in immunized 
mice. Adoptive transfer of the CTLs used before was then conducted and DCs 
injected 24hrs later: draining LN analysis revealed that DCs were killed to the same 
extent whether they were mature or not. BMDDCs were then injected in mice that 
had been immunized with gp33-DCs 7 weeks earlier: analysis of draining LNs at 
72hrs showed that LPS-matured and immature BMDDCs had been killed to same 
extent. 
 
Data from this paper had therefore weakened Medema’s findings about Spi6 role in 
DCs. Nonetheless, some considerations can be made regarding Andrew’s 
experimental protocols.  
The correlation between the measured percentages of injected DCs migrating to LN 
and their survival made by Andrew and colleagues was not fully clarified (Andrew et 
al. 2008). When recovering DC number in LNs, The group measured only the DCs 
that were able to migrate there. The LN analysis does not reflect the surviving 
population in this experimental setting, nor accounts for DC killing in the LN itself. 
Also, the system in Andrew’s paper, due to the short duration of antigen stimulation, 
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does not mimic an infection. Moreover, LPS-matured DCs are expected to have a 
half-life shorter than 72 hrs, the timepoint chosen in Andrew’s study (Ingulli et al. 
1997; Hou and Van Parijs 2004).  
The function of Spi6 in mature DCs does not involve making DCs completely 
immune from CTL killing. The absence of susceptibility to killing is seen only when 
overexpression of the protein is induced. In normal conditions, Spi6 regulates GrB-
induced apoptosis levels, in my opinion based on the level of GrB and on the levels of 
CTLs. If Spi6 were to make DCs totally unsusceptible to CTL killing then controlling 
CTL response expansion would not be possible, as antigen-loaded DCs would sustain 
new priming and activation ad infinitum. This is valid both for memory and non 
memory system. The model used by Ronchese’s group was not mimicking an 
infection model, nor measuring DC survival in an appropriate way. Finally, Spi6 has 
been seen at low levels in immature DCs, thus making these cells in certain 
conditions resistant to locally released GrB. 
 
2.8.4.3   Spi6 knock-out model and Spi6 requirement for cytotoxic T cell survival 
Despite the critics that can be moved to the experimental model choice, the results 
obtained by Andrew et al. opened a controversy regarding the role of Spi6 in 
protecting mature DC against CTL killing. Their in vivo data was nonetheless limited 
to adoptive transfer of BMDDCs and comparison of mature to immature cells. The 
two major points that had not been studied were the levels of Spi6 in physiologically-
matured DCs in an intact mouse and its role during DC priming of viral infections.  
A KO mouse for Spi6 was created and characterized by Ashton-Rickardt’s lab, in 
2006, to complete functional studies and establish the physiological relevance of Spi6 
action in CTL in an in vivo model (Zhang et al. 2006). Spi6 KO mice were obtained 
inserting a deletion in exon 7 which encodes 60% of Spi6 in mouse and includes the 
RCL. This mouse model was used in this project to study the role of physiologically-
induced wild-type levels of the protein in DCs during the priming of an infection and 
the consequences of its absence. 
LCMV Arm induces a primarily CD8-driven immune response, were CD4 T helper 
cells are not necessary for the successful resolution of the viral infection (Ahmed et 
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al. 1988) as anti-LCMV response is fully MHC-I dependent. Also, antibodies do not 
play a major role either in LCMV infection. Depletion of CD4 cells demonstrated that 
CD4 T cell help is dispensable in acute infection. In the same study was demonstrated 
how, on the contrary, CD8-depleted mice (β2-microglobulin KO mice) cannot resolve 
a LCMV Arm infection and become persistently infected (Matloubian et al. 1994). In 
Arm infection, CTL expansion is MHC-I-driven and therefore cross-presentation 
mediated: this is therefore a good model to study the survival of DC in priming of 
viral infections. The method was established in the lab and the Spi6 KO mouse strain 
gave me the opportunity to verify CD8 priming in vivo in a viral infection model. 
LCMV was used in Zhang’s work to infect Spi6 KO mice to study CTL response. A 
reduced number of antigen-specific CTLs in the cellular response to infection was 
recorded in Spi6 KO mice, as well as a higher percentage of apoptotic antigen-
specific CTLs (see Figure 28).  
Using a GrB KO Spi6 KO mouse to investigate the relevance of GrB in previous 
results, levels of CTL expansion and apoptosis were recorded and resulted 
comparable to wild-type. Zhang and colleagues concluded that, since the absence of 
GrB could restore the defect in the CTL response, Spi6 was involved at least to some 
extent in promoting the survival of effector CD8 T cells. By verifying the expansion 
levels of adoptively transferred LCMV-specific P14 cells and Spi6 KO P14 cells into 
a recipient injected with Arm, they also confirmed that the requirement for Spi6 in 
survival was cell-autonomous. P14 cells are transgenic for CD8 TCR which 
recognises the immunodominant gp33 antigen of LCMV (Pircher et al. 1990). The 
Spi6 KO P14 cells showed increased apoptosis thus demonstrating the cell-
autonomous need for Spi6. Significantly higher GrB activity was measured in Spi6 
KO CTLs compared to wild-type, and this was detected both in the cytotoxic granules 
and at the cytoplasmic level. Also, a loss of cytotoxic granules was measured with 
confocal immunofluorescece microscopy in Spi6 KO CTLs and a high level of GrB 
staining in the cytosol of these cells. These results led to the conclusion, already cited 
above, that Spi6 is responsible for ensuring the correct organization and integrity of 
cytotoxic granules, otherwise disrupted in a GrB-dependent way (Zhang et al. 2006).  
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Figure 28: Number of gp33
+ 
CD8
+
 cells at day 8 after LCMV infection and levels of YOPRO-1 
positive (apoptotic) cells (A) and levels of apoptosis in gp33-specific CD8 T cells (number of 
YOPRO-1-positive cells) at day 8 p.i. with LCMV (B and C) in Spi6 KO and WT (B6) mice 
(Zhang et al. 2006). 
 
 
In the same Spi6 KO mice, CD8 T cell loss was also measured during the 
contraction phase of the CTL response, and no significant difference was seen in the 
level of LCMV-specific CD8 T cells during the contraction phase. Spi6 is therefore 
required for the clonal burst of CTL responses but not for the contraction phase 
(Zhang et al. 2007).  
Since DCs are crucial for proper expansion of the specific CTL population (Beltz et 
al. 2007) and previous reports did not agree on results, the causal connection between 
Spi6 upregulation in mature dendritic cells and their resistance to CTL-induced 
apoptosis needs to be further investigated. 
 
2.8.4.4 Supporting in vitro data  
In vitro data obtained in our lab before my arrival by Dr. Zhang showed that Spi6 
absence in BMDDCs was correlated to increased susceptibility to CTL-induced 
granule-mediated death.  
 
A JAM assay (Matzinger 1991) with matured and gp33-pulsed BMDDCs from Spi6 
KO mice and CTL from a P14 mouse was performed. BMDDCs were grown 
according to the protocol commonly used (Lutz et al. 1999) for 9 days and with LPS 
(0.2 μg/ml) one more day. When harvested at day 10 (Figure 29), DCs were mature 
(78%), as shown by the upregulation of MHC-II (I-A
b
).  These same Spi6 KO-
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derived BMDDCs were then cultured for 4 hrs with P14 CTLs obtained by 2 days in 
culture with IL-2 and gp33 antigen. In particular, the JAM assay was used to 
determine apoptosis levels in BMDDCs after culture with CTLs. Briefly, BMDDCs 
were labelled with 
3
H-Thymidine and pulsed with gp33 (10
-7
M) for 1h and then 
incubated with P14 CTLs over a range of ratios in quadruplicate. The percentage 
specific lysis was determined after 4 hrs. 
3
H-Thymidine is incorporated during cell 
proliferation: comparison of the amount of 
3
H-Thymidine in the experimental wells 
(BMDDCs co-cultured with CTLs) compared to negative controls (BMDDCs alone) 
allows determination of the percentage of target cells that underwent apoptosis in the 
experimental well. The cells in which apoptosis is induced by CTLs will release 
3
H-
Thymidine in the culture medium. When cells are harvested, 
3
H-tymidine from dead 
cells is washed away and the measured remaining radioactivity can be correlated to 
the amount of cells which survived (particularly to the DNA amount), therefore 
allowing the calculation of apoptosis levels (Matzinger 1991).  
 
 
Figure 29: BMDDC maturation status: CD11c and MHC-II (I-A
b
) 
expression in immature BMDDC, left panel, and LPS-matured ones, 
right panel (by M. Zhang). 
 
 
The experiment showed that Spi6 KO BMDDCs are more susceptible to P14
+
 CTL-
mediated PCD, as described in Figure 30, than WT ones. As the JAM assay measures 
DNA fragmentation, which is a late event in apoptosis, specific lysis was then 
measured with the 
51
Cr-release assay (see Figure 31).  
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The next step was to demonstrate that the killing was granule-dependent and not 
triggered by Fas-FasL pathway. Figure 30 B shows the level of apoptosis measured in 
the same assay as above when CTLs are treated with concanamycinA (CMA), which 
inhibits granule-mediate cytolysis. In this case, apoptosis in gp33-pulsed BMDDC is 
abolished, indicating that the levels of apoptosis revealed before were specifically 
induced by a granule-dependent pathway.  
Spi6 KO-derived BMDDC apoptosis was in this experiment specifically granule-
mediated. Moreover, Figure 30 C shows that anti-Fas antibodies induce PCD both in 
Spi6 KO-derived and in B6-derived BMDDCs with no difference. This suggests Spi6 
could have a role in protecting BMDDC from granule-mediated apoptosis pathway, 
but not from the Fas-activated killing pathway.  
 
 
Figure 30: Apoptosis of Spi6KO-derived BMDDC. A) Apoptosis levels measured via DNA 
fragmentation in gp33-pulsed BMDDC (target, T) after 4h culture with P14 CD8 T cells 
(effector, E). B) Apoptosis levels when CMA is added to the effector cells: CMA abolishes PCD in 
gp-33 pulsed BMDDC (T). C) BMDDCs were incubated with anti-Fas mab (JO2) for 16hr with 
cyclohexamide (by M. Zhang). 
 
 
In Figure 31, results from the measurement of apoptosis levels in a 
51
Cr-release 
assay are showed. Spi6 KO and B6-derived BMDDCs were labelled with 
51
Cr, pulsed 
with gp33 and mixed to CTLs. Lysis was measured as an indicator of apoptosis, and 
indicated that in Spi6 KO-derived BMDDCs is increased compared to wild type ones. 
A                                   B                                C 
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Figure 31: BMDDC specific lysis, 
51
Cr release assay on LPS-matured 
Spi6 KO- and B6- (WT)-derived BMDDCs (by M. Zhang). 
 
 
On the basis of these data and previous reports, my hypothesis is that Spi6 can 
indirectly allow for a wider CTL response in two ways: promoting the survival of 
activated CD8
+
 T cells through the inhibition of cytosolic GrB and conferring 
resistance of GrB-mediated apoptosis to DC. Moreover, Spi6 is responsible for 
optimal development of CD8 T cell responses to viral infections making DCs 
resistant to GrB-induced apoptosis. 
 
 
2.8.5 Hypothesis 
 
The project addresses the role of Spi6 in DC survival during CD8 T cell priming, 
both during primary effector responses and during secondary memory recall 
responses. Mature, antigen-loaded DC elimination by CTL has been shown to be 
perforin-dependent and consequently involve GrB action (Yang et al. 2006) and to be 
part of a negative feedback regulatory loop which keeps CTL responses in check. 
Notably, several reports have highlighted how sustained and prolonged priming, 
mediated by DCs both in secondary lymphoid organs and in peripheral tissues, is 
necessary for optimal expansion of effector antigen-specific cells in viral infections.  
Spi6 expression in mature DCs might therefore play a very important role in 
protecting these cells from PCD, as previously reported with some controversy 
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(Andrew et al. 2008). Controversial results, obtained by several groups in a debate 
that has now been unsolved for ten years, clearly suggest that the function of Spi6 in 
mature DCs is at present not understood. This work addresses the issue through the 
use of an in vivo model of infection in which Spi6 expression is abolished: a Spi6 KO 
mouse. DCs are expected to depend on Spi6 for survival both during primary and 
secondary responses. I therefore investigated the role of this protein in the DC subsets 
responsible for priming and support of CD8 T cells antigen-specific responses to 
LCMV infection in both primary and secondary responses. The subsets of choice are 
CD8α+ DC and pDCs. 
The hypothesis is that Spi6 KO DCs, priming wild-type non Spi6-deficient CD8 
naïve (or memory) T cells in LCMV infection, will be eliminated through PDC to a 
higher extent than wild type DC. The CTL response is expected to be hampered in 
Spi6 KO mice due to defective priming. This assumption is based on previous results 
showing a direct correlation between DC number and T cell expansion levels, due to 
the specific cross-presentation-dependent nature of CD8 responses in LCMV 
infection.  
 
This study aims: 
To study whether Spi6 is required for the survival of dendritic cell exposed to CTL-
released GrB;  
To examine the expression of Spi6 in different murine DC subsets in vivo; 
To determine whether Spi6 enhances DC survival when priming CD8 T cell 
responses against viruses; 
To verify if CTL and CD8
+
 memory cell expansion levels in vivo are affected by Spi6 
absence in DC; 
To confirm that Spi6 protects DCs from CTL killing by inhibiting GrB in CD8 T cells 
in vivo. 
 
 
The following chapters will describe the materials and methods (Chapter 3) and the 
results obtained from the experiments performed to address the points above (Chapter 
4), and a discussion of the results with an overview of future directions (Chapter 5) 
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3. MATERIALS and METHODS 
 
 
 
3.1 Mice 
 
C57BL/6J Spi6 KO mice (Phillips et al. 2004) and P14 mice (Zhang et al. 2006) 
were bred in house. Thy1.2
+
 and Thy1.1
+
 C57BL/6J wild-type and GrB KO mice 
(Heusel et al. 1994) were purchased from Jackson Lab.  GrB KO P14 Thy1.1 mice 
were generated by inter-crossing and screening by PCR for the GrB allele (Heusel et 
al. 1994) and flow-cytometry for the P14 TCR (Vα2+) and CD90.1 (Thy1.1) and 
CD90.2 (Thy1.2) in the blood (Zhang et al. 2006). P14 Thy1.1 mice were obtained by 
inter-crossing and screening for the P14 TCR (Vα2+) in the blood. All animals were 
maintained in a pathogen-free environment at Imperial College London and all 
experiment were conducted in accordance to Home Office (UK) regulations. 
 
  
3.1.1 Mouse genotyping 
 
In order to uniquely identify the product of mice intercrossing, each pup’s genotype 
was analysed between 4 and 6 weeks of age through antibody staining for leukocytes 
markers in the blood, or by DNA analysis.  
For blood staining: 5μl of blood were obtained by bleeding the tail vein at about 6 
weeks of age. The blood was mixed to EDTA 5M pH 8.0, then the antibody mix was 
added in 30μl of FACS buffer (PBS + 0.5% BSA from Sigma). The blood was 
incubated with the antibodies for 30 minutes in the dark, and then red cell lysis was 
performed with Red Blood Cell (RBC) Lysis Buffer (eBioscience). The samples were 
then washed with FACS buffer and resuspended in more FACS buffer for Flow 
Cytometry analysis. Blood staining was performed for the following mouse strains: 
for P14 mice, using PE-conjugated αV-β2 TCR antibody from eBioscience or PE-
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conjugated gp33 tetramer from Proimmune. For Thy1.1 mice, identification of 
genotype was carried out using CD90.1-PacificBlue and CD90.2-PeCy7 from 
eBioscience. 
 
 DNA analysis: biopsies were taken from mouse ear according to a precise 
identification scheme based on the number of ear marks and on their position. DNA 
was extracted from the ear biopsies through a salting-out procedure. Briefly: biopsies 
were digested overnight with Lysis buffer (STE buffer: 0.1M tris pH 8.0 + 200mM 
NaCl + 5mM EDTA + 0.2% SDS in water) and Proteinase K (20 mg/ml) (Sigma P-
2308) in a water bath at 55° C. Saturated NaCl (5M) was then added and samples 
mixed and incubated on ice for 15 minutes. Samples were then centrifuged for 40 
minutes at 13,000rpm. The supernatant was then removed and placed in a new tube. 
100% EtOH in equal amount was added to precipitate the DNA. The samples were 
then spun for 30 minutes at 13,000rpm. The supernatant was removed and 75% EtOH 
was added to the pellet to wash the salt away. Samples are resuspended and then 
centrifuged for 6 minutes. Supernatant is completely removed and the DNA is 
resuspended in TE buffer (10mM Tris pH 8.0 + 0.1mM EDTA in water) and allowed 
to dissolve in it overnight at 4° C. The following day the DNA is resuspended 
carefully in its buffer and concentration is determined by use of NanoDrop machine 
(Thermo Scientific). 
 
PCR. Granzyme B and Spi6 genes were detected through Polyclonal chain reaction. 
DNA was then used for PCR reaction with primers specific for the Spi6 gene or the 
granzyme B gene. 
 
The primers are: 
Primer 8970 (Common): 5’ GGG GTA CAA GGT CAC AGA GC 3’  
Primer 9596 (Wild type): 5’ CAG AAA CCA GGC CCA TTC TA 3’  
Primer Reverse 7415 (Mutant reverse): 5’ GCC AGA GGC CAC TTG TGT AG 3’ 
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PCR mix for Gzmb gene: 
 
REAGENT VOLUME 
ddH20 17.22μl 
TAQ 10X buffer 3.6μl 
dNTP mix 10mM 0.72μl 
MgCl2 2.88μl 
Primer 8970 1.8μl 
Primer 9596 1.8μl 
Primer 7415 1.8μl 
TAQ polymerase 0.18μl 
DNA 6μl 
TOTAL 30μl 
Table 2: GrB PCR reaction mix 
 
The PCR conditions are: 
1. 94° C for 3 min 
2. 94° C for 30 sec 
3. 62° C for 1 min  
4. 72° C for 1 min 
5. (Repeat steps 2-4 for 35 cycles)  
6. 72° C for 2 min 
7. 4° forever 
 
The expected results: 
Mutant = 217 bp 
Heterozygote = 217 bp and 386 bp 
Wild type = 386 bp 
 
The Spi6 PCR mix was changed a number of time dues to problems in due course. 
The first PCR mix (Table 3) used the following primers: 
 
F1 (wild-type forward): 5’ TGG TGG GCA GTA GAT TGT GCA TT 3’ 
R1 (common reverse): 5’ GAG GAC CCT GAT TAC AGA ACG 3’ 
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And the following reaction parameters: 
1. 94° C for 5 min 
2. 94° C for 45 sec 
3. 56° C for 45 sec 
4. 72° C for 3 min 
5. (Repeat steps 2-4 for 30 cycles) 
6. 72° C for 10 min 
7. 4° C forever 
 
The readout was: WT = 2.5 kb 
Spi6 KO (NEO deleted) =  800bp 
Heterozygous = 2.5 kb and 800 bp 
 
Spi6 PCR reaction mix: 
REAGENT VOLUME 
ddH2O 28μl 
Biolase TAQ 10X buffer 5μl 
dNTP mix 2.5mM 4μl 
MgCl2 50μM 2μl 
Primer F1 2.5μl 
Primer R1 2.5μl 
Biolase TAQ polymerase 1μl 
DNA 5μl 
TOTAL 50μl 
Table 3: First Spi6 PCR reaction mix 
 
 
This reaction had been tested before, but as problems arose with it and it was 
modified. It was substituted with 2 PCR to be done in sequence to identify both 
Heterozygous and WT if the WT band (2.5kb) was weak.  
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The first the PCR mix is in Table 4, the second in Table 5: 
REAGENT VOLUME 
ddH2O 34.5μl 
NEB TAQ 10X buffer 5μl 
dNTP mix 2.5mM 4μl 
MgCl2 50μM (included in buffer) 
Primer F1 0.5μl 
Primer R1 0.5μl 
NEB TAQ polymerase 0.5μl 
DNA 5μl 
TOTAL 50μl 
Table 4: New PCR reaction mix for Spi6 
 
The PCR conditions were the following: 
1. 94° C for 4min 
2. 94° C for 1min 
3. 56° for 1min 
4. 72° for 3min 
5. repeat steps 2-4 for 35 cycles 
6. 72° C for 7 min 
7. 4° C forever 
 
Second PCR mix for Spi6: 
REAGENT VOLUME 
ddH2O 34.2μl 
NEB TAQ 10X buffer 5μl 
dNTP mix 2.5mM 4μl 
MgCl2 50μM (included in buffer) 
Primer F2 0.5μl 
Primer R1 0.5μl 
NEB TAQ polymerase 0.8μl 
DNA   5μl 
TOTAL   50μl 
Table 5: Second reaction of new PCR reaction mix for Spi6 
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F2 (mutant forward) of the second PCR mix (Table 5) was:  
5’ TGG TGG GCA GTA GAT TGT GCA TT 3’ 
 
The PCR was run with the following conditions: 
1. 94° C for 4 min 
2. 94° C for 1 min 
3. 58° for 1 min 
4. 72° for 1 min 
5. Repeat steps 2-4 for 35 cycles 
6. 72° C for 7 min 
7. 4° C forever 
 
With these primers the Spi6 KO allele gives no band and the WT allele gives a 
910bp band. 
When the PCR would still not give any visible band for both the samples and the 
positive control, a Gradient PCR machine was used to modify the annealing time 
between 54° C and 59° C. This was performed both with the NEB and with a HOT 
START polymerase. When again no results were obtained, Q solution (Invitrogen) 
was added to the PCR mix and the annealing temperature kept at 58° C. Given the 
high cost of Q solution, Betaine (Sigma) was then purchased and added to the 
previous PCR mix (5μl). 
 
The amplified DNA was then run in a 1% Agarose gel, stained with Ethidium 
Bromide and read under UV light (Trans-illuminator). 
 
 
 
3.2 Cell culture, in vitro materials and methods 
 
In vitro experiments were conducted with ex vivo-obtained and grown bone 
marrow-derived dendritic cells and with splenocyte-derived CD8 T cytotoxic T cells. 
The former were used to measure Spi6 expression and, cultured with the latter, to 
measure susceptibility of this cell type to CTL-dependent killing. 
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3.2.1 Cell culture reagents 
 
All cultures were performed in complete media composed of Roswell Park 
Memorial Institute (RPMI)-1640 (Invitrogen) supplemented with 10% heat-
inactivated Fetal Calf Serum (Invitrogen), 5ml PenStrep-Glutamine 100X from 
Invitrogen (final concentration: Streptomycin 1ug/ml, Penicillin 1U/ml, .29mg/ml L-
Glu), 1% ß-mercaptoethanol (Invitrogen) final concentration 0.1mM. Complete 
media was filtered through 0.2 μm pore membrane filters. 
Collagenase type II was from Sigma and Collagenase D and DNaseI grade II from 
bovine pancreas was from Roche. 
 
 
3.2.2 Bone marrow-derived dendritic cell origination 
 
Dendritic cells were cultured from bone marrow progenitors according to Lutz 
protocol (Lutz et al. 1999). Briefly: bone marrow was flushed out of femoral bones 
taken from 6-8 weeks old mice. Cells were washed in PBS, counted and plated at 
2x10
6
 in 10ml of complete media (as described above) in a 10cm diameter Petri dish. 
The culture is supplemented with murine recombinant-GM-CSF (200 U/ml i.e. 20 
ng/m, from Peprotech) on the day of culture. At day 3 of culture, 10 more ml of fresh 
complete media are added, supplemented with new rmGM-CSF (20 ng/ml). At day 6 
of culture, half of the supernatant (10ml) is replaced with fresh complete one and 
more rmGM-CSF (20 ng/ml) is added. The same is repeated at day 8, but the 
concentration of GM-CSF is dropped to 10ng/ml. 
 
3.2.2.1 Maturation of bone marrow-derived dendritic cells 
To mature BMDDC for use in killing assay (CalceinAM) experiment and for 
adoptive transfer into B6 mice, LPS from E.Coli (Sigma), 1 ng/ml, and gp33 peptide 
(KAVYNFATM) from LCMV GP antigen, at 10
-6
 M, were supplemented at day 8 of 
culture. The control group, immature BMDDC, were instead supplemented on the 
same day with gp33 (10
-6
 M) only. Both immature and mature BMDDC cell cultures 
were harvested and resuspended in fresh complete medium 24 hrs later. 
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Confirmation of BDMMC maturation was obtained through surface staining of the 
cells with the following antibodies: CD11c-PE, MHC-II (I-A
b
)-FICT, CD86-APC (all 
from eBioscience). 
 
 
3.2.3 Development of cytotoxic T cells in culture 
 
To obtain CTL from P14 Thy1.1 mice for killing assays, CD8 cells were isolated 
from the spleen of these mice. A single cell suspension was obtained from processing 
the spleen with the use of Cell Strainers (from BD) in complete media (as above). 
Lympholyte (from Cedarlane), 2ml in 10ml of single cells suspension, was used to 
separate the lymphocyte layer through centrifugation for 15 min at 2,000rpm, with no 
brake. The obtained layer of leukocytes was then washed in PBS and resuspended in 
complete medium at 10
6 
cells/ml. Splenocytes were cultured in 12well-plates (2 
ml/well) and supplemented with recombinant murine IL-2 (10 U/ml) and gp33 (10
-6 
M) for 2-3 days, monitoring the formation of clumps of activated proliferating CTL to 
determine when the cells were mature and activated (Zhang et al. 2006). After about 
48 hrs, clumps could be observed and the cells were harvested and CD8 cells were 
enriched through magnetic bead sorting. Specifically, cells were washed in cold 
MACS buffer (0.5% BSA + EDTA 2mM in PBS), resuspended in 9/10 MACS buffer 
and 1/10 beads with volumes depending on the number of cells (100μl of beads and 
900μl of MACS buffer for 108 cells) and incubated at 4° C for 15 minutes, then 
washed with 10ml of cold MACS buffer, and loaded onto the LS column in 2ml.  The 
column was washed three times with additional MACS buffer and cells were eluted 
with the provided plunge in 5ml of cold MACS buffer, washed and resuspended 
according to the needs. 
 
 
3.2.4 Intracellular staining for Spi6 
 
Spi6 level analyses were carried out through intracellular staining of the protein 
performed with a primary antibody obtained from the serum of an immunized rabbit 
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(Aston-Rickardt lab) and a secondary, fluorocrome-conjugated, anti-rabbit antibody. 
Briefly: cells were first stained for surface markers to identify CD8 T cells versus 
pDC and CD8α+ DC in splenocytes as described below. Cells were then washed with 
FACS buffer and incubated with Cytofix/Cytoperm™ solution for 20 minutes at 4° C. 
Cells were then washed with Perm/Wash™ buffer (BD) and resuspended in 
Perm/Wash™ buffer containing primary antibody (or pre-immune serum as a control) 
at 1/1000 + goat serum 1/10. Cells were incubated at in the dark at RT for 40 minutes. 
They were then washed with Perm/Wash™ buffer and spun down. A second 
incubation with the secondary antibody as performed in Perm/Wash™ buffer + 
1/1000 secondary antibody (APC-goat anti-rabbit from Jacksons immunobiology or 
PE-Cy7-goat anti-rabbit) + 1/50 goat serum (Zhang et al. 2007). Cells were incubated 
for 40 minutes at RT in the dark and successively resuspended in Perm/Wash™ 
buffer to be analysed.  
 
 
 
3.2.5 Dendritic cell killing assay with Calcein, AM 
 
Mature and immature BMDDC were generated as described above from Spi6 KO 
and WT mice. CTL from P14 Thy1.1 mice were obtained as described above from 
wild-type or GrB KO P14 Thy1.1 mice. 
To measure CTL-induced lysis, gp33-pulsed LPS-matured BMDDC were also 
labelled with the cell-permeant non-fluorescent acetomethoxy derivate of calcein 
(Calcein, AM) according to the manufacturer’s protocol (Invitrogen). Briefly: 
BMDDC were washed and resuspended at 5x10
6
 cells/ml. 50μg of desiccated 
Calcein, AM were diluted in 50μl sterile DMSO and, for a final concentration of 
1μg/ml, 15μl are added to each millilitre of cells. Cells were incubated for 30 minutes 
at 37° C with occasional shaking and then washed three times in serum-free medium, 
counted and resuspended at the desired concentration.  
 
P14 CTLs were obtained as described above and resuspended at the desired 
concentration (10
6 
cells/ml). BMDDC were then mixed to P14 CTL in a V-shaped 96-
well plate over a range of E/T ratios starting at 50:1 (with serial 1: 2 dilutions) in 
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200μl, in triplicates. As negative and positive controls, “Spontaneous release” 
(BMDDC target only in medium) and “maximum release” wells (BMDDCs in 
medium with 2% Triton X-100) were added for each BMDDC group in triplicates. 
After incubation at 37°C in 5% CO2 for 4 or 8 hours, half of the supernatant was 
harvested and transferred into new 96-well flat-bottom plates (Costar 3596; Corning 
Inc). The release of fluorescent calcein into the supernatant was then measured with a 
dual-scanning microplate spectrofluorometer (Versamax microplate reader; excitation 
filter 485 ± 9 nm, band-pass filter 530 ± 9 nm). Percentage of BMDDC lysis was 
calculated with the same formula used for the 
51
Cr-release assay and presented as 
follows (Wang et al. 2004): 
 
% cell lysis = (experimental wells − spontaneous release) / (maximum release − 
spontaneous release) X 100 
 
The percentage specific lysis of RMA cells in the absence of gp33 was <10% and 
the spontaneous release was <10% of the maximum release. 
 
 
 
3.3 In vivo analysis of dendritic cell survival and CD8 
responses to LCMV infection 
 
In vitro experiments were followed by the analysis of DC survival in an in vivo 
model of infection. Spi6 KO mice were adoptively transferred with gp33-specific 
CD8 T cells (P14 CD8 T cells) and infected with LCMV Arm for primary infection 
and subsequently with LCMV CL13 for secondary infections.  
 
3.3.1 CD8 T cell isolation from the spleen of naïve mice 
 
Naive Thy1.1
+
 CD8
+
 T cells were isolated from spleens of P14 Thy1.1 mice or GrB 
KO P14 Thy1.1 mice through bead enrichment (MACS beads, Miltenyi Biotech) with 
positive-selection LS columns for use in adoptive transfers and priming assays. 
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Briefly, spleens were processed to single cell suspension and Lympholyte was used 
to isolate lymphocytes from Red Blood Cells as above. Enriched lymphocytes were 
washed in PBS and mixed with anti-CD8 beads at the concentration advised by the 
manufacturer (100μl for 108 cells) and incubated for 15 minutes on ice (or at 4⁰C). 
The cells were then washed in cold MACS buffer and added to LS columns for 
enrichment. Once enriched, the CD8 T cells were counted with Trypan Blue and 
resuspended in sterile PBS at 10
5 
cells/ml: 10
4
 cells (100μl) were injected i.v. into the 
recipient mice.  
 
 
3.3.2 Dendritic cell isolation from the spleen of infected mice  
 
Spleens of Spi6 KO and WT/B6 mice were cut into small fragments and digested 
with Collagenase D grade II (1 mg/ml) and DNaseI grade II (20 μg/ml) (both from 
Roche) in complete medium for 25 min at room temperature. EDTA (0.2mM) was 
successively added for another 5 min to disrupt DC-T cell interaction. Spleen 
fragments were then filtered through mesh (70μm) and centrifuged at 2,000 x g for 5 
min at room temperature. Cells were re-suspended in MACS buffer and magnetically 
sorted with anti-CD11c beads (Miltenyi Biotec).  
 
3.3.2.1   Enrichment of CD11c+ cells 
CD11c
+
 enriched cells were used for Spi6 level analysis and for determination of 
CD8α DC and pDC numbers in the spleen of infected Spi6 KO and WT/B6 mice. 
They were also used for sorting of CD8α+ DC (see below). 
Red blood cells were deleted from the splenocyte preparation with 1ml of RBC 
Lysis Buffer and washed in MACS buffer. Cells were then resuspended in 900μl of 
MACS buffer + 100μl of CD11c magnetic beads (100μl for 108 cells) and incubated 
in the fridge for 15 minutes to allow binding to the CD11c surface molecule. The 
procedure for isolation of cells with the anti-CD11c beads was the same as described 
for CD8-beads. The cells obtained were then washed in MACS buffer and 
resuspended in MACS buffer (450μl MACS buffer + 50μl CD11c magnetic beads) 
for a second purification, to be performed in the same way as the first. The CD11c-
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enriched obtained cells were counted with CV Acetic Acid and resuspended at 
desired concentration in complete RPMI medium.  
The number of CD8α DC in each spleen was determined by determining the % of 
CD11c
+
 Ly6-C
low
 CD8α+ CD4- cells then multiplying by the number of enriched 
CD11c
+
 cells. The number of pDC in each spleen was determined by multiplying the 
% of CD11c
+
 Ly6-C
+
 cells by the number of enriched CD11c
+
 cells.  
 
3.3.2.2 Sorting of splenic dendritic cells 
CD8α+ CD11chi CD4- cells were sorted from the pool of CD11c+ cells enriched 
from the spleen of infected Spi6 KO and WT/B6 mice for ex vivo priming and 
expansion experiments. CD8
+
 DCs from the spleens of infected mice were FACS-
sorted after antibody staining (MoFlo; DakoCytomation).  
 
 
Figure 32: Purity of CD8α DCs after FACS sorting using 7AAD, CD11c-PE, CD8-PAcBlue, 
CD4-FITC antibodies for surface markers. 
 
 
 Briefly, CD11c
+
 enriched cells (protocol as above) were stained for surface markers 
with CD11c-PE, CD4-FITC, Ly6C-PeCy7 and CD8-PacificBlue. CD11c
hi 
CD8
+   
Ly6-C
lo
 CD4
-
 cells (8% CD11c
+
-enriched cells in wild-type, 3% in Spi6 KO) were 
purified by FACS sorting. The purity of live cells obtained through the sorting was 
about 90% and verified with a purity check (see Figure 32: >98% pure). Cells were 
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sorted in RPMI-1640 medium + 20% FCS, spun down and resuspended at 2.5x10
5
 
cells/ml.  
 
 
3.3.3 Cell counting 
 
When it was needed to determine the total cell number in a specific organ, the cells 
obtained from that organ (spleen or LN) in a single-cell suspension were counted with 
counting Beads from Caltag. Briefly: Single cell suspensions from the spleen, or from 
pooled inguinal lymph nodes, of WT/B6 and Spi6 mice were obtained with the use of 
Cell Strainers. 10μl of cells were fixed with 50μl of Cytofix/Cytoperm™ solution 
(BD). FACS buffer (9 volumes) and 10μl of counting beads were then added to the 
cells. Cells were well shaken and mixed before being run into a Cyan ADP (Beckton 
Coulter) at high speed with a time limit of 1 minute. Total counts were obtained as 
follows: 
 
Cells/μl = (Tot count live Leukocytes / (dim beads count + bright beads count)) * 
Number of Beads 
 
Cells/ml= cells/μl * 1000 
 
Tot cells/organ= cells/ml * X ml  
(where X is the number of ml the total cells of that organ were resuspended in) 
 
The number of beads is variable for each batch of Caltag Counting Beads. The same 
cell suspensions were stained with appropriate mAbs to detect surface expression of 
lymphocyte markers as described below. Mean cell counts were determined by 
multiplying the frequency of each cell type, determined by FACS, by the total 
number of cells in the organ(s) and are ± SEM (n = 5 mice).  
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3.3.4 CD8 T cell priming by ex vivo-isolated dendritic cells  
 
CD11c
+
  CD8α+ DCs purified after sorting were used in a CD8 T cell priming assay 
to test their ability to present physiologically acquired antigens from LCMV and 
induce CTL proliferation. 
 
3.3.4.1  Priming assay with EdU incorporation 
CD11c
hi
 CD8α+ CD4- Dc, obtained by sorting as per above from the spleen of 
infected mice, were mixed with naïve P14 CD8 T cells, isolated from the spleen of 
P14 Thy1.1 mice as previously described. EdU (5μM) was added to the culture to 
measure the proliferation of CD8 T cells (Click-iT® EdU Invitrogen). EdU is a 
substitute to BrdU for direct measurement of newly synthesized DNA due to cell 
proliferation. EdU (5-ethynyl-2´-deoxyuridine) is a thymidine analogue and as such is 
incorporated into DNA when new DNA is synthesized due to proliferation. Detection 
of this analogue is based on click chemistry: a covalent reaction catalyzed by copper 
which happens between an azide and an alkyne. In particular, EdU can be detected in 
FlowCytometry thanks to the coupling of the azide with Alexa Fluor ® 488. FACS-
purified CD8α DCs (0-5x104 per 96 U-bottom well/0.2ml) were incubated with bead 
sorted CD8
+
 T cells from wild-type P14 mice (5x10
4
 cells/well). Cells were diluted 
serially with a E/T starting ratio of 2: 1 DC to CD8 T cells and cultured at 37º C in 
5% CO2 for 60 hours. Harvested cells were washed, fixed and stained for EdU 
according to the manufacturer protocol. Briefly: cells were washed in FACS buffer 
and then 100μl of Click-iT® fixative was added for 15 minutes at RT. Cells were 
washed and suspended in of Click-iT® saponin-based permeabilization and wash 
reagent (100μl) and incubated for another 15 minutes at RT. Cells were spun down 
and resuspended in Click-iT® reaction cocktail (PBS, D-PBS, or TBS 438μl per 
sample + CuSO4 10μl per sample + Fluorescent dye azide 2.5μl per sample + 
Reaction Buffer Additive 50μl per sample ). After 30 minutes of incubation at RT and 
in the dark, cells were washed once with Click-iT® saponin-based permeabilization 
and wash reagent and then resuspended in the same reagent for FACS analysis. The 
percentage of EdU
+ 
cells was then determined by flow-cytometry according to 
manufacturer instructions.  
 
 148 
 
3.3.5 Adoptive transfer of cells into wildtype or Spi6 knock-out mice 
 
Cells were adoptively transferred into WT and Spi6 KO with the purpose of 
studying the CD8 gp33-specific T cell response. To repeat Andrew’s experiment, 
mature BMDDCs from Spi6 KO and WT mice were first adoptively transferred into 
WT mice to study the ability of these cells to prime a CD8 T cell response. Once this 
was verified, DCs were studied in an in vivo model of viral infection. In order to 
obtain a mouse model in which CD8 T cells were competent for Spi6 and not subject 
to GrB autocrine action, WT P14 CD8 T cells or P14 CD8 memory cells were 
adoptively transferred into Spi6 and WT mice.  
 
3.3.5.1 Adoptive transfer of bone marrow-derived dendritc cells 
Mature dendritic cells (BMDDCs) to be adoptively transferred into Spi6 KO and B6 
recipients were obtained through culture with GM-CSF of bone marrow cells as 
described above. BMDDCs were harvested at day 10 and resuspended at 5x10
6
 
cells/ml in sterile PBS: 5x10
5
 mature Spi6 KO/WT BMDDCs were injected into B6 
mice i.v. trough the tail vein. 
 
3.3.5.2 Adoptive transfer of naïve P14+ Thy1.1+ CD8 T cells 
Naïve CD8
+
 cells were purified (>90%) from the spleens of P14 (Thy1.1
+
) or GrB 
KO P14 mice (Thy1.1
+
) by positive sort with anti-CD8 magnetic beads (Miltenyi 
Biotec) as described above. Enriched CD8 T cells were resuspended at 5x10
4
 cells/ml 
in sterile PBS and adoptively transferred (5x10
3
) by i.v. injection into WT (Thy1.2
+
) 
or Spi6 KO (Thy1.2
+
) mice. 
 
3.3.5.3 Adoptive transfer of memory P14+ Thy1.1+ CD8 T cells 
For the adoptive transfer of memory cells into Spi6 KO/WT mice, naïve CD8 T 
cells from a P14 Thy1.1 mouse were first isolated (according to the protocol above) 
and adoptively transferred into a WT/B6 mouse. The mouse was then infected with 
LCMV Arm and let recover. At 40 days post-infection, memory Thy1.1
+
 CD8
+
 T 
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cells were isolated from the spleen with anti-Thy1.1 magnetic bead enrichment 
(Miltenyi Biotec) with positive selection-LS columns. The protocol for magnetic 
beads enrichment was the same as for isolation of CD8 naïve T cells.  
Enriched memory cells were resuspended in sterile PBS and injected in Spi6 KO/B6 
mice (10
3
, 10
4
 or 10
5 
cells total). 
 
 
3.3.6 LCMV infection 
 
Two variants of LCMV were used to infect the mouse models after adoptive 
transfer of P14 CD8 T cells. LCMV Armstrong (Arm) is non-cytolytic and it is easily 
eliminated by immunocompetent mice in 8-10 days. LCMV CL13 causes chronic 
infection when injected in immunocompetent naïve mice. In my study the latter was 
used to stimulate a re-expansion of memory cells, therefore being eliminated before 
being able to establish a chronic infection. Notably, LCMV infection of a H-2D
b
 
mouse results in 3 H-2D
b
-restricted immunodominant epitopes, each against one of 
the proteins NP, GP1, and GP2. The epitope against NP is NP396–404 
(FQPQNGQFI), the epitope from GP1 is GP33–41 or GP33-43 (KAVYNFATC/GI) 
and the epitope for GP2 is GP276–286 (SGVENPGGYCL) (Gairin et al. 1995). The 
GP33 epitope is both H-2Db and H-2Kb restricted (Hudrisier et al. 1997): gp33 
stimulates both T cell clones but each clone recognises only one of the two GP33 
antigens, epitope 33-41, which is the shrorter of the two. 
 
3.3.6.1 LCMV Armstrong  
LCMV Arm was obtained from Ray Welsh. Intra-peritoneal injection of 10
5
 PFU of 
LCMV Arm was performed in mice under anaesthesia with Fluravent. 
 
3.3.6.2 LCMV Clone 13  
For memory cell experiments, LCMV Armstrong recipients were re-infected after 
40 days with intravenous injection of clone 13 variant of LCMV Armstrong, obtained 
from Annette Oxenius (10
6
 PFU). Mice were placed in a heated environment (heath 
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box) with a maximum temperature of 30⁰ C, to allow for vein dilatation which 
facilitates i.v. injections. 
The same PFU were injected into Spi6 KO/B6 mice after adoptive transfer of 
memory cells. 
 
 
3.4 Viral titre analysis 
 
In order to verify the correlation between CTL response expansion and ability of the 
cells to efficiently clear the infection, viral titres were analysed through measurement 
of viral RNA. Total RNA was extracted from the spleen of infected mice at day 6 
post (primary) infection, or at day 5 post (secondary) infection. 
 
 
3.4.1 Total RNA extraction 
 
To measure the level of LCMV in infected mice, a quantitative PCR method was 
used as described by McCauslan and Crotty (McCausland and Crotty 2008). Whole 
spleens from infected mice were conserved in RNAlater RNA Stabilization (Quiagen) 
weighed and a known amount disrupted using a glass mortar and pestle in buffer RTL 
Plus (QIAGEN) followed by homogenisation using a QIAshredder homogenizer 
(QIAGEN).  
Once the tissue was homogenized, RNA was extracted according to the RNeasy 
Plus Handbook (QIAGEN). The flowthrough was then transferred to a gDNA 
eliminator column placed in a 2ml tube, and centrifuged for 30 seconds at 10,000rpm. 
600μl of 70% EtOH was added to the flowthrough solution, which was then 
transferred to an RNeasy spin column (including any precipitate). The column was 
centrifuged for 15 seconds at 10,000rpm. 700μl of RW1 buffer was then added to the 
RNeasy column, and spun for 15 seconds at 10,000rpm. The flowthrough was then 
discarded and 500μl of RPE buffer added to the RNeasy column. The column was 
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spun down, the flowthrough discarded and the column placed on a new tube (clean). 
40μl of RNase-free water were added for elution of the total RNA. To obtain the 
RNA the column was spun at 10,000rpm for 1 minute to recover total RNA.  
 
 
 
3.4.2 Reverse transcription 
 
The RNA concentration was then measured on Nanodrop and 2.5μg of RNA are 
used for cDNA transcription. cDNA was synthesized with the SuperScript III reverse 
transcriptase from Invitrogen according to the manufacturer instructions (Invitrogen) 
1μl dNTP + 1μl GSP + ddH2O (RNase free) to 13μl total. The sample was heated to 
65º C for 5 minutes and then incubated on ice for 1min. 4μl of 5X buffer + 1ul DTT + 
1μl RNaseOUT + 1ul Transcriptase were added and the sample was incubated at 50º 
C for 30-60 minutes if random primers,or at 55º C for the same time if primers were 
gene-specific. The transcriptase was then inactivated by heating at 70º C for 15 
minutes. At the end of this process, complementary RNA was eliminated through 
incubation with E.Coli RNase H, 1 μl, at 37º C for 20 minutes. 
 
 
3.4.3 Real Time-PCR 
 
After the first strand cDNA synthesis was performed, the cDNA was used as the 
template for real-time PCR using primers specific for the glycoprotein (GP forward 
and reverse primers) and nucleoprotein (NP2 forward and reverse primers) of LCMV 
previously described (McCausland and Crotty 2008).  
 
Primers: 
Forward GP:  GP-R, GCAACTGCTGTGTTCCCGAAAC 
GP-F, CATTCACCTGGACTTTGTCAGACTC 
Forward NP:  NP2-R, CAGACCTTGGCTTGCTTTACACAG 
NP2-F, CAGAAATGTTGATGCTGGACTGC 
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Using iTaq SYBR Green Supermix with ROX (Bio-Rad, USA), plated in 96-well 
plate format and run on a GeneAmp 5700 (ABI, Redwood City, CA). Amplification 
was done for 40 cycles, with each cycle consisting of two steps: 95º C for 15 seconds; 
60º C, 30 seconds. All QPCR samples were run in duplicate. A standard curve with 
linearized plasmids encoding LCMV GP and NP genes was used to calculate the 
number of copies of LCMV genome per milligram of spleen.  
 
 
 
 
3.5 Flow cytometry analysis 
 
The fluorescently labelled monoclonal antibodies anti-CD86- (allophycocyanin 
[APC]-labeled), anti-I-A
b
- (fluorescein isothiocyanate [FITC]-labelled), anti-CD11c- 
(R-phycoerythrin [PE]-labeled), anti-CD8-APC, anti-CD90.1-AlexaFluor450 were 
purchased from eBioscience. The following fluorescently labelled antibodies were 
purchased from BD Pharmingen: Ly-6C-PE-Cy7, CD4-FITC. The gp33 peptide 
[KAVYNFATM] /H-2D
b
-APC tetramer was purchased from Becton Dickinson 
(Zhang et al. 2006). Lymph-node cells, splenocytes and BMDDC were prepared and 
stained with tetramers and mAb as before (Zhang et al. 2006). DC were subjected to 
ICS with rabbit anti-Spi6 antiserum (1/1000 dilution) or rabbit pre-immune serum 
(1/1000 dilution) then goat anti-rabbit IgG-APC (1/100 dilution; Jacksons 
ImmunoResearch). Stained cells were acquired on a Cyan ADP machine (Beckman 
Coulter) and analyzed with FlowJo software (TreeStar Inc.).  
 
 
3.6 Statistical analysis  
 
Calculation of means, standard deviations and P-values were carried out using MS-
Excel™ and GraphPad Prism. Statistical analysis was conducted with GraphPad 
Prism. Normal standard distribution was assumed for all data: Student’s t test was 
used for all data sets 
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4.   RESULTS 
 
 
Spi6 is an intracellular serpin (serine protease inhibitor) which is expressed by CTLs 
and NK cells upon activation and by DCs upon maturation. Mimicking a GrB target, 
it irreversibly binds to the enzyme, causing inhibition of GrB and leading to 
degradation of the Spi6/GrB complex. The protective function of Spi6 in mature DCs 
against ectopic GrB, released by CTLs during priming, has been proven in in vitro 
systems. When overexpressed in DCs, Spi6 has been demonstrated to protect these 
cells from CTL-inducted apoptosis (Medema et al. 2001). In another study, Hirst and 
colleagues showed upregulation of the human homologue PI-9 in mature DCs and 
suggested a correlation between the presence of ectopic GrB during CTL priming and 
the upregulation of PI-9 (Hirst et al. 2003). 
 
The model suggesting that Spi6 could confer protection against CTL-induced 
apoptosis has been challenged by an in vivo study. Showing that mature bone 
marrow-derived dendritic cells (BMDDC) injected subcutaneously in a mouse could 
be retrieved in the draining LN in the same number as immature ones, Andrew and 
colleagues suggested that mature and immature BMDDCs have an equal degree of 
apoptosis-susceptibility (Andrew et al. 2008). My hypothesis proposes that Spi6 
confers protection to DCs against CTL-delivered GrB-mediated apoptosis during 
priming of CD8 T cell responses in vivo. 
 
As a first step it was decided to confirm previous in vitro results obtained by my 
colleague Dr. Zhang. It was therefore shown that Spi6 is upregulated in WT mature 
DCs and absent in Spi6 KO-derived ones, and that Spi6 KO BMDDC susceptibility to 
CTL-directed apoptosis is GrB-dependent (Chapter 4.1). The ability of these cells to 
stimulate a CD8 T cell response in vivo in a naïve and/or memory mouse was 
subsequently tested (Chapter 4.2). Expression of Spi6 was then measured in splenic 
CD8α DC and pDC subsets in vivo, and their numbers measured at various stages 
post-infection (Chapter 4.3). The functionality of the CD11c CD8α DC subset, 
measured as ability to prime CD8 T cell responses ex vivo, was also verified in Spi6 
KO-derived DCs versus WT ones (Chapter 4.3.4). After clarifying the functional 
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status of dendritic cells in Spi6 KO mice and WT mice, the levels of antigen-specific 
CD8 T cell response were measured both in primary and secondary responses 
(Chapter 4.4). The secondary response was further investigated through analysis of 
re-expansion levels of known memory pools in Spi6 KO and WT mice (Chapter 
4.4.3). GrB involvement in the shaping of these responses was investigated in 
relationship to DC survival and CD8 T cell response expansion. To conclude, CTL 
responses in these mice were tested for their ability to efficiently clear viral infections 
(Chapter 4.7). 
 
 
 
 
4.1 Spi6 protects bone marrow-derived dendritic cells 
from GrB-mediated apoptosis in vitro 
 
 
Spi6 had, up till now, been measured in DCs using human anti-PI-9 antibody 
staining and/or PCR for mRNA levels in both humans and mice. These methods are 
not accurate for the measurement of this protein in mice as the human PI-9 is 
structurally different from the mouse one and RNA levels are not always 
representative of levels of intracellular protein, as in the case of GrB (Fehniger et al. 
2007). Prof. Ashton-Rickardt’s group had previously developed a polyclonal anti-
Spi6 rabbit serum that allowed a more specific identification of the mouse protein 
(Zhang et al. 2007). This serum was used to verify the intracellular expression of Spi6 
in BMDDC from WT (B6) and Spi6 KO mice and correlate this expression to 
protection from CTL-induced apoptosis. The need to identify the role of physiological 
levels of Spi6 in DC protection against CTL-killing is the aim of the first set of 
experiments. 
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4.1.1   Spi6 is expressed at low levels in immature bone marrow-
derived dendritic cells and it is up regulated upon maturation  
 
Spi6 expression had been measured in a dendritic cell line, D1, by determining 
mRNA levels (Medema et al. 2001) or using anti-PI-9 antibody (Andrew et al. 2008), 
but nothing had been reported on the measurement of intracellular protein levels. 
Rabbit anti-Spi6 serum was used to carry out intracellular staining for Spi6 on 
BMDDCs, in order to assess if Spi6 is up-regulated at the protein level upon LPS-
induced maturation. BMDDCs were generated from C57BL/6 mice (referred to as 
WT hereafter) and from Spi6 KO mice as previously described by Lutz et al. (Lutz et 
al. 1999). After 8 days in culture with GM-CSF, BMDDCs show an immature 
phenotype, with expression of the DC-specific marker CD11c, low levels of the 
antigen-presenting molecule MHC-II (I-A
b
) and low levels of the maturation marker 
CD86, as shown in Figure 33 A.  
 
 
 
Figure 33: LPS maturation of BMDDCs (48 hrs). A) Surface expression of CD11c, I-A
b
 
and CD86 on WT BMDDC before and after LPS stimulation (1 ng/ml). B) Expression of 
CD11c, I-A
b
 and CD86 on gp33-pulsed LPS-stimulated (bold line) versus gp33-only 
pulsed cells (dotted line). C) Expression of markers on WT- (bold line) and Spi6 KO-
derived (dotted line) BMDDCs after LPS treatment. 
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To induce maturation, these cells were stimulated with LPS (1 ng/ml) for 24 hrs. 
After LPS stimulation, BMDDCs up-regulate expression of CD11c, MHC-II and 
CD86, becoming CD11c
hi 
I-A
b
 CD86
high
 (see Figure 33 A), which indicate a mature 
phenotype. As expected, BMDDCs cultured in absence of LPS after 24 hrs still 
displayed an immature phenotype (MHC-II
low
 CD86
low
 Figure 33 B, dotted line). 
BMDDC from Spi6 KO showed no defects in maturation, as shown by the levels of 
maturation markers, which are comparable to WT (Figure 33 C). 
 
Intracellular expression of Spi6 in WT and Spi6 KO BMDDCs, was carried out 
using polyclonal rabbit anti Spi6-serum. The results for mature BMDDCs (bold line) 
and immature ones (dotted line) are shown in Figure 34. As expected, mature WT 
BMDDCs up-regulate Spi6. Also, the levels of Spi6 in immature BMDDCs are lower 
than in mature cells, both in WT and Spi6 KO-derived cells, but higher than 
expression in pre-immune serum (solid grey area). This is likely due to cross-
reactivity with other serpins, or to basal low expression of Spi6 in these cells. In Spi6 
KO cells no up-regulation following maturation is seen. 
 
 
 
Figure 34: Spi6 expression levels in immature and LPS-matured WT and 
Spi6 KO BMDDCs. Intracellular Spi6 was measured using polyclonal rabbit 
anti-Spi6 serum. Solid grey histogram: negative control (intracellular staining 
with pre-immune serum). Numbers within histograms indicate mean 
fluorescence intensity for Spi6 in the negative control (top left of histogram), 
and in the immature/mature DCs (bottom right). 
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By directly comparing intracellular staining for Spi6 in WT immature versus 
immature Spi6 KO BMDDCs (Figure 35) and on WT LPS-matured versus their Spi6 
KO counterparts, the up-regulation of Spi6 in mature cells can be better appreciated. 
 
 
 
Figure 35: Spi6 expression (intracellular staining) in immature 
(left panel) and mature (right panel) BMDDCs: red histogram 
WT, blue histogram, Spi6 KO cells. 
 
 
LPS stimulation of WT BMDDC for 48 hrs therefore results in up-regulation of 
Spi6 expression and concomitant high protein levels. As expected, neither immature 
nor mature Spi6 KO-derived BMDDCs express Spi6. Our results show that Spi6 is 
present and up-regulated in the cytoplasm of LPS-matured WT BMDDCs. This data 
complement observations from previous work by M. Zhang, which reported how Spi6 
KO mice are susceptible to CTL killing, in supporting a protecting role for Spi6 in 
mature DCs. 
 
 
 
4.1.2   Spi6 protects mature dendritic cells from granzyme B-
mediated killing in vitro  
 
Medema and colleagues demonstrated how overexpression of Spi6 protects DCs 
from CTL-mediated killing (Medema et al. 2001): however, early studies in our lab 
demonstrated the correlation between physiological levels of Spi6 and protection 
from CTL-killing (by M. Zhang). Having ascertained that Spi6 is up-regulated upon 
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maturation in WT BMDDCs in vitro, the next step was to confirm early data showing 
how lack of Spi6 leads to increased susceptibility of DCs to CTL-mediated killing in 
vitro, and investigate whether this was due to GrB-specific killing.  
 
51
Cr-release killing assay have been used in our lab to verify DC susceptibility to 
CTL-induced programmed cell death (PCD) in addition to DNA fragmentation 
analysis, as described above (2.8.4.4). I sought to recapitulate these experiments 
albeit using a different read-out reagent. Immature and LPS-matured Spi6 KO- and 
WT-derived BMDDCs were used as target of CTLs from P14 mice (effector cells) in 
an assay where calcein acetoxymethylester (AM) served as an indicator of cell death. 
CalceinAM is a non-fluorescent cell-permeable compound that undergoes hydrolysis 
by intracellular esterases in the cytoplasm. In this process it is converted into a cell-
impermeable, strongly fluorescent anion (calcein), which is retained by live cells. 
BMDDCs were generated after 8 days of culture with GM-CSF, then pulsed with 
gp33 only, or pulsed with gp33 and stimulated with LPS, for 24 hrs, harvested and 
loaded with calceinAM. Once loaded, BMDDCs were used as CTL target: BMDDCs 
(targets) were co-cultured at different ratios with fully activated P14 CTLs (effectors).  
P14 CTLs are TCR-Tg for LCMV-gp33. After 4 hrs, the percentage of killing was 
evaluated by measuring the levels of calcein in the supernatant. Once entered the cell 
and gained access to the cytosol, calceinAM is irreversibly modified and it can no 
longer permeate the cell and be released. The levels of calcein present in the 
supernatant after 4 hrs of co-culture with P14 CTLs are therefore due to membrane 
damage and correlate with apoptosis of BMDDCs.  
 
We first tested whether there were any differences in survival between immature 
and mature WT DCs. We found that immature DCs, which express low levels of Spi6 
and do not present antigen, undergo less apoptosis at 4 hrs than mature DCs, which 
express higher levels of Spi6 and are able to cross-present antigen to CTLs (Figure 
36). Nonetheless, the difference between immature and mature killing was not 
significant in these experiments, where the ratio was 25 to 1. In the same way, the 
difference between killing of WT and Spi6 KO BMDDCs was not significant. 
 
The difference in killing, although not significant, in this case was probably not 
directly due to Spi6 expression, but to the ability of mature DCs to induce activation 
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and degranulation of CTLs, as previously shown (Andrew et al. 2008). Immature DCs 
are not equipped to present antigen as the recycling rate of MHC-I and MHC-II is 
very high, thus leading to unstable antigen presentation capacity, in addition to low 
co-stimulatory molecule expression (Smith et al. 2011). Mature DCs can induce CTL 
differentiation and concomitant production of cytotoxic mediators. The results in 
Figure 36 confirm that mature DCs are preferential targets of GrB lysis.  
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Figure 36: Mature BMDDCs are more susceptible to granzyme B-mediated 
killing compared to immature BMDDCs. The plot shows percentage of 
killing of BMDDCs (WT and KO) by P14 effectors at 25 : 1 ratio, measured 
by calceinAM release in cultures 4 hrs post-stimulation. All mean values are 
±SEM and are representative of three independent experiments. 
 
 
Killing of mature BMDDCs was further analysed using different effector (P14 CTL) 
to target (WT or Spi6 KO BMDDC) ratios. Results obtained show that percentages of 
target killing are proportional to effector cell numbers and more prominent in Spi6 
KO-derived BMDDCs (Figure 37). The difference in the level of apoptosis confirms 
that mature DCs from WT mice are less susceptible to CTL-induced apoptosis 
compared to Spi6 KO-derived LPS-matured DCs. Also, they show that at high ratios 
DCs are killed at the same level. 
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Figure 37: Lack of Spi6 confers susceptibility to CTL-mediated apoptosis. Plot 
shows percentage killing of LPS-matured WT and Spi6 KO BMDDCs (targets) by 
P14 CTLs (effectors) at different ratios, measured by calcein release in culture 
supernatants 4 hrs post-stimulation. All mean values are ±SEM and are 
representative of three independent experiments; *p < 0.05. 
 
 
 
 
4.1.3   Susceptibility of bone marrow-derived dendritic cells to CTL-
mediated death is abrogated in absence of granzyme B 
 
As Spi6 specifically inhibits granzyme B, elimination of this mediator of 
cytotoxicity is predicted to counteract the protective function of Spi6. To verify that 
the apoptosis levels measured in the previous experiment were due to GrB activity 
and not to triggering of the Fas-FasL pathway, the same calceinAM-based assay was 
performed using P14 CTLs from GrB KO mice.  
Using the same experimental conditions as above, we found that GrB KO P14 CTLs 
do not induce apoptosis in WT and Spi6 KO cells after 4 hrs of stimulation (Figure 
38). This result is consistent with the hypothesis that DC apoptosis is due to GrB-
dependent CTL killing. 
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Figure 38: Early apoptosis in WT and Spi6KO BMDDCs is mediated by granzyme 
B. The plot shows percentage of killing of LPS-matured WT and Spi6 KO BMDDCs 
by GrB KO P14 CTLs at different effector/target ratios, measured by calcein 
release in culture 4 hrs post-stimulation. All average values are ±SEM of triplicate 
measures and representative of three independent experiments. 
 
 
We decided to verify whether the absence of killing at 4 hrs was due to the absence 
of GrB, which is an early apoptosis inducer, and to demonstrate that alternative 
apoptotic pathways are activated at later stages. Apoptosis levels of WT and Spi6 KO 
BMDDCs were thus determined at a later time-point, 8 hrs. After 8 hrs of culture with 
GrB KO CTLs, apoptosis was measured for both WT and Spi6O BMDDcs but no 
significant difference in apoptosis levels was observed between the two (Figure 39).  
 
These results suggest that GrB acts by inducing apoptosis within the first 4 hrs of 
interaction between CTLs and DCs. They also confirm that CTL priming by mature 
DCs confers the mature DCs susceptibility to GrB-mediated apoptosis. 
Moreover, from these results we can hypothesise that other mediators can contribute 
to DC apoptosis, like Fas-FasL and other granzymes stored in cytotoxic granules, but 
these have slower kinetics and are therefore not the primary cause of DC killing. Spi6 
up-regulation and inhibition of GrB function in DCs is therefore required to protect 
these cells from CTL- mediated killing. 
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Figure 39: Protection of BMDDCs from apoptosis is independent of Spi6 
at later time-points. Plot shows percentage killing of BMDDCs (WT and 
Spi6 KO) by GrB KO P14 CTLs measured by calcein release after 8 hrs. 
All mean values are ±SEM of triplicate measure and representative of 
three independent experiments. 
 
 
 
4.2 Priming capacity of antigen-loaded mature bone 
marrow-derived dendritic cells 
 
CD8 T cell responses can be stimulated in vivo by adoptively transferring antigen-
loaded mature dendritic cells into naïve or antigen-boosted mice (Ludewig et al. 
2001). Using the protocol adapted by Ludewig and colleagues, the ability of LPS-
matured antigen-loaded WT and Spi6 KO-derived BMDDCs to promote CTL 
responses in naïve and antigen-experienced mice was studied. This also allowed the 
indirect study of Spi6 function in DC priming of CTL responses in vivo. 
  
BMDDCs from Spi6 KO and WT mice were used to stimulate gp33-specific 
immune responses in WT mice. BMDDCs were generated in vitro with GM-CSF 
from WT and Spi6 KO mice for 8 days and matured with LPS and gp33, as described. 
BMDDCs were loaded with gp33 which is one of the two immunodominant LCMV 
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epitopes and which was also used in the in vitro CTL killing assay. MHC-I-specific 
gp33 peptide tetramers (H-2D
b
) were used to detect antigen-specific CTLs. Tetramers 
are a complex formed of four identical MHC-I complexes. Their development was 
originally reported by Altman and colleagues in 1996 to allow enumeration of 
antigen-specific CTLs in a system (Altman et al. 1996). Tetramers recognise specific 
MHC-restricted TCR: in this study, gp33 tetramers conjugated with the fluorescent 
dye PE (phycoerythrin) were used.  
In this chapter will be described how BMDDCs pulsed with LCMV gp33 were used 
to prime CTLs by adoptively transferring them into WT mice intravenously. The 
ability of DCs to stimulate a CD8 response by cross-presenting the soluble antigen 
was verified by measuring CD8 T cell expansion.  
 
 
 
4.2.1  CD8 T cell response in naïve mice after adoptive transfer of 
antigen-loaded bone marrow-derived dendritic cells 
 
BMDDCs were grown from the bone marrow of WT and Spi6 KO mice and 
matured with LPS as described above. Cells were then harvested and injected (5x10
5
 
cells) i.v. into the tail vein of WT mice. Mice were bled at day 4 to check the 
development of a CD8 T cell response and sacrificed at day 7 post-injection. Blood, 
inguinal LNs and spleen were analysed for gp33-specific CTL response. 
 
Gp33-loaded mature BMDDCs adoptively transferred into a WT mouse were able 
to stimulate CTL-responses. The analysis of gp33-specific CTL levels in the spleen 
and inguinal LNs (in Figure 40) showed that both WT and Spi6 KO BMDDCs were 
able to induce CD8 T cell responses. 
However, no difference was seen in the numbers of tetramer-positive CD8 T cells in 
both organs. In addition, no difference was measured in the gp33-specific CTL levels 
in the blood on days 4 and 7 post- transfer (Figure 41). 
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Figure 40: Absolute numbers of CD8
+
 gp33
+ 
CD44
+
 T cells in the spleen (left) and inguinal LNs 
(right) of naïve WT mice adoptively transferred with WT or Spi6 KO BMDDCs, on day 7 post 
injection. Cells were quantified by MHC-I tetramer staining (gp33 tetramer). All mean values 
(middle horizontal bar) are ±SEM and are representative of three independent experiments (n = 
4-5). 
 
 
Nonetheless, since this model does not mimic a viral infection but rather an 
immunisation with limited antigen presentation, these antigen-specific CTLs may be 
induced by an autopilot mechanism. Several groups have in fact demonstrated how 
LPS-matured BMDDCs are quickly eliminated once injected into a mouse, thus not 
being able to sustain a prolonged antigen presentation (Hou and Van Parijs 2004).  
 
WT Spi6 KO WT Spi6 KO
0.0
0.2
0.4
0.6
C
D
8
+
g
p
3
3
+
C
D
4
4
+
 c
e
lls
 i
n
 b
lo
o
d
 (
%
)
day 4 day 7
n.s.
 
Figure 41: Frequency of gp33-specific activated CD8 T cells in the 
blood of naïve WT mice adoptively transferred with Spi6 KO or WT 
BMDDC on day 4 (left) and 7 (right) post-transfer. All mean values 
(middle horizontal bar) are ±SEM and are representative of three 
independent experiments (n = 4-5), n.s. Not Significant. 
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4.2.2   CD8 T cell responses in antigen-experienced (memory) mice 
after adoptive transfer of mature bone marrow-derived 
dendritic cells 
 
To verify the ability of in vitro matured BMDDCs to stimulate a secondary immune 
response, gp33-loaded BMDDCs were then adoptively transferred into antigen-
experienced (memory) mice. Memory mice (WT) had been infected with LCMV 
Armstrong at least 40 days prior transfer, to allow for development of memory gp33-
specific CD8 T cells. In this scenario, gp33-loaded mature BMDDCs could present 
LCMV gp33 antigen to cognate memory CTLs, thereby stimulating their activation 
and re-expansion. Data obtained is shown in Figure 42: no difference was seen in the 
number of responding CD8 T cells in the spleen 5 days after adoptive transfer of WT 
or Spi6 KO BMDDCs.  
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Figure 42: Absolute numbers of gp33-specific CD8 T cells in WT 
memory mice (spleen) after adoptive transfer of BMDDCs generated 
from WT or Spi6 KO mice. All mean values (horizontal bar) are ±SEM 
and are representative of three independent experiments (n = 4-5). 
 
 
A significant difference, on the contrary, was seen in the inguinal LNs (Figure 43).  
This difference may reflect the effect of the specific route of administration and may 
be due to the distribution of BMDDCs introduced into the circulation. It might also be 
explained in terms of the different memory T cell subsets present in the LN and 
spleen of memory mice, which might differently depend on Spi6-upregulating DCs 
for proper priming. 
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Figure 43: Absolute numbers of CD8
+ 
gp33
+ 
CD44
+
 T cells in the lymph nodes of 
WT memory mice 5 days after adoptive transfer of LPS-matured, Spi6 KO or 
WT BMDDCs. All mean values (horizontal bar) are ±SEM and are 
representative of three independent experiments (n= 3), *p < 0.05. 
 
 
In the blood, levels of CTLs were comparable at all the time-points that were 
analysed in both naïve and memory mice (Figure 44). Donor-derived gp33-specific 
CD8 T cells in blood were measured as percentage of the total lymphocytes and not 
as absolute numbers due to the variability of the blood samples. 
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Figure 44: Percentage of gp33
+
 CD8
+ 
CD44
+
 T cells in the blood of memory WT 
mice, 5 days after adoptive transfer of LPS-matured, Spi6 KO or WT 
BMDDCs. All mean values are ± SEM and are representative of three 
independent experiments (n = 4-5). 
 
 
Adoptive transfer of antigen-loaded LPS-matured BMDDCs in our hands induces a 
gp33-specific response and no difference is seen in the levels of these CD8 T cells in 
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the spleen. A difference is, on the contrary, seen when measuring absolute numbers of 
gp33-specific CD8 T cells in the inguinal LNs. 
 
 
 
 
 
4.3 Dendritic cells in vivo: lessons from the spleen 
 
Our observations in the previous section suggest that BMDDCs generated from WT 
or Spi6 KO mice are equally able to stimulate CTL responses in naïve and memory 
mice. We therefore sought to verify if Spi6 could protect endogenous DCs from CTL 
killing in an in vivo infection model. 
LCMV, as already described, is a non-cytolytic, MHC-I dependent virus. Its 
infection is efficiently cleared in 8-10 days in immunocompetent mice and it has two 
immunodominant H-2D
b–restricted epitopes: gp33 (glycoprotein 33-41) and np396 
(nucleoprotein 396-404). P14 mice (Kaech and Ahmed 2001) are transgenic mice 
whose entire T cell repertoire has been manipulated to recognise the gp33 antigen in 
the context of MHC-I. They are widely used to study CD8 T cell dynamics: in 
particular CTL primary responses, development of the memory pool and re-expansion 
of memory CD8 T cells. The LCMV infection model was therefore chosen to study 
CTL responses in Spi6 KO and WT mice.  
 
Various groups have previously demonstrated that DCs are the sole antigen-
presenting cells able to prime CD8 T cell responses in LCMV infection (Belz et al. 
2004). Mouse dendritic cells can be subdivided in several populations depending on 
tissue distribution, presentation and stimulation capacity, and lifespan. In the spleen, 
mainly three types of DCs, called resident conventional DCs (cDCs), can be 
identified and distinguished by the expression of CD8α and CD4: CD8α+ DCs, CD8α- 
CD4
+
 DCs and CD8α- CD4- DC. In inflammatory conditions, monocyte-derived and 
peripheral antigen-loaded mature DCs can also enter the spleen. For instance, the 
CD11c
int 
B220
+ 
Ly-6C
+
 migratory plasmacytoid DCs gain access to the spleen from 
the circulation and locate to the marginal zone. In the LNs, similarly, one CD8α+ and 
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two CD8α- populations of cDCs are present, together with a population of migratory 
DCs circulating from peripheral tissues. During inflammation, Langerhans cells and 
dermal DCs migrate to the LN, where they pass on antigens to resident CD8α+ and 
CD8α- DCs to allow these to prime CD4 and CD8 T cells. The SLO-residing 
populations have been studied for their properties to capture and present self and non-
self antigens and the current model supports a main role for CD8α+ DCs in priming 
CD8 T cell responses supported by their phagocytosis receptors, their antigen-
processing machinery and their location in the spleen and LNs (see 2.5.10).   
CD8α+ DCs and pDCs were thus chosen among these subsets for their specific role 
in viral infections. CD8α DCs have been shown to be responsible in particular for 
cross-presenting LCMV-derived antigens in Armstrong infection (Belz et al. 2004; 
see 2.5.10) and pDCs are responsible for interferon production which enhances viral 
clearance (see 2.5.11). 
 
In immunocompetent mice, the dynamics of infection have been described as 
follows: by 24 hrs CD8α+ DCs stimulate naïve T cells: by day 3 apoptosis of CD11c+ 
CD8α+ is started and by day 4 there is an increase in the number of pDCs and 
production of IFN (Montoya et al. 2005). These results by Montoya and colleagues 
were the basis on which the following experiments were designed.  
 
 
 
4.3.1 Expression of Spi6 in splenic dendritic cells 
 
We first set up a primary study to develop a protocol for the identification of DC 
subsets in the spleen of our mouse model and study Spi6 expression, and we tested it 
using intact WT mice. The WT mice were infected with LCMV Armstrong intra-
peritoneally (i.p.; 10
5
 PFU) and the spleen was analysed on various days p.i. to verify 
the development of CD8α DC and pDC populations in terms of numbers and Spi6 
expression. CD8α DC and pDC subsets were identified among CD11c+ cells isolated 
from the spleen using flow cytometry (Figure 45).  
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Figure 45: Gating strategy of mouse splenic DCs using FACS analysis 
of antibody staining for surface markers. Conventional DCs are 
defined as CD11c
++
 Ly6C
low
, pDCs are CD11c
+
 Ly6C
hi
. 
 
 
Total cell numbers were obtained using Caltag counting beads and used to calculate 
the absolute numbers of each subset (i.e. the total number of those cells in the organ). 
CD8α DCs were identified as CD8α+ CD4- among conventional DCs (identified as 
CD11c
hi 
Ly6C
low
), and pDCs were identified as CD11c
int
 Ly6C
hi
,
 
according to the 
identification used by Sancho and colleagues (Sancho et al. 2008). 
 
Analysis of DC numbers showed that the total number of cDCs increased by day 2 
post-infection and decreased by day 4, probably due to killing by activated CTLs, 
followed by a further increase on days 6-8 post-infection (Figure 46). These results 
are nonethelss only indicative as only 2 samples were tested. 
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Figure 46: Absolute numbers of cDCs (CD11c
hi
 Ly6C
low
) in the spleen of 
LCMV Arm-infected intact WT mice at time-points indicated. All mean 
values (middle horizontal line) are ± SEM (n = 2). 
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Interestingly, when CD8α DC and pDC subpopulations were analysed individually, 
CD8α DC decreased at day 4 p.i. only to increase again from day 6 p.i. Plasmacytoid 
DCs, on the other hand, decreased on day 2 p.i., and were at undetectable levels in the 
spleen at day 6 p.i. Also, results indicated that numbers of CD8α DCs were at their 
lowest at day 4 post-infection (Figure 47). 
 
Since Spi6 KO mice lack Spi6 in CD8 T cells, high levels of apoptosis are induced 
in CTLs when these cells mature to the effector status. Responses to viral challenge in 
these mice are thus are impaired as the expansion phase fail to reach the levels seen in 
WT mice (Zhang et al. 2006). The Spi6 KO intact mouse is therefore not a good 
model to study DC killing by CTLs. To study the effect of GrB in a Spi6-competent 
pool of CTLs, naïve WT P14 CD8 T cells were adoptively transferred into WT and 
Spi6 KO mice.  
The immunodominant epitopes for LCMV, as previously mentioned, are gp33 and 
np396. This study will mostly concentrate on CD8 responses to gp33 because of the 
availability of transgenic mice expressing a TCR specific for this antigen, LCMV 
gp33 (gp33-41) in a 2-HD
b
-restricted context. This mouse strain is called P14.  
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Figure 47: Absolute number of CD8α DCs and pDCs in the spleen of an Arm-
infected intact WT mouse, at indicated days post-infection All mean values are 
± SEM (n = 2). 
 
 
Congenically marked naïve P14 CD8 T cells (Thy1.1
+
) were transferred into WT 
and Spi6 KO (both Thy1.2
+
) mice and both test groups were infected with LCMV 
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Arm. Mice were sacrificed on days 2, 4, and 8 post-infection and analysis of DC 
subpopulations in the spleen was carried out as described above (Figure 48). The 
adoptively transferred P14 cells are, in this model, primed by endogenous antigen-
loaded DCs, matured by physiological inflammatory stimuli and signals triggered by 
viral recognition. DC numbers were studied in the spleen of these mice, as isolation 
of DCs from the LN is more challenging due to lower cellularity.  
 
 
Figure 48: Protocol for study of DC responses in Spi6 KO and WT mice after 
acute LCMV infection. Naïve Thy1.1
+
 P14 CD8 T cells were adoptively 
transferred into WT and Spi6 KO mice, which were subsequently infected with 
LCMV Arm. Analysis of DC subsets was carried out on day 0 (pre-infection), 2, 
4 and 8 post-infection. 
 
 
Intracellular expression of Spi6 was analysed in the CD8α DC and pDC subsets in 
order to correlate expression of this protein and survival of each subset. As expected, 
CD11c
+
 cells from Spi6 KO mice did not show expression of Spi6 (Figure 49, dotted 
lines). In WT cells, on the other hand, Spi6 was up-regulated at various stages. Spi6 
was up-regulated in WT CD8α+ DC from day 2 and until day 8. Spi6 levels in pDCs 
increased from day 4 in both Spi6 KO and WT mice, thus being not significantly 
different at any time-point (Figure 49).  
 
Analyses of the mean fluorescence intensity (MFI) of the intracellular stain for Spi6 
in in CD8α DCs showed a significant difference in the expression of Spi6 between 
Spi6 KO and WT mice from day 2 onwards, while no difference in Spi expression 
was observed in pDCs.  
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Figure 49: Spi6 expression in CD8α DCs and pDCs in Arm-infected WT (bold line) 
and Spi6 KO mice (dotted line) adoptively transferred with WT P14 cells at various 
days post-infection. Numbers represent mean fluorescence intensity (MFI) obtained 
with intracellular staining of Spi6 in WT/Spi6 KO DCs. Values are representative of 
three independent experiments (n = 5-6). 
 
 
Expression of Spi6 in pDCs was nonetheless increased to some extent in both WT 
and Spi6 KO pDCs from day 6, suggesting that upregulation of other serpins, which 
cross-react with the polyclonal anti-Spi6 serum, might take place (Figure 50). 
 
 
Figure 50: Mean fluorescence intensity (MFI) intensity for the intracellular staining of 
Spi6 in WT (black) and Spi6 KO (white) mice at indicated days post-infection. The left 
panel shows the expression of Spi6 in CD8α DCs and the right one shows Spi6 
expression in pDCs in the spleen of LCMV Arm-infected mice. Both WT and Spi6 KO 
mice were adoptively transferred with P14 Thy1.1
+ 
CD8 naïve cells before infection 
according to the protocol. All mean values are ±SEM and are representative of three 
independent experiments (n = 5-6), * p < 0.05 
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4.3.2  The absolute number of CD8α+ dendritic cells is reduced in 
the spleen of Spi6 KO mice when challenged with LCMV 
 
Upregulation of Spi6 in mature WT DCs from day 2 post-infection indicates a need 
for these cells to protect themselves against GrB activity; cells lacking this protein are 
expected to be more susceptible to CTL-induced apoptosis. Absolute numbers of 
CD8α DCs and pDCs were thus measured to verify if Spi6 expression in CD8α+ DC 
or pDC contributed to the survival of these cells. Reduced numbers of live DCs were 
seen in the spleen of Spi6 KO mice during the first phase of the response (Figure 
511). On day 4 p.i., a 75% reduction (p = 0.040) in the number of CD8α DCs was 
measured in Spi6 KO mice compared to WT. As CD8α DC is the subpopulation 
responsible for presentation of LCMV antigen to naïve CD8 T cells (Belz et al. 2004), 
Spi6 is thought to be required by these cells to avoid apoptosis triggering by GrB 
locally released by CD8 T cells during/after priming.  
 
 
Figure 51: Absolute numbers of CD8α DC (left) and pDC (right) in WT (black) and Spi6 KO 
(white) mice infected with LCMV Arm and adoptively transferred with P14 CD8 T cells, at 
indicated days p.i. All mean values are ±SEM and are representative of three independent 
experiments (n = 5-6), * p < 0.05. 
 
 
Interestingly, we did not observe any difference in the number of pDCs in the spleen 
of infected mice at all time-points studied. This data is consistent with the lack of 
Spi6 up-regulation in pDCs at any time during infection. Up-regulation of Spi6 is in 
fact expected to occur only in cells that are susceptible to lysis by GrB, which pDCs 
due to their non-presenting function are not. These results showing Spi6 upregulation 
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in CD8α DCs and absence of upregulation in pDCs support the hypothesis that Spi6 
is important for survival of DC involved in CTL priming.  
 
Alternatively, absence of Spi6 in pDCs might mean that levels of these cells do not 
need to be regulated, suggesting that they do not take part in regulating CTL 
expansion (Fuchsberger et al. 2005). It also further supports the hypothesis that pDCs 
do not actively participate in antigen presentation during LCMV infection. 
 
 
4.3.3  CD8α dendritic cells in Spi6 KO mice are restored to wild-
type levels in absence of granzyme B 
 
Spi6 inhibits GrB activity, thereby preventing it from triggering intracellular 
apoptotic pathways. To verify whether reduced DC levels in Spi6 KO mice were 
directly dependent on GrB-triggered apoptosis, GrB was subtracted from the system. 
GrB absence was expected to restore DC levels to WT. In order to obtain GrB 
removal, CD8 T cells from GrB KO mice were used, on the basis that the majority of 
the GrB in the system would come from donor CTL. 
 
 
Figure 52: Endogenous (black) versus adoptively transferred donor (white) gp33-specific 
CTL (absolute numbers) in the spleen of infected mice during primary response (day 8 post-
infection). CD8 T cells are stained with Gp33, CD44, Thy1.1 and Thy1.2 antibodies to 
distinguish donor Thy1.1 from endogenous Thy1.2 antisgen-specific CD8 T cells. All mean 
values are ±SEM and are representative of three independent experiments (n = 5-6). 
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To verify that adoptive transfer of GrB KO P14 T cells effectively resulted in 
elimination of GrB, the composition of the CTL response to gp33 in our model was 
analysed. It was verified that gp33-specific CD8 T donor cells (Thy1.1) were 
accounting for more than 90% of the gp33-specific response and were on average 14- 
to 17-fold more than the endogenous cells (Thy1.2) when measured at day 8 p.i. (see 
Figure 52). Therefore, it could be assumed that 90% of the GrB in the system was 
provided by degranulating donor-derived P14 CTLs and that, eliminating this source, 
the remaining amount of GrB in the system would have been negligible.  
 
 
GrB KO P14 Thy1.1 cells were adoptively transferred into Spi6 KO and WT mice 
and the levels of CD8α DCs were measured at day 4 post-infection. This time point 
was chosen as analysis of CD8α DC levels had showed the biggest difference 
between WT and Spi6 KO at day 4 p.i. thus suggesting Spi6 function to be critical at 
this specific time point for DC survival. To isolate, identify and enumerate the two 
populations, the same protocol was used as above (Figure 48). 
When priming occurred in absence of GrB, CD8α DC levels in the spleen of Spi6 
KO mice were found to be rescued to WT levels, while higher numbers of pDCs were 
measured in Spi6 KO mice compared to WT (Figure 53 and Figure 54). 
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Figure 53: CD8α DCs are rescued to WT levels after infection when GrB KO P14 
CD8 T cells are adoptively transferred into Spi6 KO mice. Absolute numbers of 
CD8α DC and pDC in the spleen of LCMV Arm-infected mice adoptively 
transferred with GrB KO P14 CD8 T cells are shown. All mean values are ±SEM 
and are representative of three independent experiments (n = 3-4), *p = 0.036. 
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Figure 54 shows how the adoptive transfer of GrB KO P14 CD8 T cells into Spi6 
KO mice results in the levels of DCs, at day 4 post-infection, being restored to the 
same level of WT mice. These results strongly indicate that DCs are eliminated by 
cognate CTLs in a GrB-dependent way during the initial phases of infections and that 
this is regulated by Spi6 expression in DCs. 
 
 
Figure 54: CD8α DC levels are rescued when priming occurs in absence of GrB 
in spleen. Absolute numbers of CD8α DC in the spleen of WT and Spi6 KO 
mice adoptively transferred with WT or GrB KO P14 cells and infected with 
LCMV Arm. All mean values are ±SEM and are representative of three 
independent experiments (n = 3-4), * p < 0.05; n.s. Not Significant. 
 
 
It can be concluded that, during viral infections, DCs priming antigen-specific CD8 
T cells are a target of GrB released by CD8 T cells themselves. 
During LCMV infection in our Spi6 KO model, DC levels are especially affected at 
day 4 post-infection, showing significantly decreased numbers of CD8α DCs 
compared to WT, coincidentally with the acquisition of effector functions by primed 
CTLs. 
 
 
4.3.4   Dendritic cells from Spi6 KO mice are functionally equivalent 
to wild-type  
 
To date, no data has been produced on the effect of Spi6 on DC function. Therefore, 
once established that the number of CD8α DC is impaired in Spi6 KO mice when 
infected with LCMV, the functionality of these cells was assessed, to verify if the 
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lack of Spi6 had any consequence in presenting and priming functions. As CD8α DCs 
are the ones involved in antigen presentation to CD8 T cells, these cells were chosen 
for the functional study. 
 
Following the same protocol as in the previous experiments, WT P14 cells were 
adoptively transferred into WT and Spi6 KO mice and the mice were then infected 
with LCMV Arm. Once again, day 4 post-infection was chosen as the preferred time-
point, due to the difference measured in CD8α DC levels. At day 4 p.i. the mice were 
sacrificed and CD8α DC isolated from the spleen to test their ability to induce CTL 
maturation and proliferation (protocol shown in Figure 55). 
 
 
Figure 55: Protocol for functional study of DCs from WT and Spi6 KO mice. WT and Spi6 KO 
mice are adoptively transferred with P14 CD8 T cells and infected with LCMV Arm. CD8α DCs 
are sorted from the spleen of the mice at day 4 p.i. and mixed to naïve P14 CD8 T cells for 60 hrs 
in vitro.  
 
 
CD11c
+
 cells were isolated through enzymatic digestion followed by FACS sorting 
of CD8α+ DCs, and used in a proliferation assay where an incorporating base, EdU, 
was used to measure proliferation. EdU is used for proliferation assays and preferred 
to Thymidine incorporation due to its non-radioactive nature. 
CD8α+ DCs were sorted using the same surface markers used for identification of 
CD11c
hi CD8α+ CD4-. These cells were used to prime naïve CD8 T cells from P14 
mice. Naïve CD8 P14 cells (5x10
4) were mixed to titrated CD8α+ DC and EdU (5 
μg/ml) and, according to a previously described protocol, cells were harvested after 
60 hrs (Belz et al. 2004). EdU incorporation was analysed with flow cytometry, as 
shown in Figure 56. Analysis of the percentage of cells in active proliferation status 
after 60 hrs of culture with WT (left panel) or Spi6 KO (right panel) CD8α DCs 
shows no difference in the ability of sorted DCs to prime CD8 T cells.  
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Figure 56: EdU staining for proliferating CD8 T cells measured after 60 hrs in 
culture with sorted CD8α DCs at a 2 to 1 ratio, from infected WT and Spi6 KO 
mice adoptively transferred with P14 CD8 T cells. Data are representative of 
three independent experiments. 
 
The results show a proliferation rate of 14% of the total number of CD8 P14 T cells 
when half the number of CD8α DCs (target) are used to prime CD8 T cells (effector). 
The level of proliferation measured at a ratio of 2 : 1 was more than 10-fold the levels 
of basal proliferation. These data demonstrate that Spi6 KO-derived DCs are 
functionally not impaired. Also, titration of the CTL to DC ratio was performed and 
the proliferation measured showed that CD8 T cell proliferation is dependent on the 
levels of DC (Figure 57) 
 
 
Figure 57: Percentage of EdU
+
 cells at different P14 CD8 T cells to CD8α DC 
ratios. The dotted line represents basal proliferation. Positive control cultures 
that were pulsed with gp33 peptide at a 1:1 ratio gave 20% EdU
+ 
cells and 
negative control cultures (5x10
4
 P14 CD8 T cells alone/well) gave 0.7% EdU
+ 
cells. All mean values are ±SEM and are representative of three independent 
experiments. 
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4.4 Dendritic cell priming of CD8 T cell responses in vivo 
 
It has been hypothesised that Spi6 would have a role in DC priming of primary and 
secondary CD8
+
 responses. To demonstrate it, an in vivo infection system in which 
DCs lack Spi6 but CD8 T cells do not was used. As the current theory hypothesizes 
that the CTL burst is dependent on DC priming and given that sustained antigen 
presentation is required for optimal CTL expansion (van Montfoort et al. 2009), it 
was investigated whether the impaired survival of CD8α DCs seen in previous 
experiments was mirrored by a deficit in the CTL response. A positive response to 
this question would also support the theory that a negative feedback loop is in place 
to regulate CTL expansion levels: the higher the killing of DC, the more the CTL 
burst is reduced. 
 
 
 
 
4.4.1   Expansion of LCMV-specific adoptively transferred cytotoxic 
T cells is defective in Spi6 KO mice 
 
 Antigen-specific cytotoxic CD8 T cell levels were analysed in adoptively transferred 
mice to test whether a defect in CD8α DC population in the spleen of the mice 
resulted in defective CTL expansion.  
 
Spi6 KO and control mice (WT mice), both Thy1.2, were injected with 5x10
3
 CD8
+ 
P14 Thy1.1
+
 cells and subsequently infected with LCMV Armstrong i.p. Half of the 
mice for each test group were analysed at day 8 post infection, the peak of CTL 
expansion, while the other half were re-infected at day 35 post infection, to allow for 
memory cell development (see Figure 58 for protocol). Mice were bled at regular 
intervals until day 8 post-infection and then sacrificed to analyse P14 CTL response 
in the spleen and inguinal LNs. Inguinal LNs were chosen due to their position 
relative the i.p. infection.   
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Figure 58: Experimental protocol for in vivo analysis of CTL responses to LCMV Arm. Two 
groups of mice (n=5-6) were adoptively transferred with 5x10
3
 P14 Thy1.1 CD8 T cells and 
infected 2 days later with Arm (i.p.). Mice were bled from day 2 and half of each test group 
was sacrificed at day 8 p.i., while the other half was bled and memory cell formation 
allowed. After 40 days at least, the mice (n=5-6) were infected with LCMV CL13 i.v. and 
sacrificed 5 days p.i.  
 
 
CTLs were identified in whole spleen preparations, whole LN preparations and red 
blood cell-depleted blood preparation, by surface staining with gp33-tetramers, anti-
CD8, anti-CD44 and anti-Thy1.1 (CD90.1) antibodies. 
 
The gating strategy for individuation of donor-derived gp33-specific CD8 T cells is 
shown in Figure 59. CD8
+
 T
 
cells are first identified among lymphocytes. Gp33
+ 
Thy1.1
+
 cells are then isolated from the CD8
+
 T cell population. This gating strategy 
allows for identification of autologous CD8 T cells which recognise gp33 as well: 
these cells are CD8
+
 gp33
+
 Thy1.1
- 
(see Figure 59). 
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Figure 59: Gating strategy for CD8 P14 donor-derived cells. Gp33 tetramers are used to identify 
P14-derived cells and Thy1.1 and Thy1.2 are used to distinguish donor-derived from autologous 
CD8 T cells. 
 
 
The population identified as donor-derived Thy1.1+ gp33+ CD8 T cells with FACS 
analysis of surface markers is shown in more detail in Figure 60. 
 
 
Figure 60: Representative FACS plot for the identification of donor P14 cells as 
Gp33
+
 Thy1.1
+
 among CD8 T cells. Spi6KO cells on the left panel and WT cells 
in the right panel. 
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The dynamics of the gp33-specific CD8 response in the spleen was followed from 
day 2 to day 8 at regular intervals. Data reported in Figure 61 show a significant 
difference from day 6 p.i., as expected from the findings that DC survival is impaired 
at day 4. The number represented total gp33-specific CD44
+
 CD8
+
 cells in the spleen 
of Spi6 KO and WT mice at indicated days post-infection (Figure 61). 
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Figure 61: Total gp33-specific CD8 cell levels in WT and Spi6 KO mice 
adoptively transferred with P14 CD8 T cells after Arm infection. All mean 
values are ±SEM and are representative of two independent experiments 
(n= 3). Error bars are covered by the data point in some cases. 
 
 
The results obtained from mice bled and analysed for gp33-specific CD8
+ 
Thy1.1
+
 
cells indicated that CTL expansion in Spi6 KO mice is defective at day 8 post-
infection compared to WT. The levels of donor-derived gp33
+
 CD8
+
 cells in Spi6 KO 
mice were seen to be decreased by 2-fold (p = 0.01) in the spleen and by 8-fold (p = 
0.003) in the lymph nodes, compared to WT mice (Figure 62). 
 
These results are in agreement with the measurement of a 15-fold higher donor 
gp33-specific CTL response compared to the endogenous one reported above in 
Figure 52.  
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Figure 62: Donor-derived CTL gp33-specific response in WT and Spi6 KO mice at day 8 pi. Both 
Spi6 KO and WT mice (recipient) were adoptively transferred with P14 CD8 T cells (donor 
CTL). All mean values are ±SEM and are representative of three independent experiments (n= 
5-6), ***p = 0.01; **p = 0.01. 
 
 
Data showed that CD8 T cell primary response is defective in absence of Spi6. The 
experimental conditions also allow the conclusion that the deficit in the CTL 
expansion is independent of Spi6 role in CD8 T cells themselves The shortfall in 
antigen-specific CTLs from day 6 p.i. observed in Spi6KO mouse is not cell-
autonomous  On the basis of the results obtained from the analysis of splenic DC 
levels during LCMV infection after adoptive transfer of gp33 P14 CD8 T cells, the 
decrease in the levels of live CD8α DCs in the spleen of Spi6 KO mice resulted in a 
lower CTL response. 
 
 
4.4.2   Gp33-specific donor CD8 T cell memory pool in adoptively 
transferred mice 
 
Since elimination of DCs by memory cells has also been reported as being part of a 
feedback mechanism for the control of the re-expansion of these cells, it was decided 
to investigate whether Spi6 deficiency had a role in secondary responses as well.  
The development and the levels of the donor-derived memory pool were studied in 
both Spi6 KO and WT mice from day 8 to day 40 post-infection. Mice were bled at 
regular intervals in order to follow the development of the memory cells. The 
percentage of donor-derived gp33-specific CD8 T cells in the blood is recorded in 
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Figure 63 and shows that, despite a difference in the effector pool between Spi6 KO 
and WT mice at the peak of the secondary response in the spleen and LN, the levels 
in the blood were comparable. Also, no difference in the percentage of antigen-
specific CD8 T memory cells was seen in the blood of Spi6 KO compared to WT 
mice during the contraction phase and up to day 40 post-infection. Notably, after re-
infection with CL13 LCMV, WT donor-derived gp33-specific memory cells re-
expend to higher levels compared to Spi6 KO ones.   
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Figure 63: Blood levels of donor-derived gp33-specific CTLs shown as 
percentage of gp33
+
 Thy1.1
+
 CD8 T cells in the blood at the indicated time 
points after infection. Secondary infection, with CL13 strain of LCMV, was 
performed at day 40 (see arrow). All mean values are ±SEM and are 
representative of three independent experiments (n = 5-6). 
 
 
To better describe the gp33-specific donor-derived memory pool, analysis of spleen 
and inguinal LNs was carried out on memory mice, on day 40 post-infection. 
Absolute numbers of memory cells were measured as before (CD8
+
 gp33
+
 Thy1.1
+
 
cells in whole spleen and whole LNs). Results in Figure 64 show that levels of donor 
memory cells (Thy1.1
+
) in the spleen of Spi6 KO mice were 2-fold higher than level 
of these cells in WT, while in the inguinal LNs no difference was seen (Figure 65).  
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Figure 64: Absolute numbers of donor-derived P14 CD8 memory cell pool 
(gp33-specific Thy1.1
+
 CD8 T cells) in the spleen of WT and Spi6 KO mice >40 
days post-infection. All mean values (horizontal bar) are ±SEM and are 
representative of three independent experiments (n = 5-6), ***p = 0.0002. 
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Figure 65: Absolute numbers of donor derived P14 CD8 memory cell pool 
(gp33-specific Thy1.1
+
 CD8 T cells) in the inguinal LN of WT and Spi6 KO mice 
>40 days post-infection. All mean values (horizontal bar) are ±SEM and are 
representative of three independent experiments (n = 5-6). 
 
 
These results are consistent with previous studies from Zhang and colleagues that 
showed how, despite a defective primary responses that fails to peak around day 8 p.i. 
memory in Spi6 KO mice develops to levels comparable to WT after LCMV Arm 
infection (Zhang et al. 2007) 
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4.4.3   Re-expansion of LCMV-specific adoptively transferred 
cytotoxic T cells is defective in memory Spi6 knock-out mice 
 
In a typical CD8 T cell response, memory CD8 cells start developing during the 
CTL contraction phase, and a stable memory pool can be clearly identified 35 days 
after the infection. To verify whether Spi6 absence could interfere with memory cell 
re-expansion, Spi6 KO and WT mice were re-infected with LCMV CL13 i.v. (10
6
 
PFU) 40 days after the primary infection. The CL13 LCMV variant strain can cause 
chronic infection in immunocompetent naïve mice. Nonetheless, as reported by Nolz 
and Harty in 2011, who adoptively transferred antigen-specific memory cells into 
naïve mice (Nolz and Harty 2011), antigen-specific memory cells can prevent chronic 
infection and efficiently clear the virus in 5-6 days.  
 
 
Figure 66: Secondary response experiment protocol. WT and Spi6 KO mice were adoptively 
transferred with 5000 WT or GrB KO P14 naïve CD8 T cells and infected with LCMV Arm. 
After 40 days from primary infection, the mice were infected with LCMV CL13. Donor-derived 
gp33
+
 Thy1.1
+
 CD8 T cells were measured in the spleen and LNs 5 days after the secondary 
infection.  
 
 
Infection with CL13 was performed as, due to the high levels of donor-derived 
memory cells, a high titre of an aggressive virus was needed to stimulate memory cell 
proliferation and avoid elimination of the virus without secondary spread. The 
measurement of blood levels of gp33-specific memory cells confirmed that CL13 
infection involved a re-expansion of the memory pool. The chart in Figure 63 shows 
how specific gp33
+ 
Thy1.1
+
 CD8 T cell levels increase from day 40 (the day of 
secondary infection) to day 45 (day 5 after secondary infection). 
To measure memory response levels, mice were bled and spleen and inguinal lymph 
nodes were analysed as before: the total number of cells was counted, and 
lymphocytes stained for CD8,
 
gp33 tetramer, and Thy1.1. As shown in Figure 67, in 
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the spleen of Spi6 KO mice the level of donor cells after re-expansion was 2-fold 
lower than in WT mice (p = 0.0014) and in the LNs this was 4-fold lower (p = 
0.0006). When looking at these results in the light of the pre-existing memory pool 
(Figure 64 and Figure 65), this means a 4-fold expansion for the memory cells 
occurred in the WT mice.  
 
 
Figure 67: Levels of donor-derived gp33-specific memory cells after re-expansion. Donor cells 
are gp33
+
 Thy1.1
+
 CD8
+
. All mean values (horizontal bar) are ±SEM and are representative of 
three independent experiments (n = 5-6), **p = 0.0014, ***p = 0.0006. 
 
 
These results suggest that Spi6 is needed for re-expansion of memory responses. This 
is likely to be due to a specific need memory cells have for DC priming of re-
expansion, in absence of which they cannot be activated to re-acquire effector 
functions. Memory cell re-expansion is therefore dependent on Spi6 and the defect is 
not ascribable to a CD8 T cell autocrine mechanism. 
 
 
 
4.5 Expansion of antigen-specific CTL response in absence 
of granzyme B 
 
Spi6 is a GrB inhibitor and it therefore has an anti-apoptotic role in CTLs and in 
DCs. To prove that the deficit in the DC number and CTL response levels seen is due 
to the lack of Spi6 in DCs, it was once again decided to eliminate the target of Spi6 
from the system. 
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Having established that the gp-33 response was mainly due to donor cells and 
therefore the contribution of endogenous GrB was negligible, GrB KO P14 T cells 
were used once more to study the dependence of the CTL response on this cytotoxic 
molecule in WT and Spi6 KO mice. Since in an adoptively transferred mouse, GrB 
absence could restore the levels of DC to normal (see 4.3.3) it was decided to verify if 
the rescue of DC levels was accompanied by a rescue of the antigen-specific CTL 
expansion. 
 
 
4.5.1   Cytotoxic T cell expansion defect is rescued by granzyme B 
absence in primary responses against LCMV 
 
P14 Thy1.1
+
 mice were bred in our facilities with GrB KO mice to obtain Thy1.1 
P14 GrB KO mice. GrB KO P14 CD8 naïve T cells were isolated from the spleen of 
these mice in order to be adoptively transferred to WT and Spi6 KO mice with the 
same protocol as before. WT and Spi6 KO mice were adoptively transferred with a 
low number of either WT P14 Thy1.1
+
 CD8 naïve T cells or GrB KO P14 Thy1.1
+
 
CD8 naïve T cells ones and successively infected with LCMV Arm i.p. Analysis of 
spleen and LNs was carried out at day 8 post-infection: donor-derived gp33-specific 
CTLs were measured.  
 
 
Figure 68: Rescue of CTL deficit in Spi6 KO mice. WT mice were adoptively transferred with 
GrB KO P14 Thy1.1 CTL and their levels after infection (day 8 p.i.) were compared to adoptive 
transfer of WT and GrB KO P14 CD8 T cells in Spi6 KO mice. All mean values (horizontal bar) 
are ±SEM and are representative of 3 independent experiments (n= 5-6): **p < 0.005; *p < 0.5. 
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Results showed CTL expansion restored to WT level in Spi6 KO mice adoptively 
transferred with GrB KO P14 T cells both in the spleen and in the inguinal LNs 
(Figure 68). Therefore when GrB was eliminated from the system, the deficit in the 
primary response was rescued. This suggested a direct correlation between the 
absence of GrB and the absence of Spi6. 
 
 
 
 
4.5.2   Cytotoxic T cell expansion defect is rescued by granzyme B 
absence in recall responses 
 
Having shown that GrB deletion could rescue CTL levels to normal in Spi6 KO 
mice, we wanted to test if GrB was also responsible for the re-expansion defect in 
memory responses. The contribution of the donor-derived CTL to the antigen-specific 
re-expansion was measured and it was once more verified that donor cells contributed 
for more than 90% being 12.7-fold higher than endogenous in WT and 17.8-fold in 
Spi6 KO mice, as shown in Figure 69. 
 
 
Figure 69: Endogenous (black) VS adoptive transferred donor (white) CTL 
levels in the spleen of CL13-infected memory mice at day 5 post-secondary 
infection. Donor cells are Thy1.1, endogenous cells are Thy1.2. All mean 
values are ±SEM and are representative of three independent experiments (n 
= 5-6). 
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To note, the contribution of endogenous GrB derived from np396-specific 
endogenous cells has not been studied and it would be an interesting issue to 
investigate. Nonetheless, my results show how in the system because the exogenous 
response is overwhelming, the rescue is still achieved.  
 
 
Figure 70: Rescue of gp33-specific donor CTL response in Spi6 KO mice adoptively transferred 
with GrB KO P14 CD8 T Cells. Number of donor-derived gp33-specific CD8 T cells at day 5 
post-secondary infection in the spleen (left) and in the inguinal LN (right) of Spi6 KO or WT 
mice (recipient) adoptively transferred with P14 CD8 T cells or GrB P14 CD8 T cells (donor 
CTL). All mean values (horizontal bar) are ±SEM and are representative of three independent 
experiments (n = 5-6), *p < 0.05. 
 
 
 
The deficit seen in secondary response in Spi6 KO mice was restored when GrB 
KO P14 CD8 T cells were adoptively transferred to Spi6 KO mice Figure 70). The 
absence of GrB in donor-derived CD8 T cells only was therefore shown to be enough 
to restore the levels of gp33-specific CTL response.  
The difference in the CTL levels at the peak of the response between Spi6 KO and 
WT mice is therefore dependent on GrB, suggesting a role for Spi6 and once more, 
the effect is not CD8-autonomous. Despite the different requirements for memory re-
expansion compared to primary responses, including short priming, limited to the 
early phases of the response, Spi6 is therefore required protecting DCs from GrB-
mediated killing in memory priming and for the priming of optimal memory CD8 
responses.  
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4.6 Re-expansion of adoptively transferred memory CD8 T 
cells in CL13-challenged mice  
 
An experiment was designed to test whether the difference in the levels of the 
secondary response expansion, seen in the previous experiments, was due to a 
difference in the number of the specific memory cells in the two groups.  
 
Although the levels of memory gp33-specific CD8 T cells had been verified in WT 
and Spi6 KO mice after 40 days, further experiments were carried out to verify that 
the secondary response defect was not due to a substantial difference in the existing 
memory pools at the time of infection.  
 
To exclude the possibility that Spi6 might play some other role in memory 
development, memory cells were developed in WT mice and adoptively transferred 
into naïve Spi6 KO and WT mice. These mice were then infected with LCMV CL13 
to analyse DC ability to prime these memory cells. P14 Thy1.1
+
 CD8 naïve T cells 
were first transferred into WT mice, which were infected with Arm i.p. as in the 
previous protocol. After 40 days, these memory P14 Thy1.1 cells were isolated from 
the WT mice with Thy1.1-specific magnetic bead enrichment and adoptively 
transferred into WT and Spi6 KO mice. The mice were then infected with LCMV 
CL13 and sacrificed for spleen and LN analysis 5 days post infection (see Figure 71). 
 
In particular, the P14 CD8
+ 
Thy1.1
+
 memory cells were adoptively transferred in 
different amounts (respectively 10
4
, 10
3
 and 10
2
 cells) into WT and Spi6 KO mice in 
order to investigate whether memory re-expansion was based on a dose-response 
effect. This would determine if high numbers of memory cells have significance in re-
expansion dynamics. 
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Figure 71: Experimental protocol. P14 Thy1.1 CD8 naïve T cells are adoptively transferred into 
a WT mouse, which is infected with LCMV Arm. After 40 days, memory cells are isolated with 
anti-Thy1.1 magnetic beads and adoptively transferred into WT and Spi6 KO naïve mice. These 
are infected with LCMV CL13 and blood spleen and LN analysed 5 days p.i. 
 
 
The results in Figure 72 show the numbers of CD8
+ 
gp33
+ 
Thy1.1
+
 donor cells in the 
spleen of Spi6 KO and WT mice 5 days after secondary infection with LCMV CL13. 
The levels of the CD8 T cell response correlate with the number of transferred 
memory cells in the spleen in both WT and Spi6 KO mice. A significant difference in 
the response levels is seen between the mice injected with 10
2
 and 10
3
 cells or 10
4
 
cells. No difference is seen between the re-expansion levels in WT and Spi6 KO mice 
adoptively transferred with the same number of gp33-specific memory CD8 T cells. 
 
The results obtained by donor-derived CD8 T cell analysis in the LNs are different. 
A deficit in the re-expansion levels is seen in Spi6 KO mice compared to WT: our 
hypothesis is that the difference in the subset composition between the spleen and the 
LN, and in the memory cell population, might play a part in the difference seen in 
levels of memory cell proliferation. Results from the LNs suggest that the levels of 
expansion correlate with the number of adoptively transferred CD8 memory cells 
only in the Spi6 KO mice. In the WT mice levels of CD8
+ 
gp33
+ 
Thy1.1
+
 cells post 
secondary-challenge seem to reach a plateau, as despite the difference in the number 
of adoptively transferred memory cells, these were similar (see Figure 72).  
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Figure 72: Re-expansion levels of adoptively transferred Thy1.1
+
 gp33
+
 P14
+
 
CD8 memory T cells in the spleen at day 5 post-infection with LCMV CL13, 
absolute numbers. The difference is non significant between WT and Spi6 KO 
in any of the sub-groups. All mean values are ±SEM and are representative of 
two independent experiments (n = 5-6). 
 
 
In the LN the levels of memory cells in the Spi6 KO mice were significantly lower 
than in the WT, showing a deficit in the re-expansion ability of these cells in absence 
of Spi6 (see Figure 73).  
 
The difference in the levels of memory re-expansion between the spleen and the LN 
might be linked to the specific “preference” of CL13 to infect DC, which is, as see 
above, due to its high affinity for α-distroglycan, expressed in high levels by splenic 
interdigitating DCs (Salvato et al. 1991). CL13 infection of splenic DC might in fact 
result in higher killing of these cells as they are recognised as target by activated 
memory cells, thus eliminating the protective function of Spi6 in WT cells. Possibly, 
this difference could also be due to the different ability of central and effector cells to 
migrate to the LN and the spleen, and their different requirements in terms of 
priming. The LN is mainly accessible to central memory cells which are activated 
specifically by resident CD8α DC. This might explain why Spi6 KO mice have 
defective memory cell levels in the LN: the DCs in this tissue are dependent on Spi6 
for survival when activating memory cells. Once primed, these cells will egress the 
LNs to reach the infected tissue. In the case of CL13, the infected tissue is the spleen, 
as just discussed, due to CL13 high preference for interdigitating DC. This would 
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mean that DC are not only killed by ectopic release of GrB due to priming, but also 
by targeted release of GrB and other killing pathways specifically aimed at these 
infected cells to eliminate the pathogen.   
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Figure 73: Re-expansion levels of adoptively transferred Thy1.1
+
 gp33
+
 
P14
+
 CD8 T cells in the LN at day 5 post-infection with LCMV CL13, 
absolute numbers. All mean values are ±SEM and are representative of two 
independent experiments (n = 5-6), *p < 0.05; **p < 0.005; ***p < 0.0005. 
 
 
Therefore in the same conditions of infection (same viral titre) and of initial CD8 
memory cell pool (same number of CD8
+ 
gp33
+ 
Thy1.1
+
 memory cells), Spi6 KO 
mice have a deficient secondary response expansion in the LN. 
From this set of experiments can be concluded that Spi6 controls the expansion of 
both primary and secondary CD8 T cell responses, independent of its role in CD8 
themselves. In the light of its ability to protect DC from CTL-induced damage, 
findings are consistent with a role for Spi6 in protecting DC from CTL in vivo. 
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4.7 Donor CD8 T cells response functionality: LCMV 
clearance  
 
LCMV Arm viral infection is efficiently cleared by immunocompetent mice within 
8-10 days with a physiological antigen-specific precursor frequency of about 10-10
3
 
cells. Having obtained results supporting the theory that Spi6 protects DCs from CTL 
killing and that its absence indirectly affects CTL responses, I wanted to verify the 
consequences of the deficient expansion seen in Spi6 KO mice in terms of viral 
clearance. Viral levels were measured in the spleen of infected mice at day 6 post-
infection. Viral peak is reached in B6 (WT) intact mice by day 3-4, therefore making 
day 6 a good time point to establish the efficiency of clearance by adoptively 
transferred CD8 cells. Due to the high precursor frequency of antigen-specific CD8 T 
cells in this model, viral clearance was expected to be reached ahead of times 
compared to an intact WT mouse. Also, a time-point at which viral levels could be 
detected before being too low for RT-PCR sensitivity was needed.  
LCMV major proteins are glycoprotein (GP) and nucleoprotein (NP). Among the 
two, Np is the most abundant protein in infected cells. It forms the capside containing 
the viral RNA (Buchmeier et al. 1978) and it is required for RNA replication as it 
encapsidates nascent viral RNA. Moreover its levels are controlling the switch of the 
polymerase activity from transcription to replication (Blumberg et al. 1981). 
 
 
 
 
4.7.1 Viral clearance of primary cytotoxic T cell response 
 
WT and Spi6 KO mice were adoptively transferred and infected as above with P14 
CD8 naïve T cells and infected with LCMV Arm (Figure 58). At day 6 p.i., the 
spleens were harvested and total RNA was extracted to measure viral titre through 
viral RNA analysis (see Chapter 3.4). Results for the two major viral proteins, gp and 
np, are shown in Figure 74 and clearly indicate a clearance defect in Spi6 KO mice 
which results in 100-fold more virus in these mice at day 6 p.i., compared to WT. 
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This indicates that higher titres of LCMV are present in Spi6 KO mice at day 6 p.i., 
compared to WT. Deficient primary response expansion is therefore associated with a 
significant defect in clearance of LCMV Arm. 
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Figure 74: Viral GP (left) and NP (right) levels in the spleen of day 6 infected mice obtained 
measuring viral mRNA levels in the spleen of infected mice with RT-PCR. All mean values 
(horizontal bar) are ±SEM and are representative of two independent experiments (n = 5-6), *p < 
0.05, **p < 0.005. 
 
 
 
 
4.7.2 Viral clearance of secondary cytotoxic T cell response 
 
Viral load was also measured after memory responses, at day 5 post re-infection. 
The results show a very low viral presence, indicating the ability of the antigen-
specific memory pool to efficiently fight the infection (Figure 75) even in an Spi6 KO 
environment as reported in previous studies (Zhang et al. 2007). A difference in the 
levels of NP was revealed, while GP levels were the same for Spi6 KO and WT 
(Figure 76). This difference suggests that clearance of LCMV CL13 is delayed in 
Spi6 KO mice, as np is a regulator of viral RNA transcription and its levels indicate 
that transcription in Spi6 KO mice is till in place at day 5 p.i. 
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Figure 75: Viral titre (Gp levels) at day 5 post secondary infection. All 
mean values (horizontal bar) are ±SEM and are representative of three 
independent experiments (n = 4). 
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Figure 76: Viral titre (Np levels) at day 5 post secondary infection. All 
mean values (horizontal bar) are ±SEM and are representative of two 
independent experiments (n = 4), *p < 0.05. 
 
 
Based on these results that show better clearance in WT mice compared to Spi6 KO 
ones despite the WT status of the effector cells, it can be concluded that Spi6 is 
required for the priming of functionally relevant CTL responses by DCs in vivo. 
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5.   DISCUSSION 
 
 
 
 
 
 
5.1 Introduction 
 
 
A big percentage of infectious diseases, which constitute a great social and 
economical burden other than of course a public walfare problem throughout the 
world, are caused by viruses. Chronic viral diseases, on the other hand, affect an ever-
growing portion of the Western and Developing Countries adult population. 
Advanced vaccination approaches, preventive and therapeutic, targeted at 
ameliorating specific responses against viruses are desirable to prevent and treat 
infectious diseases, cancer of viral origin and chronic viral diseases. Compared to 
vaccines generating antibody protection or humoral responses, CD8 T cell immunity 
has been more challenging to achieve, therefore being an area where much 
improvement is needed. Also, CD8 T cell responses are desirable due to their 
efficient and rapid methodology of clearing the body from infected and unwanted 
tumorigenic cells through induction of a self-contained death called apoptosis. 
Dendritic cells are a main target of new strategies aimed at eliciting CD8 T cell 
primary and memory responses (Butler et al. 2011; Nolz and Harty 2011).  
 
Clearance of viral infections in vivo is mainly mediated by cytotoxic CD8 T cells, 
which are specifically activated by dendritic cells among the professional antigen 
presenting cells. DCs are highly phagocytic cells which reside in peripheral tissues 
and are able to sense inflammation and pathogen-associated patterns. In inflammatory 
conditions, DCs undergo a maturation program which allows them to exit peripheral 
tissue and reach secondary lymphoid organs. Here, naïve CD8 T cell receive 
activation signals responsible for the regulation and extent of the immune response to 
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be mounted by the mature DCs. Antigen-specific CD8 naïve T cells activated by 
mature DCs, undergo maturation to cytotoxic T cells and proliferate at high rate. 
CTLs will then migrate out of the lymphoid tissue to reach the site of infection and 
kill infected cells. CTLs can kill infected cell via contact-dependent apoptosis 
induction, which can be achieved in two ways: the release of cytotoxic molecules by 
degranulation and/or Fas-FasL ligation. The importance of the granule-mediated 
pathway emerges when considering that perforin deficient mice develop spontaneous 
lymphomas and have impaired ability to clear many viruses. On the other hand, Fas-
FasL-defective mice have lymphoproliferative disorders. The hypothesis is therefore 
for the death receptor pathway to be involved in maintenance of lymphocyte 
homeostasis, while the cytotoxic molecule-release pathways is involved in clearance 
of virally infected cells and tumours. After successful clearance of the virus, the 
antigen-specific CTL population is reduced by clonal contraction, of about 9/10 to 
form a pool of resting CD8 T cells able to quickly reactivate effector functions and 
undergoing homeostatic proliferation. These cells are called memory cells: they 
survive without antigenic stimulation and their re-activation is dependent on antigen 
presentation by antigen-loaded DC (see Chapter 2.3). 
 
Due to the key role of DCs in stimulating both primary and secondary CD8 T cell 
responses, understanding the mechanisms that regulate their maturation, survival and 
migration will allow better design of vaccination and therapeutic strategy. This 
project in particular investigated the function of a protein with antiapoptotic 
properties expressed by DCs. DC survival is of particular importance since it has been 
involved in a feedback mechanism which regulates/controls the CD8 response 
expansion levels through the killing of antigen-loaded DCs (Wong and Pamer 2003; 
Yang et al. 2006). The molecules regulating balance between life and death in DCs 
will thus have an impact on CTL responses themselves. In particular, the feedback 
regulatory mechanism has been shown to depend on perforin, as in pfn KO mice DCs 
are not eliminated to WT levels (Yang et al. 2006). Granzyme B is a cytotoxic 
molecule released by CTL as part of the granule exocytosis pathway (Heusel et al. 
1994). GrB can enter the target cell, where it triggers apoptotic pathways, only in 
presence of perforin (Kagi et al. 1996). GrB is also involved in the negative feedback 
loop described above as it has been suggested to be involved in DC killing by CTL 
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(Ashton-Rickardt 2010). GrB has lately been proposed as an immunomodulator 
molecule also due to its expression in T regulatory cells (Cao et al. 2007). 
 
Serine protease inhibitor (Spi)-6 is an intracellular protease responsible for GrB 
inactivation. It was first described in CD8 T cells, where it is expressed upon 
activation, and NK cells. Spi6 protects CD8 T cells from GrB-dependent self-induced 
apoptosis and is responsible for the integrity of its cytotoxic granules (Zhang et al. 
2006). Spi6 is also expressed by immature DC at low levels and it is upregulated 
upon maturation (Medema et al. 2001). Studies conducted in vitro, demonstrated that 
overexpression of Spi6 can protect mature DCs from CTL-mediated apoptosis in both 
humans and mice (Medema et al. 2001; Hirst et al. 2003). Unpublished data from our 
lab also shows that DC lacking Spi6 are more susceptible to CTL-induced PCD. 
Nonetheless, in an in vivo study, Andrew and colleagues results contradict Medema 
and Zhang’s data on Spi6 requirement for DC survival, showing no protection in 
LPS-matured antigen-loaded BMDDCs when injected into a previously boosted 
mouse (Andrew et al. 2008). Notably, these data were obtained relying on mRNA 
level measurements to establish Spi6 protein levels. RNA measurement is not a good 
strategy to evaluate protein levels as the mRNA might be translated at a later time and 
therefore not mirror the amount of protein present at that stage in the cell. This project 
addresses the controversy regarding Spi6 protective role in DCs and aims to further 
test the consequences of Spi6 absence in mature DCs when priming CTL responses 
after viral challenge in vivo.  
 
 
The hypothesis tested in this project was that Spi6 could prevent CTL-induced 
apoptosis in DCs during the priming of both naïve and memory CD8 T cells by 
inhibiting GrB. Based on the model describing a negative feedback loop regulating 
the expansion of CTL responses, the hypothesis also predicts a defective expansion of 
antigen-specific CD8 T cells in absence of Spi6 in DCs. The confirmation of this 
hypothesis supports Spi6 involvement in the negative feedback mechanism that 
regulates CTL expansion as a regulator of the susceptibility of DCs to CTL-mediated 
killing. 
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Protection of DCs from CTL-mediated death is desirable in the design of 
vaccination strategies aimed at eliciting CD8 T cell-mediated responses. Also, DC 
enhanced survival would be desirable as part of therapeutic strategies aimed at the 
reawakening of the CTL response in chronic infections.  
 
 
 
 
 
5.2 Spi6 protects dendritic cells from granzyme B-
mediated apoptosis in vitro 
 
 
Medema’s and Hirst’s groups showed how Spi6 is expressed at low levels in 
immature DCs and upregulated in mature DCs both in humans and mice (REF). 
Medema had also demonstrated that overexpression of Spi6 could protect DCs from 
CTL-mediated killing in vitro (Medema et al. 2001), which was confirmed by 
Andrew and colleagues (Andrew et al. 2008). In vitro data obtained in my lab by M. 
Zhang showed increased Spi6 KO BMDDC susceptibility to CTL-killing compared to 
WT ones, and correlated it to degranulation of CTLs rather than involvement of the 
Fas-FasL pathway. These results all support a role for Spi6 in protecting DC from 
CTL-mediated killing, and represent the basis on which this project was developed. 
Since previous in vitro results are the basis for the hypothesis regarding Spi6 anti-
apoptotic role in DC, some of the in vitro experiments previously performed by my 
colleague Dr. Zhang were repeated. The aim was to confirm previous results and 
specifically show that Spi6 KO BMDDC susceptibility to CTL-mediated apoptosis 
was GrB-dependent. Spi6 KO- and WT-derived BMDDCs were therefore cultured 
with CTL in presence or absence of GrB obtaining protection from apoptosis in 
mature Spi6
+
 cells only (WT cells). On the other hand, the elimination of GrB from 
CTL granules could abolish DC apoptosis both in presence and in absence of Spi6 at 
4 hrs (see Figure 38). These two pieces of data suggest that CTL-derived GrB triggers 
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apoptosis pathways in DCs, and also confirming Yang results obtained in pfn KO 
mice, where no DC killing was seen (Yhang et al. 2006). Notably, in the same 
experiment involving GrB KO P14 CTLs, apoptosis was induced after 8 hrs to the 
same extent in both Spi6 KO and WT BMDDCs. This suggests triggering of 
apoptosis pathway by involvement of the death receptor pathway. GrB has been 
described as the quickest mediator of apoptosis (Martin et al. 1996) out of the 
granule.  
 
In the context of in vitro CTL-induced antigen-specific killing, granzyme B is the 
mediator of apoptosis seen in mature BMDDC culture. Spi6 upregulation in mature 
DCs is key for protection of these cells from apoptosis.  
 
 
 
 
 
5.3 LCMV infection model and adoptive transfer of Spi6-
competent CD8 T cells 
 
The physiological relevance of Spi6 upregulation in mature DCs is nonetheless not 
clear, as in vitro experiments showed a protection from CTL-mediated killing, while 
in vivo results did not. In order to analyse Spi6 function, its levels were measured in 
physiologically matured splenic DCs in an infected in vivo model. The viral model of 
choice, LCMV, stimulates a MHC-I-driven immune response and is widely used to 
study CD8-specific T cell responses. In WT (B6) mice, the virus peaks at day 3-4 
post-infection and CTLs expand up to 10-fold from the original antigen-specific 
repertoire, creating a CD8 T cell response which reached its peak at day 8 and can 
clear the virus usually by day 10 p.i. At day 8 p.i., in the spleen of a WT mouse, the 
antigen-specific CD8 T cell response is composed as follows: 33% by np396-specific 
CTL, 25% by gp33-specific CTL, 5% by other minor epitopes (Murali-Krishna et al. 
1998). Previous data from Ashton-Rickardt’s group demonstrated how the CD8 T cell 
responses, to both viral and bacterial infection, in Spi6 KO mice have a defective 
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expansion phase but normal levels of memory cells (Zhang et al. 2004). In particular, 
antigen-specific CTLs show high levels of apoptosis in these mice thus failing to 
accumulate and form a peak around day 8 post-infection as is seen in WT mice after 
LCMV challenge. Apoptosis levels are mainly GrB-mediated, as Ashton-Rickardt 
demonstrated by staining for GrB (Zhang et al. 2006). Therefore, to ensure the 
development of a proper CD8 T cell response to the virus, the adoptive transfer of 
congenically marked naïve P14 CD8 T cells was employed. The adoptive transfer 
allowed/ensured the study of Spi6 function in DCs when antigen-specific CD8 T cells 
are Spi6 competent and thus do not die of self-inflicted PCD. 
 
The adoptive transfer of naïve P14 T cells was designed to minimize non-
physiological effects due to the high number of gp-33 specific precursors. A study by 
Badovinac and colleagues reports that CTL responses deriving from the adoptive 
transfer of 60-6x10
3
 TCR-specific cells are likely not to disturb the physiological 
development of endogenous responses. This was found despite the frequency of 
transgenic cells being about 10
2
-fold higher than the number found in an intact 
mouse. In fact, after adoptive transfer, only about 30-40% of transferred transgenic 
cells will successfully colonise the host (Blattman et al. 2002; Badovinac et al. 2007). 
The expansion of 50 transgenic T cells has in fact been shown to reach up to 400,000 
times the original number, while when 5x10
5
 transgenic cells are adoptively 
transferred into a mouse, an increase of 4- to 400-fold is observed. They also showed 
that a maximum level of expansion is supported by the mouse organism (Kemp et al. 
2004). Regarding the development of memory, anticipated CTL peak and higher 
frequencies of CD127
+
 CD62L
+
 cells during the contraction phase, seen with high 
numbers of transgenic cells, could be avoided with the adoptive transfer of up to 
6x10
3
 transgenic cells (Badovinac et al. 2007). The aim was to avoid any 
modification of the physiological development of the response and the number of 
cells to adoptively transfer was therefore chosen accordingly. On this basis, 5x10
3
 
P14 CD8 T cells were adoptively transferred into Spi6 KO and WT mice and showed 
a physiological CTL peak at day 8 p.i., confirming Badovinac’s results. The dynamics 
of the endogenous and donor antigen-specific T cells were studied and found to be in 
accordance to physiological expansion in intact mice. 
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CD4 help is generally needed for the successful expansion of memory cells 
(Behrens et al. 2004), but some antigens are considered Th- independent: LCMV is 
one of these. This happens both as the virus can infect dendritic cells and because of 
the inflammatory status they provoke in the host (Lanzavecchia 1998).  More studies 
confirmed the requirement for CD4 help for an optimal memory expansion, although 
in absence of these cells during the boost did not make much difference in the 
expansion levels (Shedlock and Shen 2003). In LCMV Arm infection, on the 
contrary, the elimination of CD4 T cells did not correlate to any defect in CD8 
expansion levels or function (Matloubian et al. 1994).  
 
In order to study Spi6 role in vivo, a viral model of infection was used to achieve 
physiological maturation of DCs and study the priming of CD8 antigen-specific T 
cells in presence or absence of Spi6. As Spi6 absence has a negative impact on CTL 
survival, as reported by previous studies, transgenic CD8 T cells specific for a viral 
antigen, were adoptively transferred into these mice (both the WT and the KO). This 
approach allowed the study of the effect of CTL release of GrB on DCs in the 
presence or absence of Spi6 in these cells.  
 
 
 
 
 
5.4 CD8α dendritic cells and plasmacytoid dendritic cells 
in LCMV infection 
 
 
Due to the variety of dendritic cell subpopulations in mice, there was a need for 
focussing on specific subsets to study the expression of Spi6 in the relevant in vivo 
context. For this reason, the protein levels were studied in splenic DCs with a specific 
focus on two particular subsets: CD8α+ DCs (hereafter defined as CD8α DCs) and 
pDCs.  
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5.4.1 CD8α dendritic cells in LCMV acute infection 
 
Belz and colleagues observed that, during LCMV Arm infection, resident CD8α DC 
in the spleen and LN are the main vector in presenting antigens to naïve CD8 T cells 
(Belz et al. 2004). Because of CD8α DC central role in cross-priming to CD8 T cells 
it was decided to focus the study of Spi6 expression and function on the CD8α DC 
population of the spleen. Further data supporting the central role of CD8α DCs in 
cross-presentation of LCMV antigens include the specific TLR repertoire expressed 
by CD8α DC which allows them to sense viral DNA and RNA. Also, CD8α DCs 
express an antigen-processing machinery attaining better cross-presentation compared 
to CD8α- subsets (see 2.5.10). Since CD8α DCs are spleen and LN residential cells, it 
was unclear how these cells could present antigen deriving from peripheral infected 
tissue. A mechanism that allows for the transfer of antigen from migratory DCs to 
resident CD8α DCs, both in the LN and in the spleen, has been uncovered. It aims at 
amplifying the antigen level in the SLOs and increasing the odds for cognate antigen 
recognition by CD8 T cells (Carbone et al. 2004; Allan et al. 2006). A phenomenon 
with similar effects termed cross-dressing has also been described, whereby loaded 
MHC molecules are passed on between DCs to allow more efficient activation of 
naïve and memory CD8 response (Wakim and Bevan 2011). 
The measurement of Spi6 levels in the CD8α DC subset shows that these cells 
upregulate Spi6 at day 2 post-infection (see Figure 51). As the upregulation of Spi6 
indicates that CD8α DCs are target of GrB themselves against GrB action, these 
findings further support the hypothesis that CD8α DC cross-present LCMV Arm 
antigens to CD8 T cells. Spi6 expression in CD8α DCs is then maintained at high 
levels until the resolution of the infection, suggesting that prolonged DC involvement, 
antigen presentation and costimulation, is required for the effective development of 
antigen-specific CTLs. 
The finding of high levels of Spi6 in DCs is indicative of a requirement for 
protection from CTL-mediated apoptosis. Nonetheless, the analysis of Spi6 levels 
alone does not explain if the protein effectively protects the cells. To further/ 
investigate Spi6 ability to preserve DCs after exposure to CTL-released GrB in vivo, 
DC numbers were measured at various time points in LCMV Arm-infected WT and 
Spi6 KO mice after adoptive transfer of WT and GrB KO P14 CD8 T cells. The time 
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points were chosen on the basis of the dynamics of infection that have been described 
in immunocompetent mice. By 24 hrs after LCMV Arm infection, CD8α+ DCs can 
stimulate naïve T cells and by day 3 apoptosis of CD11c
+
 CD8α+ can be seen. 
Measurement of the apoptosis levels through surface marker staining indicates an 
increase in apoptotic cell levels from day 3, but a more detailed analysis revealed that 
this staining had included phagocytosed CD8 T cells undergoing apoptosis. As 
described above in fact (see 2.5.10), CD8α DCs are highly equipped to uptake dying 
and apoptotic cells.  
 
My results, showing a lower peak in DC numbers at day 4 post-infection, support 
Montoya’s work that shows increased apoptosis in DCs from day 4 post LCMV-
infection (Montoya et al. 2005). They also support the work by Bahl and colleagues, 
who reported a decline in DC number in the spleen of WT LCMV-infected mice after 
day 3 p.i. (Bahl et al. 2010).  
In my hands, absence of Spi6 results in higher susceptibility to apoptosis in CD8α 
DCs from day 4 p.i., as demonstrated by a significant decrease in the number of these 
cells in Spi6 KO mice compared to WT. Apoptosis levels were particularly induced in 
these cells in a GrB-dependent way by CTLs. This is supported by the correction 
obtained in CD8α DC numbers o WT level when eliminating GrB from the granules 
of antigen-specific CTLs.  
 
It is also important to also establish whether Spi6 absence could impair DC 
function. To investigate if Spi6 absence had any functional consequence on DCs, 
these cells were isolated from Arm-infected mice and used to stimulate antigen-
specific CD8 T cell proliferation. The results obtained showed no functional 
difference between Spi6 KO DCs and WT ones. These results favour the hypothesis 
that any defect in CTL response is to be ascribed to diminished survival of antigen-
presenting DC, not impaired functionality.  
On the basis of these results showing upregulation of Spi6 in CD8α DC in mice and 
demonstrating the dependence of these cells on Spi6 for protection from CTL-
mediated killing, the expression of Spi6 is expected to be upregulated in the 
correspondent subset in humans which represents the desired target of adjuvant 
strategies to improve CTL responses. 
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5.4.2 Plasmacytoid dendritic cells in LCMV acute infection 
 
According to results from Montoya, Colonna and Dalod, upon viral infection, pDCs 
seem to be able to induce the activation of components of both the innate and the 
adaptive response, depending on the virus strain. Studies with LCMV infections have 
given unclear results regarding the degree of involvement of pDCs in eliciting CTL 
function and maturation of DCs. pDCs are DCs specialised in the systemic release of 
type I IFN. This is induced by the triggering of pathogen-sensing, PRR, pathways 
induced particularly by TLR7 and TLR9 stimulation. These two TLRs are expressed 
in endocytic vesicles in the pDCs and are activated by high levels of RNA and 
unmetilated CpG-rich DNA. They can also express IL-12 and IL-6. Type I IFNs 
contribute to mediate DC maturation (Montoya et al. 2002) and IL-12 has a 
stimulatory effect on CD8 T and NK cell-mediated release of cytotoxic molecules. 
Interestingly, in murine cytomegalovirus (MCMV) infection, whose target is mainly 
is splenic DCs, pDCs production of IFNα/β is needed for accumulation of this cell 
type in the spleen and has an adjuvant effect on cross-presentation as it enhances 
MHC-I expression and support CD8α DC maturation in particular (Dalod et al. 2003). 
In humans, patients with chronic infections like HCV (Kanto et al. 2004) and HIV 
(Fitzgerald-Bocarsly and Jacobs 2010) have diminished pDC circulating levels. In 
these infections, type I IFN levels are also low despite stimulation of TLRs. 
Plasmacytoid DC role in LCMV infection has been studied by Colonna and 
colleagues who used a BDCA-1-DTR mouse to study pDC role in LCMV Arm 
infection. The BDCA-1-DTR mouse has the peculiarity of allowing for the selective 
elimination of pDCs by DT administration. A DT receptor is coupled with the 
promoter for BDCA-1 making all the cells that express DTR sensitive to the toxin. 
BDCA-1 is the marker for pDCs in humans and its promoter is present in the same 
position and role in mice. Comparable CTL responses, cytokine levels and viral 
clearance were seen in the pDC-deleted mouse and the WT counterpart. In LCMV 
infection, cleared effectively both in the pDC-defective mouse and in the WT, the 
source of interferon needed for a strong CTL antiviral response is likely to be 
redundant. The authors suggest that pDC production of IFN might be required in 
weak CTL responses (Barchet et al. 2005). A different study suggests instead that 
LCMV itself inhibits pDC capacity of secreting type I IFNs and pDC numbers 
decrease until day 4-5, to then increase until day 10 p.i (Zuniga et al. 2008). 
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Nonetheless, Montoya and colleagues’ study established that an increase in the 
number of pDC and in the production of type I interferon occurs early after LCMV 
infection and it is mirrored by a decrease in the number of cDCs. IFNs peak at day 3 
post-infection to decline steadily (Montoya et al. 2005; Lee et al. 2009)  and pDC 
numbers are shown to increase in the first days of the response. In the same report, 
susceptibility of pDC to PCD was also measured and no increased apoptosis was 
measured at day 3 p.i. compared to day 1.  Interestingly CD11c
+
 total cells were also 
tested for apoptosis susceptibility and increased apoptotic cells were measured at day 
3 p.i. Finally the turnover rate of pDC was established and found to be slower 
compared to CD11c
+
 DCs (Montoya et al. 2005).  
 
 
Findings are contrasting to date and have been mainly carried out over the very 
initial stages of the response, as type I interferons are typically released early and 
transiently. The study of pDC “evolution” during the development of CD8 T 
responses to LCMV is therefore of particular interest. In order to verify whether 
pDCs are involved in the presentation of antigen to CTLs during the expansion phase, 
the number of pDCs and intracellular expression of Spi6 were measured in the spleen 
of infected mice. In my hands, pDC do not upregulate Spi6 at any point during 
LCMV Arm infection. These data support the theory that pDCs are not involved in 
antigen presentation to CTL in LCMV Arm infections, as suggested by studies 
showing their poor antigen-presenting properties (Barchet et al. 2005). These results 
suggest that no protection against GrB is required for pDCs to properly deploy their 
functions. Nonetheless, the lack of Spi6 does not rule out the possibility that pDC 
contribute to LCMV clearance through IFN secretion or other cell-contact 
independent mechanisms. The high level of cross-staining seen from day 5 p.i. 
onwards in particular indicates that other serpins are upregulated instead, and are 
needed in these cells. My data regarding the number of pDCs in the spleen of infected 
mice mirror both Colonna’s and Montoya’s results: pDCs decrease from day 1 to day 
3-4 p.i. and subsequently increase till day 8 p.i.  
 
 
CD8α DC and pDCs were chosen as the subsets in which to study Spi6 expression 
due to their specific role during LCMV Arm infection. CD8α DCs in particular are 
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the subset responsible for cross-presenting CMV-derived antigens to CD8 T cells, and 
pDCs support CD8α DC maturation and cross-presentation activity and aid the 
cytotoxic activities of CTLs. The analysis of Spi6 expression revealed upregulation in 
the former subset early after infection and maintenance of the expression levels until 
day 8 p.i., while pDCs did not show to express Spi6. CD8α DC levels are impaired in 
Spi6 KO mice, despite the levels of aiding pDC are not different from WT levels. It is 
therefore expected that CD8α DC numbers are affected by the lack of SPi6, which 
makes them more susceptible to GrB-mediate apoptosis, and not by the lack of 
maturation signals deriving from pDCs. 
 
 
 
 
 
5.5 Importance of sustained antigen presentation by 
dendritic cells during primary responses 
  
Having shown that the survival of DCs is impaired in absence of Spi6 but their 
functionality is preserved it was of interest to investigate whether the diminished 
number of DCs affected CD8 T cell responses to the pathogen. In order to determine 
whether primary and memory CD8 T cell expansion levels in vivo are affected by 
Spi6 absence in DCs, the levels of donor CTL were measured in Arm-infected P14 
CD8-adoptively transferred WT and Spi6 KO mice. 
According to the antigen persistence theory, described by VanMoonfort, the 
presence of antigen and its continuous presentation are needed for optimal expansion 
of antigen-specific CTLs in viral and bacterial infections. In particular, Von Monfoort 
supports the need for sustained antigen stimulation throughout the expansion phase of 
CD8 responses (Jusforgues-Saklani et al. 2008; van Montfoort et al. 2009). This 
theory contrasts with the previously formulated theory of the “autopilot”. The 
autopilot theory asserts that a short-term initial contact between a CD8 T cell and a 
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DC is enough to trigger activation, proliferation and effector functions in the CD8 T 
cell. This process is not negate by the antigen persistence theory, but rather included 
in it in that the initial contact is certainly key for activation and proliferation but it is 
not enough to sustain a maximal expansion. Curstinger and colleagues had suggested 
how continuous antigen presentation and costimulation during CD8 T cell priming 
resulted in a larger cell number and higher lytic activity. They showed in particular 
that cytolytic activity requires 40hr of antigen presence to be fully developed in CTL 
(Curtsinger et al. 2003). More recently, Van Montfoort’s work demonstrated the 
presence of antigen stored in intracellular compartment in DCs and that DCs could 
present antigen on MHC-I complexes despite their quick turnover rate of 24 hrs (van 
Montfoort et al. 2009). Dolfi and colleagues also showed in a recent report how the 
CD8α DC subset in particular is required to sustain viral-specific responses during the 
effector phase in order to have maximal expansion levels (Dolfi et al. 2011). 
Dynamics of DC-T cell interaction are also being studied. John and colleagues 
described short-time contacts happening between T cells and several DCs in a 
normal, non-inflammatory status in the LNs, while during pathogen invasion, the 
contacts between DCs and T cells become longer and less frequent (John et al. 2009). 
The results described, taken together, depict a model in which: initial DC-T cell 
interaction are quite sustained, DCs can store antigen in intracellular compartment for 
cross-presentation, DC-mediated presentation of antigen is required during the whole 
expansion phase, and CD8α DCs are not just required for initial cross-presentation of 
viral antigens to CD8 T cells but are also required to cross-present the viral antigens 
at later stages during the effector response. Sustained antigen presentation is therefore 
required for efficient CD8 T cell activation not only in the early phases of an 
infection, but during the expansion phase as well.  
 
According to the antigen persistence theory, DCs mediate antigen presentation to 
CD8 T cells throughout the expansion phase also thanks to their antigen. The results 
obtained through priming of CTLs by adoptively transferred BMDDCs should be 
seen in light of van Monfoort’s model of prolonged antigen presentation. The 
experimental model involving BMDDC adoptive transfer described in Chapter 4.2 
specifically addresses this issue. BMDDCs injected into a host have an average 
survival rate of 3 days due to their half-life, maturation stage, and LPS pro-apoptotic 
action (Hou and Van Parijs 2004). They will therefore be able only to contribute to 
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the initial phase of a CD8 T cell response. As these cells are eliminated by day 3 (as 
shown in Belz et al. 2004), they are not be able to sustain further CTL expansion. 
Also, due to the nature of the experiment, the source of foreign antigen in this 
experiment was limited to the peptides presented on injected mature BMDDCs. This 
model therefore replicates a toxin invasion rather than a viral infection. 
 
The adoptive transfer of antigen-pulsed ex vivo-matured BMDDC does not mirror a 
viral infection as, in the case of an infection, the system provides continuous source 
of antigen which is continuously presented to CTL to sustain the expansion. As 
shown by Pham and colleagues (see Figure 77), DC immunisation alone, or 
accompanied by early or late inflammation elicits a transient effector proliferation 
and earlier CTL peak and formation of memory. DC immunisation needs to be 
accompanied by constant and concomitant inflammation to induce a physiological 
expansion and formation of memory comparable to (viral) infections. LPS-matured 
DCs are both killed by activated CTL and by the apoptosis process induced by LPS 
itself (Lutz et al. 1999; Heath et al. 2004).  
 
When considering the number of DCs retrieved at the draining LN as a measure of 
surviving DCs, Andrew and colleagues failed to discriminate between death induced 
by CTL action and death induced by LPS action. For this reason, Andrew’s 
experiment represents a non-physiological condition and its conclusions regarding 
Spi6 protection cannot be extended to physiological context. In LCMV-infected mice, 
the CD8 T cells localise in the red pulp and not in the T cell areas like in the naïve 
mice. Abrogation of T cell naïve migration to the T cell zone is reconnected to the 
downregulation of CCL21, and this impacts DC migration as well (Mueller et al. 
2007). These dynamics demonstrate how the SLO environment changes between the 
steady state and infection, therefore making some in vitro models not suitable to test 
priming. Among these is Andrew’s model. 
 
Andrew and colleagues had, moreover, compared the survival of mature versus 
immature DCs, not the effect of Spi6 absence in mature DCs versus the wild-type 
situation. The main difference resides in the ability of mature DCs to prime CD8 T 
cells, while immature DCs cannot do so. Immature cells will therefore not be target of 
CTL-mediated killing in the same way as mature antigen-loaded cells are, thus 
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making the study of Spi6 protective function in the latter not comparable to the 
function in the former. 
 
 
Figure 77: DC immunisation in inflammatory context shaping the 
composition of the effector and memory pool (Pham et al. 2009). 
 
 
The same experiment was thus repeated as in Andrew and colleagues to collect 
preliminary data, with some modifications. Mature DC functionality and survival 
were in fact measured in presence and absence of Spi6. Quite interestingly, it has 
been reported that injected BMDDC, when mature, accumulate in the spleen when 
injected i.v., therefore stimulating re-expansion of both CD8 central memory and T 
effector memory cells, and in the LN when injected i.p. (Huck et al. 2008) Gp33-
specific CTL responses were measured in the spleen and inguinal LN of the mice. 
 
 No difference in the ability of BMDDCs injected into naïve mice to induce a CD8 T 
cell response was measured. The hypothesis is that the lack of difference in expansion 
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levels at the early stage of a CD8 T cell response is due to the absence of GrB. In this 
experiment in fact, DCs only take part to the initial CD8 T cell priming and no 
prolonged antigen presentation occurs at a later stage as DC are quickly removed. 
Notably, staining of blood levels of gp33-specific CTLs suggests the peak of the CTL 
expansion is around day 4, rather than at day 7, when CD8 cell levels are declining 
(see Figure 61). We can deduce that Spi6 expression is required in DCs not for the 
initial priming, but at later stages of the CTL expansion. This is further confirmed by 
the fact that DC elimination is seen from day 4 post-infection in LCMV Arm-infected 
mice. It also shows that in vivo, DCs lacking Spi6 are able to prime CD8 as 
efficiently as WT DCs. Consistently with previous reports, this work confirms that a 
short stimulation/brief exposure to antigen is sufficient to promote naïve CD8 T cell 
proliferation and multiple rounds of cell division, but it is not sufficient to induce an 
effective anti-viral response. In particular, injection of gp33-pulsed BMDDC 
represents an immunization rather than mimicking a viral infection. The CTL 
response generated by this immunization is 10-folds lower than the one generated by 
viral infection. 
 
Due to the need of prolonged antigen presentation during CD8 T cell responses, and 
based on these preliminary results, deficient DC levels caused by Spi6 absence were 
expected to affect antigen-specific CTL responses in two ways. Premature death 
induced by CTL, will cause shorter DC life-span, thus accounting for less naïve 
antigen-specific CD8 T cells being primed. Moreover, higher death levels of DCs will 
impact the negative feedback regulatory loop which is in place to control CTL 
expansion levels. The negative feedback loop is a regulatory mechanism which 
depends on DC numbers (and therefore their survival) to regulate CTL expansion 
levels. The theory is based on the assumption that CTLs kill antigen-loaded DCs 
during primary CD8 T cell responses. When a higher number of CTL is activated, a 
higher level of DC killing will occur, due to CTL-released GrB action on these cells. 
The increased DC death levels will then feedback negatively on further CTL 
activation and priming. The antigen persistence theory supports indirectly this model. 
In fact it describes the need for prolonged antigen-presentation, therefore involving 
prolonged DC-T cell interaction and exposure of DC to CTL-killing, this prolonged 
exposure to GrB-loaded CTLs is at the basis of the regulatory feedback mechanism, 
as just seen above. The two theories taken together form a model whereby CTLs can 
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induce DC apoptosis during the prolonged antigen presentation required for an 
optimal expansion of effector cells. DC survival is therefore threatened by the 
prolonged priming need of CD8 T cell responses.  
To measure the effect of deficient DC levels mice on CTL expansion in Spi6 KO, 
the dynamics of CTL expansion and the levels of donor-derived antigen-specific CD8 
T cells at day 8 post-infection were analysed. The results showed a difference in the 
CTL levels, starting from day 6 p.i. and continuing to day 8 p.i., in the spleen of Spi6 
KO mice compared to WT. The antigen-specific CD8 T cell levels in the Spi6 KO 
mouse were lower. The defect in CTL levels was particularly significant at day 8 p.i. 
and resulted in impaired viral clearance in the Spi6 KO mice when measure at day 6 
p.i (See Figure 74). The defective CTL expansion and the inability of clear the viral 
infection to WT levels point towards the importance of guaranteeing a proper full 
expansion of CD8 T cells in viral response, indicating this is fundamental for the 
efficient clearance of the pathogen.  
 
These results confirm that antigen persistence during CD8 T response is important 
to shape the CTL expansion, and also prove that Spi6 is important in protecting 
antigen-loaded DCs from CTL killing during the expansion phase. The defect in CTL 
expansion seen in Spi6 KO mice can be correlated to Spi6 absence in DCs: the 
experimental design in fact excludes any autocrine effect of Spi6. The difference seen 
in the P14-adoptive transfer experiment between Spi6 KO and WT mice is due to the 
absence of Spi6 in DCs which makes these cells more susceptible to CTL-mediated 
killing thus bringing about a lack of sustained presentation during the expansion 
phase. “The results, showing hampered CTL expansion in P14 adoptively transferred 
LCMV-infected Spi6 KO compared to WT mice, and showing no difference in CTL 
expansion levels between mice SPI6 KO- and WT-BMDDC transferred, can be 
explained in the light of the prolonged antigen stimulation requirement and the 
negative feedback loop that regulates CTL expansion”(Lovo et al. 2012). 
 
Other studies correlate the survival of DCs to the expansion of CTL response in vivo 
(Loyer et al. 1999; Hermans et al. 2000), showing how pfn-dependent killing of DCs 
regulate priming of CD8 T cell responses. These results taken together further support 
the regulatory role played by mature DC levels in shaping CD8 T cell responses. 
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5.6 Dendritic cells in secondary response priming 
 
Secondary immune responses arise from the re-activation of memory cells, whose 
characteristics are quick triggering of degranulation, proliferation and a lower 
threshold for activation. Memory CD8 T cells are formed during primary responses 
and survive in absence of antigen due to their ability to undergo homeostatic 
proliferation. At day 40 after the primary infection, CD8 T memory cells can be 
measured in the spleen and LN. These cells require lower costimulation and are 
activated in presence of low levels of antigen. Despite the lower threshold, memory 
CD8 T cells have specific activation requirements. Recent studies have shown that 
CD8α DCs but not other DC subsets can prime re-expansion of memory CD8 cells.  
 
The killing of DCs as a self-containment mechanism for limiting the expansion of 
the immune response has been shown by Wakim and colleagues in memory re-
expansion (Wakim et al. 2008). On the observation that DCs are target of 
degranulation-mediated apoptosis when priming memory CD8 responses, it was 
hypothesized that Spi6 expression could sustain DC survival during the priming of 
memory cells. Memory CD8 T cells are loaded with cytotoxic granules and can 
degranulate very quickly upon recognition of antigen in MHC context. During the 
expansion of secondary responses, DC survival was thus expected to be impaired in 
Spi6 KO mice due to the lack protection against granule-released GrB. This was 
expected to have a consequence on the ability of DC to prime memory responses and 
therefore to result in deficient memory cell expansion. In order to study Spi6 
requirement in priming of memory responses, CTL re-expansion levels were 
tested/analysed after secondary infection. 
 
As a means to study Spi6 role in memory responses priming, the same experimental 
protocol as above was used: Spi6 KO and WT mice were adoptively transferred with 
P14 CD8 T cells (Thy1.1) and infected with LCMV Arm. In this experiment, mice 
were not sacrificed at day 8 p.i. The test group was instead monitored for donor-
derived P14 cells in the blood and re-infected with LCMV CL13 40 days after the 
primary infection. This strain was used because, due to the high number of adoptively 
transferred P14 CTL and to the efficiency of CD8 T cell responses in eliminating 
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Arm, a high titre and more virulent strain was needed to ensure re-expansion of the 
memory cells and therefore make sure DC were involved in the process.  
 
As described above (see 2.7.2.1), CL13 infects DCs with much higher affinity than 
Arm, due to an aminoacid change in its glycoprotein sequence. CL13 in particular has 
a high tropism for interdigitating DCs in the spleen, which causes low expression 
levels of MHC-I and MHC-II and costimulatory molecules in these cells and 
ultimately a failure in T cell stimulation long-term. CL13 leads to chronic infection in 
immunocompetent naïve mice, but it has been shown that in memory mice CL13 can 
be easily cleared (Borrow et al. 1995). 
Cross-presentation is not as important for CD8 T cell priming after CL13 infection, 
as DCs themselves are infected and will therefore present viral antigens on MHC-I 
even if they are poor cross-presenters. More DC subsets might therefore be involved 
in activating CD8 memory cells in this case. During LCMV CL13 infection, the 
spleen represents the infected tissue, and due to its memory cell composition which 
includes both effector memory and central memory cells, DCs are expected to be 
eliminated via two mechanisms. The first one is GrB-mediated killing during 
priming, and the second is direct, targeted killing by effector memory cells (Marzo et 
al. 2007), as DCs are as infected cells. DC will be subject to both local and indirect 
release of GrB due to priming, and targeted release of granzymes and triggering of 
the death receptors.  
 
The results obtained by donor-derived antigen-specific CD8 T cell analysis at 5 
days post-infection show that CL13 induces a re-expansion of memory donor 
(Thy1.1) cells when injected >40 days after p.i. (see Figure 63). This expansion is 
very contained in Spi6 KO mice and it is defective compared to WT. The difference 
in re-expansion levels does not depend on different levels of existing CD8 memory 
cells in the two test groups. No difference was in fact seen in the LN of Spi6 KO and 
WT mice when donor-derived CD8 memory cell were measured at day 40 p.i. A 
difference could be seen in the spleen, where donor-derived CD8 memory cell levels 
were higher in Spi6 KO mice compared to WT. This is consistent with the results 
shown by Zhang and colleagues regarding memory formation in Spi6 KO mice: the 
defective peak in the primary response is corrected by homeostatic mechanisms that 
increase the development of the memory pool (Zhang et al. 2007). As the memory T 
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cell pool levels in Spi6 KO mice were higher than in WT mice, the deficit in the re-
expansion levels in Spi6 KO mice is even more considerable. The failure of Gp33-
specific memory cell in Spi6 KO mice to expand to WT levels is possibly due to 
defective priming and lack of proper co-stimulation.  
 
To further confirm the findings obtained by measuring the memory pool at day 40 
p.i., the correlation between memory pool size and expansion levels was investigated. 
Equal numbers of memory cells congenically marked were adoptively transferred into 
naïve Spi6 KO and WT mice before infection with LCMV CL13. It was further 
addressed whether the difference seen in the re-expansion levels was due to a 
difference in the memory pool size and functionality. When the same amount of P14 
CD8 T memory cells were injected in naïve Spi6 KO and WT mice, re-expansion 
levels in Spi6 KO mice were, when compared to the WT, deficient in the LN, but not 
in the spleen (see Figure 72 and 73). The data collected therefore concurs with 
previous findings describing DC killing by memory cells and describing memory 
development in Spi6 KO mice, but also suggest that at the LN level a different 
requirement for Spi6 might exist.  
 
Secondary memory cells have been shown to display different characteristics from 
primary ones. They in fact fail to express CD62L, thus not being able to access the 
LN, and exhibit sustain expression of GrB (Masopust et al. 2006). Also, in the LN 
five populations of DC can be found: two migratory ones, Lagerhans and dermal 
DCs, and three resident ones, CD8α+, CD8α- CD4+ CD8α- CD4- DCs. In this organ, 
the LN, in Spi6 KO mice, the levels of secondary expansion of CD8 gp33-specific 
memory cells were dependent on the number of donor gp33-specific memory cells 
adoptively transferred. In the WT mice, on the other hand, the CD8 gp33-specific 
donor memory cell expansion levels seem to reach a plateau, irrespectively of the 
number of memory cells adoptively transferred. One hypothesis might be that, even at 
low number, memory cells adoptively transferred are in too high number compared to 
a physiological situation, and the mature antigen-bearing resident DCs are only able 
to prime a limited number of them. As CD8α DCs are responsible for the priming of 
CD8 memory cells in the LN, and since these cells have a much lower activation 
threshold and quicker degranulation dynamics than CTLs, it can be inferred that 
CD8α DCs in Spi6 KO mice are killed to a much higher extent than in WT mice. This 
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higher level of killing would explain the lower levels of memory CD8 re-expansion, 
consistent to the impairment in memory cell re-expansion observed in CL13 infection 
-secondary response- experiments (see Figure 67). This suggests a role for Spi6 in 
protecting CD8α DCs in priming of secondary responses in the LN is therefore. The 
same results also show that the size of the memory cell pool influences the re-
expansion in the spleen but not in the LNs. The hypothesis is that DCs in the LN are 
only eliminated through indirect GrB released shortly after priming.  
 
Additionally, in the spleen, during the priming of secondary responses, the antigen-
loaded CD8α DCs, due to the expression of gp33 in MHC-I context and their 
proximity to the memory cells during priming, are targeted by degranulating effector 
memory cells both directly and indirectly. One explanation as to why CD8α DCs in 
the spleen are killed to the same extent in the WT and Spi6 KO could be that the anti-
apoptotic effect of Spi6 is not sufficient to counteract high levels of GrB and the 
triggering of other apoptotic pathways. The levels of GrB and the contribution of 
other apoptosis pathways are likely to render Spi6 unable to prevent DC killing in this 
context. 
 
  
 
 
 
5.7 Spi6 inhibition of granzyme B 
 
The results reported in chapter 4.4 illustrate that, in absence of Spi6, the donor-
derived CTLs are not able to expand to WT levels. The defect is not cell autonomous, 
as the adoptively transferred naïve CD8 T cells are from WT mice. To verify that the 
defect was due to the action of GrB, as Spi6 is a physiological inhibitor of GrB, 
elimination of GrB from the system was sought. The absence of GrB was expected to 
result in rescue of the defect in CTL expansion, in both primary and memory 
responses. This verification was important to correlate CTL expansion levels with 
Spi6 absence. It also intended to verify if Spi6 function as a GrB inhibitor was 
specifically the cause for CTL defects in the KO mice. Confirmation of the 
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fundamental function of Spi6 in shielding DCs from GrB -mediated CTL killing was 
obtained with the elimination of GrB from antigen-specific CTLs and was linked to 
CTLs’ ability to proliferate. 
 
The contribution of endogenous versus donor gp33-specific CD8 response was 
measured to verify that elimination of donor-derived GrB would account for reducing 
the total GrB of more than 90% in the system. Endogenous levels of anti-gp33 CTL 
were negligible in my model both during the primary and the secondary CD8 T cell 
response. As shown in Figure 52 and Figure 69, due to the adoptive transfer of 
transgenic TCR cells, the donor gp33-specific response is dominated by Thy1.1
+
 
cells, which are on average about 15-fold higher than the endogenous Thy1.2 cells.  
 
GrB KO CTLs, which were used in order to eliminate GrB from the system, are not 
impaired in their killing functions (Zajac et al. 2003). CTLs in pfn KO mice, on the 
other hand, have been shown to be deficient in their ability to clear LCMV infection 
(Kagi et al. 1994; Walsh et al. 1994). In GrB KO mice, the kinetics of viral clearance 
is delayed compared to WT but substantially similar, with complete clearance reached 
by 8-10 days p.i. when LCMV Arm is used for infection i.p. (Fiigure 78). On the 
other hand, pfn KO CTL have impaired killing functions due to the inability to 
deliver the content of granules to the cytosol of the target cell (Kagi et al. 1994) and 
they accumulate without being able to clear the infection (Matloubian et al. 1999; 
Stepp et al. 2000). The accumulation of these cells further supports the existence of a 
feedback regulatory loop driven by DC elimination. Pfn deficient CTL cannot induce 
GrB-dependent apoptosis in DCs, thus failing to eliminate them. 
 
The  levels of antigen-specific CTL in the spleen have been shown to be the same as 
WT in LCMV-infected mice (Zajac et al. 2003). Moreover, from a functional point of 
view GrB KO CD8 T cells are equally able to induce apoptosis in target cells as WT 
ones in a 
51
Cr-release assay. This was also reproduced by the results reported above 
in CalceinAM assays (see Figure 39). In my hands, the only difference between GrB 
KO and WT CTL is the time-lapse between target-effector contact and apoptosis 
onset: GrB KO CTLs are less able to induce rapid (within 4hr) DNA fragmentation. 
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This is due to the longer dynamics of apoptosis induced by other granzymes release in 
the IS together with GrB, like GrA. 
 
 
Figure 78: Viral titre in GrB KO mice (triangles) infected with LCMV 
compared to viral titres in WT mice (squares) and pfn KO (circles) at 
various time points after infection (Zajac et al. 2003). 
 
 
On this basis, the adoptive transfer of GrB KO P14 was chosen as to validate GrB 
role in DC survival, thus maintaining the ability of these cells to eliminate antigen-
loaded DC and to clear the virus. In agreement to the initial hypothesis, the 
elimination of GrB in Spi6 KO mice restored CTL expansion to WT levels.  
 
The results from the correction of CTL deficient expansion in secondary response in 
particular further support the hypothesis that a feedback regulation loop might exist in 
secondary responses as well.  
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5.8 Concluding remarks 
 
 
The function of Spi6 in DCs during priming of viral responses was studied in this 
project using LCMV infection as a model. The controversy raised by Andrew and 
colleagues, regarding the ability of Spi6 to protect DCs from GrB-induced apoptosis 
in vivo, was addressed using a Spi6 KO mouse. The results described in this 
manuscript showed a higher susceptibility to GrB-mediated death in CD8α DCs 
lacking Spi6 during priming of CD8 responses, therefore suggesting a physiological 
role for Spi6 in protecting DC from apoptosis.  
Andrew’s results after the adoptive transfer of mature BMMDC, can be looked at in 
the context of an initial priming of CTL response because manipulated BMDDCs, 
matured with LPS stimulation, have a relatively short half-life once injected into a 
naïve mouse. These results show how the initial priming phase does not require Spi6 
for DC survival, while prolonged antigen presentation, which happens in the case of 
viral and bacterial infection, requires Spi6 to allow for the occurring of a negative 
feedback mechanism regulating CTL levels based on the levels of DC killing. These 
data taken together reinforce the theory of Spi6 role in protecting DCs during 
priming, which is especially important from day 3 p.i. onwards. Spi6 protection 
granted to DC depends on the amount of GrB in the system, thus allowing for DC 
killing when CTLs are in high numbers. This is in line with the theory that describes 
the existence of a negative feedback loop mechanism, which states that DC are killed 
by CTL therefore sending a feedback signal that allows for diminished further 
priming. Moreover, Fas-FasL engagement can mediate DC killing, but it is not the 
main mechanism in physiological conditions. The final proof is that Spi6 KO DCs are 
killed to a higher extent than WT, but these are still subject to GrB action and 
therefore a fraction of them is still killed in physiological conditions. 
 
Preservation of DC by pharmacological inhibition of GrB would enhance not only 
the priming of naïve CD8 T cells but also the boosting of vaccine responses by 
presentation to TEM cells. In the analysis of CTL responses the deficit in the 
expansion level is therefore well documented as being due to CD8α decreased levels.  
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The results presented in this manuscript further reinforce the antigen persistence 
hypothesis and also the negative feedback regulating loop, showing that DC killing 
can modulate the levels of CTL expansion. The Spi6 role is to be seen in this context, 
as allowing for proper and efficient expansion of viral responses through its role in 
DCs and CTLs. 
 
Given the results obtained in this project, the dispute about Spi6 role in protecting 
DC and allowing for a negative regulation feedback to control expansion of CTL 
response is seen in a specific context: the function of Spi6 does not, in fact, consist in 
making DCs completely unsusceptible to GrB-mediated apoptosis, but in maintaining 
a balance between life and death which depends on the CTL levels and therefore on 
local and systemic GrB levels.  
 
Experiments with Vaccine virus and LCV and others showed how parenchymal 
cells may have a role in antigens presentation to CD8 cells as T memory’s cardinal 
feat has historically been those of having a lower threshold for activation, rapid 
proliferative capacity, less stringent requirement for costimulatory molecules than 
naïve CD8. These cells might be studied for Spi6 expression to further analyze their 
role in CD8 cell response sustainment. 
 
 
 
 
5.9 Future directions 
 
Granzymes are fundamental players in cellular immunity, being the mediators of 
infected cell killing and the weapon to rely on for tumour elimination. On the other 
hand, granzymes have been implicated in the pathogenesis of several diseases, 
transplant rejection and inflammation. 
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Among inflammatory and autoimmune diseases in which granzymes play a key role 
are graft versus host disease, (Graubert et al. 1997), rheumatoid arthritis (Goldbach-
Mansky et al. 2005), Crohn’s disease (Jenkins et al. 2000) and systemic lupus 
erythematosus (Blanco et al. 2005). The pathogenic function of granzymes has been 
in particular associated with tissue damage and, in humans, PI-9 has been measured 
in the serum of patients with the above-mentioned pathologies, at the sites of 
inflammation in association with non-lymphoid cells, as mentioned above (2.6.1), and 
at immune-privileged sites, where it is likely to have a protective role against 
misdelivered GrB or uncontrolled CTL activity (Bladergroen et al. 2001).   
Transplant acute rejection is also mediated by GrB released by degranulating CTLs: 
renal transplant recipients have been shown to present subclinical rejection in 
correlation with high levels of PI-9 (Rowshani et al. 2004), while acute rejection is 
associated with low levels of this GrB-inhibitor.  
The use of recombinant GrB inhibitors might be relevant in these cases and would 
be potentially interesting as a supportive therapy to reduce inflammation. 
Nonetheless, recombinant protein therapeutics are unfortunately a non-ideal 
therapeutic strategy as, due to their pharmacokinetics, the bioavailability is reduced 
when given per os, and i.v. route of administration imply a complex patient 
management system, higher costs and immunity problems. 
 
On the other hand, PI-9 serum levels have been shown to correlate to tumour 
aggressiveness in advanced stages. PI-9 has also been shown to be expressed in 
tumours on their membrane but not on adjacent non-transformed tissue. Inhibition of 
PI-9 is desirable to overcome the protection from CD8 T cell human tumours 
achieved by overexpression of PI-9, as these use the serpin inhibitor to escape the 
immune response. The release of extracellular inhibitors of GrB has also been 
exploited by tumours to achieve immune escape, thus opening a route for new 
studies. A therapeutic approach that uses inhibition of Spi6 to overcome Spi6 
protective function in these tumours would nonetheless have bring along the 
disadvantage of inhibiting Spi6 from CTL as well. An approach that takes into 
account the regulation of Spi6 or that is designed as a 2-step method, so to first 
downregulate Spi6 in cancer cell and successively induce CTL responses, might be 
more appropriate in this case. 
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As the results in this project support, inhibition of GrB is correlated with 
preservation of DCs, which in turn enhances not only priming of naïve CD8 T cells 
but also the boosting of secondary responses by presentation to TEM cells. DNA 
vaccines are a good putative mean to induce CTL responses, both primary and 
secondary, although the results currently achieved show the achievement of only 
short-lived CD8 T cell responses (Hassett et al. 2000). Increase efficacy of DNA 
vaccines could be obtained by increasing viability of DCs through protection from 
CTL killing  (Radcliffe et al. 2007). 
A main goal in the development of vaccines is the induction of protective antibodies 
and CTL responses, especially against highly mutating virus like HIV and HCV and 
parasites like malaria. CD8α+ DC, for their capacity to elicit both CD8 T cell and TH1 
responses, are considered at present the key tool for vaccine development. Among 
various methods, protein vaccines have been shown to be good candidates but they 
are poorly immunogenic to T cells. At present, the use of proteins must therefore 
either be in conjunction with attenuated viral vectors or other vectors, or with 
adjuvant whose role is fundamental. The recent publication of several reports 
showing antibody-mediated delivery of antigen to CD8α DC to induce potent 
antibody and CTL responses is an example of how the use and manipulation of DC 
might be the right way to go (Boscardin et al. 2006; Caminschi et al. 2009). The 
receptors involved in this process in particular are DEC-205, Clec9A, and α-langerin. 
The delivery of proteins in conjunction with monoclonal antibodies directly targeted 
to DCs has been shown to increase by almost 100 fold the efficiency of antigen 
presentation (Idoyaga et al. 2011). 
Other studies showed the advantage of prolonging DC survival in DNA vaccines 
(Kim et al. 2003; Porter and Harty 2006). One strategy might be to target antigens to 
DCs via the scavenger receptors mentioned above (like Clec9A) and link them to 
Spi6 to promote survival of DCs. The use of Spi6 as an adjuvant, in order to achieve 
enhanced DC survival in these particular formulations has been explored by Kim and 
colleagues in a very elegant approach (Kim et al. 2004). A DNA vaccine encoding for 
Spi6 and a human papilloma virus E7 were injected intradermally in mice and linked 
to molecules targeting MHC-II loading pathway. They observed increased CD8 and 
CD4 antigen-specific responses and tumour resistance. The use of a viral vector 
encoding for Spi6 could also be exploited to achieve inhibition of GrB in those 
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autoimmune and inflammatory diseases mentioned above where GrB has a 
pathogenic role. The development of small molecule might be another valid 
alternative for which the differences between the human and the murine proteins will 
have to be kept into account. 
 
Definition of localisation, migratory ability and specific function of each DC 
subtype is also of primary importance due to these cells growing application in 
vaccine design and therapeutic strategies. The ability to understand which DC subset 
more efficiently stimulates which T cell type and how this can be achieved is of 
fundamental importance in designing protocols to manipulate DC to be used in 
therapy or vaccines. DC manipulation would in fact allow for activation or 
tolerization of the T cell of interest. For example, in the absence of inflammatory 
signals DCs can tolerize T cells: this mechanism is thought to be of main importance 
for maintenance of peripheral self-tolerance (Lutz and Kurts 2009) Not just the 
environment but also the subset determines the outcome of a DC-T cell interaction. 
The current paradigm describes for example contrasting function for cDCs: CD8α- 
DCs are thought to mainly participate in the induction of TH2-biased responses, while 
CD8α+ ones are key to the induction of CD8 T and TH1 responses (Maldonado-Lopez 
et al. 1999). These two subsets in fact differ in the specific surface receptor pool, in 
the PAMP receptors, in the ability to respond to inflammatory signals and to produce 
cytokines. CD8α+ DCs produce much higher levels of IL-12p70 and can produce a 
small amount of IFN-α and IFN-β, while CD8α- DCs produce mostly IFN-γ. 
CD8
+
CD4
-
 DC seem, instead, to be poor producers of any of these cytokines 
(Hochrein et al. 2001). Moreover, the coreceptor molecules expressed by each subset 
are different both qualitatively and quantitatively, therefore accounting for different 
costimulatory signals delivered to T cells and specific cytokine production by the 
activated T cell itself (Winkel et al. 1997). 
One further point on which to focus research efforts is the study of how DCs 
circulate and how they reach the SLOs. Studies to fully understand how DCs circulate 
both in a mature and immature state and how they reach target tissue, be them 
lymphoid or not, are of growing importance since antigen-loaded DC have been used 
as immune response stimuli as anti-cancer vaccine (Steinman and Banchereau 2007). 
One of the most studied routes is i.v. injection, which results in DC accumulation, 
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both in humans and in mice, mainly in lungs and liver, and to a lower extent to spleen 
and BM. A study by Cavanagh and colleagues demonstrated that a small number of 
DCs can in fact access the BM, where they can prime memory cells when antigen-
loaded. This is very important for DC-based vaccination strategies and central 
memory activation (Cavanagh et al. 2005).  
The development of GrB inhibitors and of DNA vaccinations aimed at prolonging 
DC survival might prove useful in the designing of drugs or therapeutic strategies 
aimed at the treatment of a variety of conditions, from autoimmune diseases to 
transplant rejection to cancer. 
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